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SUMMARY
Tuberculosis (TB) is a ~?,:!d~i_<!e_pr~ which is particularly serious in the clt!v~2piI1g_~0!!!!t!.!~_s.
In ~h Africa_,_as with many other countries, HIV is a serious compounding factor in trying to
control the spread of the disease. There is much evidence that host genetic factors influence the
outcome of disease as only 10% of individuals who are infected with Mycobacterium tuberculosis
(M tuberculosis) will actually go on to develop active disease.
The innate immune response is the body's first line defence before the acquired immune response is
initiated. It is probably in these early stages after inhalation of the bacilli that the fate of the
bacterium is decided. The collect in molecules are an important part of the innate immune response
particularly in the lung and include, most importantly, mannose binding lectin, and the surfactant
proteins (SP) -A and -D. These three colleetin molecules have been shown to playa role in the host
defence with respect to M tuberculosis.
In this investigation particular attention was paid to the surfactant proteins which seem to play
important yet distinct roles in the response to the inhaled bacilli. SP-A acts to enhance attachment
of M tuberculosis to alveolar macrophages and increase phagocytosis whereas SP-D agglutinates
M tuberculosis thereby reducing phagocytosis of M tuberculosis by macrophages.
Case-control genetic association studies have been performed using polymorphisms within these
genes and have shown association with TB in numerous populations including the South African
Coloured population in Cape Town. A polymorphism within the amino terminal region of the SP-D
gene was associated with susceptibility to TB. A family-based study was therefore undertaken to
replicate the result obtained in the case-control study. Discrepant results were obtained that
appeared dependent on the family structure used. The number of families analysed was relatively
small and therefore one cannot conclude that the association previously detected was spurious, and
a larger study should be performed. The impact of this polymorphism was studied further to
determine whether it affected the overall structure of the protein. We also examined the effect this
polymorphism had on the concentration of SP-D in the serum of active TB patients compared to
controls. We were not able to determine what role, if any, the polymorphism plays in the overall
structure of the SP-D molecule. However, we showed that the serum concentration of SP-D was
significantly increased in active TB patients compared to controls (p < 0.0001). Furthermore we
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demonstrated that the concentration of SP-D was significantly increased particularly in TB patients
with a TT genotype compared to controls (p < 0.000 I). The TT genotype was previously associated
with susceptibility to TB in a case-control association study (T. Roos, unpublished data).
Numerous allelic variants have been identified in the SP-A genes (SP-A I and SP-A2) which make
up the fully functional SP-A protein. Polymorphisms that were recently identified within the
collagen-like region of SP-A 1 and SP-A2 (Madan et aI., 2002) as well as one novel polymorphism
identified in this study were investigated in the South African Coloured population. We found a
significant association between a polymorphism in the collagen-like region of the SP-A2 gene and
susceptibility to TB (p = 0.007).
Our study demonstrates the importance of human genetics in understanding human susceptibility to
infectious diseases.
ii
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OPSOMMING
Tuberkulose (TB) affekteer die hele wêreld, maar dit is veral in ontwikkelende lande 'n groot
probleem. In Suid-Afrika, soos in baie ander lande, veroorsaak die immuun-paraliserende
uitwerking van HIV -koïnfeksie dat die TB-epidemie voortwoeker. Daar is bewyse dat
genetiese faktore in die gasheer die uitkoms van die siekte bepaal, aangesien slegs 10% van
die individue wat deur Mycobacterium tuberculosis (M tuberculosis) geïnfekteer word,
uiteindelik die aktiewe siekte ontwikkel.
Die aangebore immuunsisteem is die liggaam se eerste verdedigingslinie, waarna die
verworwe immuunreaksie geïnisieer word. Die bakterium se lotgevalle word moontlik bepaal
in hierdie vroeë stadium pas nadat dit ingeasem is. Die kollektien-molekule is veral in die
long 'n belangrike deel van die aangebore immuunrespons en sluit die mannose-bindende
lektien en die surfaktantproteïene A (SP-A) en D (SP-D) in. Dit is al aangetoon dat hierdie
drie kollektien-molekule in die gasheer 'n rol speel in die verdediging teen M tuberculosis.
In hierdie ondersoek is veral klem gelê op die surfaktantproteïene, wat voorkom asof dit
belangrike en kenmerkende rolle speel in die reaksie teen die ingeasemde bakterieë. SP-A
versterk die aanhegting van M tuberculosis aan die alveolêre makrofage en verhoog
fagositose, terwyl SP-D die bakterieë agglutineer en so verhoed dat dit deur die makrofage
gefagositeer word.
Gekontroleerde assosiasiestudies in pasiënte is gedoen deur polimorfismes in hierdie gene,
wat geassosieer is met TB in ander bevolkings as ons eie, te bestudeer. 'n Polimorfisme in
die amino-terminaal area van die SP-D-geen is positief geassosieer met vatbaarheid vir TB.
'n Familie-gebaseerde studie is ook gedoen om die resultate van die gekontroleerde
assosiasiestudie te repliseer. Verskillende resultate is verkry en word moontlik bepaal deur
die familiestruktuur wat gebruik is. Die aantal families wat bestudeer is, was relatief min en
daarom kan daar nie afgelei word dat die assosiasie wat voorheen waargeneem is vals is nie.
'n Groter studie sal gedoen moet word. Die impak van hierdie polimorfisme is verder
ondersoek om te bepaal of dit die totale struktuur van die proteïen beïnvloed. Die effekte van
hierdie polimorfisme op die konsentrasie van SP-D in die serum van aktiewe TB-pasiënte is
ondersoek en vergelyk met die van kontroles. Ons kon nie vasstel watter rol, indien enige, die
polimorfisme in die totale struktuur van die SP-D-molekule speel nie, maar ons het bewys dat
die serumkonsentrasie van SP-D beduidend verhoog was in aktiewe TB-pasiënte in
iii
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vergelyking met kontroles (p < 0.0001). Verder het ons ook gedemonstreer dat die
konsentrasie van SP-D beduidend verhoog was in die IT-genotipe van die aktiewe TB-
pasiënte vergeleke met die kontroles (p < 0.0001). Die IT-genotipe is al voorheen positief
geassosieer met vatbaarheid vir TB (T. Roos, ongepubliseerde inligting).
Verskeie alleliese variante is geïdentifiseer in die SP-A-gene (SP-Al en SP-A2) wat saam die
volle funksionele SP-A-proteïen vorm. Polimorfismes wat onlangs in die kollageen-agtige
area van SP-A 1 en SP-A2 gevind is (Madan et al., 2002) en een nuwe polimorfisme wat in
hierdie studie geïdentifiseer is, is ondersoek in 'n Suid-Afrikaanse bevolking. Ons het
beduidende positiewe assosiasie tussen 'n polimorfisme in die kollageen-agtige area van die
SP-A2 geen en vatbaarheid vir TB (p = 0.007) aangetoon.
Ons bevindinge bewys die belangrikheid van die bestudering van mensgenetika, wat die
immuunkompetensie rig, om vatbaarheid vir infektiewe siektes te verstaan.
IV
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Impossible is just a big word thrown
Around by small men who find it easier
To live in the world they've been given
Than to explore the power they have to change it.
Impossible is not afaet. It's an opinion.
Impossible is not a declaration. It's a dare.
Impossible is potential. Impossible is temporary.
Impossible is nothing.
Anon
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CHAPTER 1
INTRODUCTION
If we value the pursuit of knowledge, we must be free to follow wherever that search may lead
us. The free mind is not a barking dog, to be tethered on a ten-foot chain.
Adlai E. Stevenson Jr. (1900 - 1965)
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1.1- IMPACT OF TUBERCULOSIS WOLDWIDE
Tuberculosis (TB) is an infectious disease caused by the tubercle bacillus, Mycobacterium
tuberculosis (M tuberculosis). TB is the leading cause of death due to a single infectious
agent and although it is considered by some authorities to be less aggressive than smallpox,
the bubonic plague, leprosy or acquired immune deficiency syndrome (AIDS), it is
responsible for the largest number of deaths in history. It is estimated that between 2002 and
2020, nearly 1000 million people will be newly infected, over 150 million people will become
diseased and 36 million will die of TB (The World Health Organisation (WHO),
http://www.who.int/enl) (Figure I.I). Although the largest number of cases and the highest
number of deaths occurs in the South East Asia region the highest mortality per capita is in
the Africa region. This is because the human immunodeficiency virus (HIV) has led to
dramatic increases in the incidence of TB as well as increasing the likelihood of dying from
TB (WHO Report 2004). South Africa has an incidence of 558/100000 population and a TB
mortality rate of 79/1 00 000 population (WHO Report 2004). It is alarming to note that 60%
of the adult population (15 - 49 years) who are infected with TB are also HIV positive and
1.5% of the new cases reported are multiple drug resistant (MDR) TB cases (WHO Report
2004). The Western Cape, South Africa, has one of the highest incidences in the world (up to
636/100 000) (WHO).
1.1.1 M. tuberculosis - The pathogen
M tuberculosis is a facultative, intracellular pathogen that has developed specialised
mechanisms to survive within the macrophage. This is different from most other pathogens
that avoid entering the macrophage (obligate extracellular pathogens) to escape killing (Ernst,
1998). Entry into, and survival within the macrophage is the distinguishing factor between
pathogenic and non-pathogenic mycobacteria (Ramakrishnan et al., 2000).
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FIGURE 1.1: The estimated global TB incidence rates ill 2002. (Taken from
www.who.intlgtb/country_info/index.htm).
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M tuberculosis along with Mbovis, Mbovis Bacille Calmette-Guérin (BCG), M aficanum
and M mieroti belong to the M tuberculosis complex and cause TB. The genus
mycobacterium are non-motile, rod shaped and do not form spores and are classified as acid
fast bacilli as they are able to retain carbol-fuchsin stain after washing with acid, alcohol or
both (Goodfellow and Minnikin, 1984; Kubica, 1984). The M tuberculosis bacterium is
characterised by its slow. growth, dormancy. .and C9JI)_i2~X _~_clL~nveJ_Q_pe.The cell wall
structure is different from that of other Gram-positive bacteria. Like other bacteria it has a cell
membrane and a peptidoglycan layer, but there is also a mycolyl arabinogalactan layer,
consisting of mycolic acids esterified to the cell wall. There are also numerous lipids and
glycolipids non-covalently associated with the cell envelope. These include trehalose
dimycolate, phthiocerol dimycocerate and lipoarabinomannan (LAM), many of which have
been suggested to playa role in virulence (Glickman and Jacobs, Jr., 2001). Although it is
known that there is a whole array of entities in the cell envelope, it is still poorly understood
how these molecules act in pathogenesis of disease and the roles they play in virulence
(Glickman and Jacobs, Jr., 2001).
1.1.2 Treatment of TB
1.1.2a. TB Control Programme (DOTS)
The intermationally recommended approach to TB control is Directly Observed Treatment
Short-course (DOTS). The DOTS strategy has five key elements, according to the WHO
(www.who.int.gtb):
• Government commitment to sustained TB control.
• Detection of TB cases through sputum smear microscopy among people
with symptoms.
• Regular and uninterrupted supply of high quality TB drugs.
• 6 - 8 months of regularly supervised treatment (including direct
observation of drug taking for at least two months).
• Reporting systems to monitor treatment progress and programme
performance.
To ensure the patient's progress is monitored throughout the treatment, sputum smear testing
is repeated after two months and then again at the end of treatment. In 1991 DOTS was
introduced and since then more than 13 million patients have received treatment under this
3
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strategy. By the end of 2002, all 22 countries with the highest incidences of TB (including
South Africa), together accounting for 50% of the world's estimated cases, had adopted
DOTS.
In South Africa DOTS was implemented in 1996 with the goal of extending TB control
services to the whole country. DOTS now reaches 180 districts (98%), however the quality of
DOTS has deteriorated in some areas. There are several reasons for this deterioration and why
targets are not met. There is sometimes a lack of sustained commitment to the DOTS
programme and in some instances there is insufficient staff and TB managers in certain
districts and provinces due to the high workloads and because of the increasing number ofTB
patients who are HIV positive. To help alleviate this problem home-based caregivers and
community health workers are being trained in the management of both TB and HIV. DOTS
aims to detect 70% of all new infectious TB cases and to cure 85% of those detected by 2005.
In 2002, 18 countries had already achieved these targets (WHO Report 2004).
1.1.2b. Vaccines and Drugs
The conventional drugs used for treating TB include; ethambutol, isoniazid, pyrazinamide and
rifampicin, which are effective against actively growing bacilli but may be ineffective against
bacilli that have entered the latent or slow growth phase. When M tuberculosis is confronted
with these drugs it is able to slow its growth and enter stationary phase allowing the bacilli to
persist for extended periods of time (Butler, 2000). To eliminate slow growing bacteria drugs
need to be developed that directly target against persistence genes and thereby prevent
bacteria from entering the latent phase and possibly reactivating after completion of therapy.
There is a drastic need for new and effective vaccines and drug treatments for TB;
furthermore it is essential that newly developed vaccines are superior to the currently used M
bovis BCG vaccine which has not been improved upon since 1921. Despite the long-term use
of BCG it has had no effect on decreasing the incidence of TB (Collins, 2000). No new
specific anti-TB drug has been introduced since rifampicin in the early 1970's. More recently
the development of new vaccines for TB has been receiving worldwide attention mostly
focussing on live and non-living vaccines (Mustafa, 2002). Live vaccines include genetically
modified Mbovis BCG, genetically attenuated strains of the M tuberculosis complex as well
4
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as genetically engineered vaccinia virus and Salmonella strains (Collins, 2000). Non-living
candidates include killed mycobacterial species, protein subunits and DNA vaccines. With the
sequencing of the M tuberculosis genome and identification of potential virulence genes of
the bacterium there is a better understanding of the mechanisms M tuberculosis employs to
gain access to the macrophage and how it persists. This has helped scientists to try and use
genes that are specific to the various stages of the M tuberculosis infection and use them in
potential vaccines.
Naked DNA immunisation provided the first evidence that selected antigens protected against
M tuberculosis. Examples of antigens that protect mice include Mtb8.4 (Coler et aI., 2001),
Ag85 (Huygen et al., 1996; Baldwin et al., 1999; Ulmer et al., 1997), Mtb41 (Skeiky et al.,
2000), Mtb39 (Dillon et al., 1999), MPT-63 and -83 (Morris et al., 2000), hsp65 (Lawrie et
al., 1999), PstS-3 (Tanghe et al., 1999), ESAT-6 and MPT64 (Brandt et al., 2000; Kamath et
aI., 1999) and the 36kD lipoprotein (Fonseca et aI., 2001). Although DNA vaccines have been
proven to be effective in mice they have not had the same efficacy in larger animals, such as
non-human primates. Therefore more work is needed before this approach can be used in
humans. Results obtained thus far are promising and over the next 10 years it is hoped that
once the large number of candidates has been reduced to a few suitable candidates, phase I
clinical trials and thereafter Phase II clinical studies can be done (Reed et aI., 2003).
1.1.3 Drug Resistant TB
In recent years the emergence of drug resistant and MOR TB strains has become a major
concern to health authorities worldwide. Some strains of TB are resistant to all major anti-TB
drugs. The most common anti-TB drugs are isoniazid, rifampicin, pyrazinamide, streptomycin
and ethambutol. Drug resistant TB is thought to arise initially from inconsistent or partial
treatment. There are various reasons for this. Sometimes patients cease taking medicine as
they start to feel better, healthcare workers and doctors may prescribe the wrong drug
regimes, or it could be because drug supply is unreliable. Drug resistant TB is still treatable
but it requires extensive chemotherapy (up to two years of treatment) that is often expensive
as well as being more toxic to patients. MOR TB is defined as a TB bacillus that is resistant to
at least isoniazid and rifampicin, which are the two most powerful anti-TB drugs. Preventing
the emergence and controlling the spread of MOR strains can only be achieved by ensuring
5
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that patients receive the correct and full course of medication (Gleissberg, 1999). In more
recent years, HIV has become a significant compounding factor in the spread of MDR TB. In
areas where there is a high incidence of HIV, TB transmission rates are also high and this,
coupled with poor living standards, decreases the chances of controlling TB in the near future
(Chintu and Mwinga, 1999).
1.1.4 HIVand TB
HIVand TB form a dangerous partnership with each speeding the other's progress. HIV
weakens the immune system leaving an individual susceptible to infectious diseases. A person
who is HIV positive is more likely to develop TB disease than someone who is infected with
TB and is HIV negative. TB results in an increase of HIV replication leading to elevated viral
load (Lawn et al., 1999) (Bekker et al., 2000). Patients who are HIV positive have an
increased risk of getting primary or reactivation TB (Wood et al., 2000). TB accounts for
approximately 13% of AIDS related deaths worldwide (WHO). HIV positive individuals
contracting MDR TB show a much faster progression from diagnosis to death, with a known
case fatality rate of approximatley 80% (Bloom and Murray, 1992). Africa has one of the
highest incidences of HIVand therefore it is not surprising that it is the single most important
factor in the increased incidence of TB in the past 10 years (Figure 1.2).
6
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FIGURE 1.2: Estimated HIV prevalence in TB cases.
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1.2 - HOST SUSCEPTIBILITY TO TUBERCULOSIS
TB is a major problem in numerous developing countries, including South Africa. It is
estimated that 5 - 10% of individuals infected with M tuberculosis will develop the disease
and the question that arises is: why are some people more susceptible to developing active
disease than others? Before the discovery of M tuberculosis, physicians were convinced that
TB was a hereditary disease as it was seen frequently in members of the same family, for
example the Brontë family. However with the discovery of the M tuberculosis bacterium in
1882 by Robert Koch (Koch R, 1882), scientists' attention moved away from host genetics to
focusing more on the role of the pathogen. Although M tuberculosis is necessary for
developing disease it is not the only factor influencing progression. There is evidence that
interactions between environmental factors, pathogenic variation and host genetic factors play
a role in TB progression as well as susceptibility (Schluger and Rom, 1998). The most
important environmental factor, which impacts on a global scale, is co-infection with HIV, as
discussed above in Section 1.1.4. Co-infection with HIV increases the risk of developing TB
from a lifetime risk of 10% to an annual risk of 10% (Corbett and De Cock, 1996). Socio-
economic and nutritional status is also likely to have an impact on susceptibility to TB
(Cegielski and McMurray, 2004). Genetic variation of the bacterium itself is another
important factor influencing host susceptibility, although sequence diversity of M
tuberculosis is lower than other pathogens (McShane, 2003; Lopez et aI., 2003; Sreevatsan et
al., 1997).
In the late 1800's and early 1900's it was recognized that there were racial differences in
susceptibility to TB (Budd W, 1867; Cummins SL, 1908; Millar JG, 1908). More recently this
was supported by Stead et al. (1990) who showed that black individuals were twice as likely
to become infected with M tuberculosis than white individuals. They were all living in the
same nursing home. This suggested that there is a genetic basis for susceptibility to TB as
these patients were living in the same environment (Stead et aI., 1990). Evidence that host
genetics played a role in TB susceptibility also came from the Qu' Appelle Indian Reservation,
Saskatchewan in 1890. When the population was first exposed to TB the annual death rate
was approximately 10% of the population. Over half of the families died over the next 40
years and the annual death rate during this time decreased to 0.2% (Motulsky, 1960). It is
speculated that this decrease in the annual death rate resulted from selective pressure against
TB susceptibility genes supporting a role for host genetics in disease susceptibility. The most
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compelling evidence for a host genetic component to susceptibility to TB comes from twin
studies (Kallmann FJ, 1942; Comstock, 1978). These studies showed that there is a much
higher concordance for disease among monozygous (identical) twins than dizygous (non-
identical) twins which suggests that genetic factors are involved, as environment within a
family is similar.
With advances in technology the identification of disease genes has progressed at a very rapid
rate. The use of the polymerase chain reaction (PCR) in screens for polymorph isms,
mutations and in linkage studies has simplified the methods used to identify genes. Infectious
diseases can be influenced by a number of different susceptibility genes with each gene
making a contribution to the outcome of the disease. There are a number of methods for
identifying susceptibility genes including linkage analyses which require large families,
genome wide scans which can be performed in case-control cohorts or utilise many families
with affected sibling pairs (Blackwell et al., 1997; Bellamy et al., 2000a), and association
studies with candidate genes that are potentially involved in the host response to infection.
These methods are described in detail in Section 1.3. The identification of susceptibility or
resistance genes is important as it could lead to a better understanding of disease progression,
which in tum could ultimately lead to the development of new treatments for diseases such as
TB.
Insights into host genetics have been gained through studies involving animals, in particular
mice. This is demonstrated by work on natural resistance associated macrophage protein 1
(NRAMPl, now known as solute carrier family Il member 1 (SLC11al)) which was
identified by studies on mice that were genetically susceptible to BCG infection (Gros et al.,
1981; Vidal et al., 1993; Malo et al., 1994). Although a number of studies in humans had
reported association between human leukocyte antigen (HLA) markers and TB, for example
HLA-DR2 (Singh et al., 1983), the first non-HLA gene associated with susceptibility to TB
was SCUlal. The initial report by Bellamy et al. (Bellamy et al., 1998) showing association
in a case-control study in the Gambia, has subsequently been supported by studies in African
(Awomoyi et al., 2002; Cervino et al., 2000; Hoal et al., 2004), Asian (Ryu et al., 2000; Gao
et al., 2000; Delgado et al., 2002) and in North American populations (Ma et al., 2002).
The interferon gamma (IFN-y) signaling pathway has also provided valuable information
regarding host susceptibility to TB (Jouanguy et al., 1996; Newport et al., 1996). Mice with
9
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disruptions in the IFN-y gene as well as the receptor have been shown to be susceptible to
mycobacterial infections (Cooper et al., 1993; Kamijo et al., 1993). A family in Malta was
identified who appeared to have a single gene defect that was inherited recessively resulting
in increased susceptibility to mycobacterial infection (Levin et al., 1995; Newport et al.,
1995). A genome search using microsatellite markers identified a region on chromosome 6q
in which the gene for IFN-y receptor 1 (IFN-yRl) is located and appeared to be the likely
candidate (Newport et al., 1996). It was found that this susceptibility was caused by a
mutation in the IFN-yRI gene. The mutation produces a premature stop codon resulting in a
truncated protein being formed. Immunologic studies revealed that the affected children are
unable to produce tumour necrosis factor alpha (TNF-a) in response to endotoxin as well as
being unable to upregulate this cytokine in response to IFN-y (Levin et al., 1995).
A number of other genes have been associated with susceptibility to TB including; mannose
binding lectin (MBL) (Selvaraj et al., 1999; Hoal-van Helden et al., 1999), the vitamin 0
receptor (Bellamy et al., 1999), Surfactant protein AI, -A2 and -0 (Floros et al., 2000),
InterIeukin (IL) 8 (Ma et al., 2003b) the NFkappaB binding site in the IFN-y gene (Lio et al.,
2002; Lopez-Maderuelo et al., 2003; Rossouwet al., 2003) and most recently IL-12B (Tso et
al., 2004). There have also been reports of protective associations against TB. For example it
was reported that a nucleotide substitution in the promoter region of the mbl2 gene resulted in
low levels of MBL which was shown to be a protective factor against M tuberculosis
infection (Soborg et al., 2003) and another allele in the coding region of the gene (allele B,
codon 54) has been associated with protection against TB meningitis (Hoal-van Helden et al.,
1999). A single nucleotide polymorphism (SNP) in the promoter region of the P2X7 gene was
also found to be associated with protection against TB (Li et al., 2002). However, these genes
explain only part of the susceptibility to TB and it is assumed that there are other genes
involved that remain to be identified and investigated. Numerous candidate genes that have
been selected as potential genes involved in susceptibility to TB have shown no association
with TB (Ma et al., 2003a; Ma et al., 2003b), but many of these studies may have been under
- powered.
10
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1.3 IDENTIFYING SUSCEPTIBILITY GENES
There are currently numerous methods employed to identify susceptibility genes. Genetic
susceptibility factors have been identified through twin and adoptee studies. Twin studies
assess the concordance rates in monozygotic and dizygotic twins to establish the extent of
genetic contribution to susceptibility and adoptee studies determine concordance of disease
with adoptive versus biological family members providing convincing evidence that there is a
considerable genetic component to infectious disease susceptibility (Hill, 1998). Other
methods for identifying susceptibility genes are linkage studies and association studies of
candidate genes.
1.3.1 Linkage Studies
Linkage analysis involves constructing a transmission model to explain the inheritance of a
disease in pedigrees. This model is straightforward for simple Mendelian traits but can
become very complicated for complex traits. These studies are carried out using large families
and linkage of a genotype to a genetic marker and infectious disease may be specific for a
particular family and therefore cannot produce an association in the general population (Daly
and Day, 2001).
As yet there has not been a major TB susceptibility gene identified. Two putative TB
susceptibility loci were identified in a genome wide linkage analysis using African families.
This resulted in the identification of a locus on chromosome 15q, containing numerous
candidate genes. The other locus identified was on chromosome Xq27 which could explain
the higher incidence of male TB patients (Bellamy et aI., 2000a). The region on chromosome
15 was examined further by an association study discussed in Section 1.3.2b. Linkage has
also been observed between TB and chromosome 2q35 which includes SLClial in a large
aboriginal Canadian Family (Greenwood et aI., 2000).
1.3.2 Association Studies
Association studies have the advantage in that they have the power to detect genetic
contributors having minor effects. They are mostly case-control studies that follow the
distribution of a certain marker allele in unrelated affected and unaffected individuals (Abel
and Dessein, 1997; Bellamy, 2000b; Strachen and Read, 2000). Associations can be detected
Il
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whether the polymorphism being investigated is the actual cause of the genetic susceptibility,
or if it is in linkage disequilibrium (LD) with the true susceptibility polymorphism (Mathew,
200 1). There are two approaches to conducting an association study, population based case-
control association studies or family based studies. There are advantages and disadvantages to
both approaches and these are highlighted in Table 1.1.
TABLE1.1: A summary of the advantages and disadvantages of family-based and case-control
association studies.
Advantages Disadvantages
Uses parents as internal controls Specific individuals are required
Not influenced by population Possible selection bias of susceptibility
Family-based stratification genes
study
Difficulty in obtaining parental samplesNot subject to type I errors especially in a late onset disease
Lower statistical power
Comparatively easy to obtain Population stratification may bias resultssamples
POl!ulation- Power does not depend on allele
Subject to type I errorsbased Case- frequency
control study
Detect small gene effects
1.3.2a. Population-based case-control association study
This approach involves genotyping unrelated individuals with and without the disease in
question and subsequently comparing the allele and genotype frequencies in these two groups.
Association of a particular allele with disease is purely a statistical finding and is not
necessarily an indication of genetic linkage. There are some important issues to consider
when one is designing a case-control association study including the choice of candidate gene
12
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and polymorphism to be studied, recruitment methods, matching of the controls and the
number of individuals to be studied (Daly and Day, 2001). One of the most important
considerations is choosing the control group that optimally should be as similar as possible to
the cases with the important criteria that they do not have the disease of interest and come
from the same community. One way to make cases and controls more comparable is to match
them for some variables for example sex and age. Matching implies that each case is
individually matched to a control individual. Matching however is only useful for variables
that are strongly related to both the exposure and the outcome of interest (Altman, 1991b).
There are a number of advantages to this approach including the fact that these studies may
have sufficient power to detect relative risks as low as 1.5 which is usually not possible in
family studies (Risch, 2000). The major disadvantage of this approach is that false positive or
negative results are occasionally obtained, due to type I and II errors respectively (Altman,
1991b). When a type I error occurs the null hypothesis is rejected incorrectly. This type of
error is the most frequent error in case-control association studies due to population
stratification. In order to ensure that these types of errors do not occur one should consider the
following. As mentioned above, the choice of controls should be done carefully, ensuring that
they are from the same ethnic group.
Another important consideration is the Hardy-Weinberg equilibrium (HWE) within the
control group. The HWE relates genotype frequencies to allele frequencies and failure to
attain HWE in a case-control study could be due to genotyping error, inbreeding, genetic drift,
mutation or population stratification (Gillespie, 1998). Lastly, corrections for multiple
comparisons should be made using one of the numerous tests which include the Bonferroni,
Bonferroni Stepdown (Holm), Westfall and Young Permutation and the Benjamini and
Hochberg False Discovery Rate (FOR) (www.siliconegenetics.com) (Altman, 1991a). The
Bonferroni method is the most stringent and the Benjamini and Hochberg FOR the least
stringent. Using a highly stringent test such as the Bonferroni method the rate of false
negatives (genes that are reported as non-significant when in fact they are) is very high
(www.siliconegenetics.com)(Altman.1991a).ltis also advisable to replicate the results
obtained in a case-control study using a second, independent sample, or another method such
as a family-based study.
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The results of association studies on a particular gene may differ between populations. At the
population level, the IFN-yRl gene has been studied in different populations with conflicting
results. An association between microsatellite variants in this gene and susceptibility to TB
was found in a Croatian population (Fraser et aI., 2003) but not in a Gambian population
(Awomoyi et aI., 2002). Similarly, we have demonstrated (T. Lundwall-Roos, unpublished
data) an association between the T allele of a single nucleotide polymorphism (SNP) in the
amino terminal region of the SP-O gene and susceptibility to TB in our population, whereas
Floros et al. (2000) showed association with the C allele of the same SNP in a Mexican
population (Floros et aI., 2000). A difference between associations found in different
populations is not completely unexpected for a number of reasons. Populations differ
genetically, therefore different alleles could contribute to a disease phenotype in one
population but not another. There are also compounding environmental factors that could play
a large role in these observed differences in association. It is possible that the polymorphisms
do not influence the protein at a functional level (usually seen with microsatellites) but are in
LO with the causative polymorphism leading to different results in different populations.
Another important point to consider is that the original study showing association may have
had little power due to a small sample size, and this false positive association is then likely to
be contradicted by the reported lack of association in another population.
l.3.2b. Family based studies
In family based studies parents of affected offspring or unaffected siblings are used as internal
controls thereby eliminating the variable of population stratification (Spielman et aI., 1993;
Schaid, 1998). In 1987 Falk and Rubinstein proposed the "haplotype relative risk" (HRR)
method (Falk and Rubinstein, 1987). In this method the two alleles that were not transmitted
to the affected offspring were combined to create a pseudocontrol, and the association of
disease with particular alleles was assessed by traditional case-control methods. The
frequencies of the particular marker alleles in cases and pseudocontrols were used to derive an
odds ratio that is called the HRR when it is applied to pseudocontrols.
Spielman et al. (1993) proposed an alternative to the HRR method called the transmission
disequilibrium test (TDT) to be used to test for linkage in the presence of an association (i.e.
linkage disequilibrium) (Spielman et aI., 1993). This test is used in order to determine
whether the transmission frequency of alleles from heterozygous parents to an affected child
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differs from the expected Mendelian frequency when there is no linkage (Schaid, 1998). The
TOT test can be used when there is only one parent available although this may introduce bias
(Whittaker and Lewis, 1998; Strachen and Read, 2000). The associated allele may be the true
susceptibility factor or it may be in linkage disequilibrium with the real susceptibility allele.
The TOT cannot detect linkage if there is no disequilibrium (Strachen and Read, 2000). The
TOT analysis is assumed to have a lower statistical power compared to a case-control study
(Morton and Collins, 1998) and is prone to type II errors where the null hypothesis is
incorrectly accepted; in other words, an association is not detected when it is present.
After identification of the area on chromosome l5q in a genome-wide linkage study (Section
1.3.1), Cervino et al. (2002) examined this locus on further in a study involving 136 African
families and were able to identify the region 15qll-13. On closer inspection it was observed
that there was an association with a 7bp deletion in the ubiquitin protein ligase 3A gene
(UBE3A) in families screened from the Gambia, Guinea and South Africa suggesting that
UBE3A or a gene close by may be a TB-susceptibility locus (Cervino et aI., 2002).
1.4 - DISEASE PROGRESSION TO TUBERCULOSIS
M tuberculosis enters the body via the upper respiratory tract through the inhalation of
droplet nuclei, and passes through to the lower respiratory tract. Once the organisms have
made their way to the lung they have four potential fates (Figure 1.3).
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Inhalation of respiratory droplet nuclei
I
Immediate killing
of M. tuberculosis. Primary
Complex
Dissemination of
M tuberculosis
Latent Infection Primary TB,
organisms grow and
multiply immediately
Stabilisation (latency)
Acute disease
(meningitis,
milliary TB)
Reactivation TB
FIGURE 1.3: Chronologie events after inhalation of M tuberculosis adapted from van Crevel
et al. (2002).
Firstly, the initial host response can completely and effectively kill all the bacilli via the
alveolar macrophage. If, however, the bacilli are not killed immediately they will take up
residence inside the macrophage, multiply and cause the destruction of the macrophage. At
this stage other inflammatory cells and blood monocytes are recruited into the lung. The
monocytes differentiate into macrophages and both cell types ingest the bacilli, which may
not be killed. During this phase the bacteria are growing logarithmically, blood derived
macrophages accumulate in the lungs but little tissue damage occurs during this stage.
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Most often the infection will be stabilised at this point and infection becomes dormant. Bacilli
can then be in a dormant non-replicating state, or actively replicating but the cytotoxic
immune response is able to keep up with the replicative rate of the bacteria, conversely the
bacilli could be metabolically altered having limited replicative cycles. These bacilli could
remain dormant and never cause active TB, but in some cases these dormant organisms
eventually begin to grow because of a breakdown of the immune responses that are required
for containment of the bacilli and cause re-activation TB, with necrosis and lung damage.
Infection with HIV, treatment with corticosteroids, alcohol or drug abuse as well as ageing
can all increase an individual's risk of latent TB reactivation (Selwyn et aI., 1989; Spencer et
aI., 1990; Rajagopalan and Yoshikawa, 2000a ; Rajagopalan and Yoshikawa, 2000b).
In a few individuals active TB will develop immediately once the organisms have entered the
respiratory tract (primary TB) and in some cases dissemination leads to acute disease.
Dissemination may occur after primary infection but could also take place many months or
years later (post-primary TB) in the case of a depleted or inefficient immune system. Cavity
formation in the lung could lead to rupture of the bronchi which allows the spread of M
tuberculosis through the airways to other parts of the lung as well as to the outside
environment. Thus the final outcome of the disease is dependent on the interaction of the
bacillus and the host defence mechanisms that it encountered.
1.5 - INNATE IMMUNITY
Host defences in the lung involve both innate and acquired immune responses. The acquired
immune response is effective when the host has been previously exposed to the invading
pathogens. Clonal expansion of Tand B lymphocytes takes approximately 24 - 72 hours to
develop and it is suggested that this gap in host immunity is filled by the molecules of the
innate immune system.
The innate immune response consists of structural defenses, antimicrobial molecules
generated in the airways and phagocytic defences (alveolar macrophages and
polymorphonuclear leukocytes) that protect the host from pathogens before the generation of
acquired immunity. These molecules are recruited into the lung in response to pulmonary
infection. They are responsible for the removal of microbes found on the surface of the
airways and for the elimination of bacterial pathogens from the alveolus. The innate immune
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response is responsible for limiting infection during the first few hours of exposure and it
plays a role in modifying the manner in which the acquired immune system develops.
There are numerous cells that fulfill important functions in the innate immune response in the
lung, including epithelial cells, alveolar macrophages and polymorphonuclear leukocytes.
Lung epithelial cells line the respiratory tract and provide a physical barrier against invading
pathogens. In vitro studies have shown that pulmonary epithelial cells and mononuclear
phagocytes have the capacity to produce components of the complement cascade (Cole et aI.,
1983; Strunk et aI., 1988; McPhaden and Whaley, 1993; Johnson and Hetland, 1988) which
contributes to their bactericidal function.
Alveolar macrophages are the most abundant cells that are recovered by lung lavage and
Green and Kass (1964) provided evidence that the alveolar macrophage is a primary defender
of the alveolus. They are highly phagocytic, motile cells that are able to release a variety of
inflammatory mediators and cytokines (Takemura and Werb, 1984).
Polymorphonuclear leukocytes enter the lungs in response to severe infection and
inflammation. Neutrophils are implicated in numerous noninfectious diseases such as
idiopathic pulmonary fibrosis (IPF), asthma and emphysema. They are capable of secreting
proteases, glycosidases and acid hydro lases as well as numerous other antimicrobial
substances (Wright, 1997).
Besides the cells discussed above, the upper airway of the lung has evolved an intricate
system involving mechanical, reflux and cellular mechanisms as well as locally synthesized
defense molecules (Crouch, 1998), with a delicate balance between pro- and anti-
inflammatory responses to avoid damage to the lung (Wright, 1997). These defences include:
serum leukocytes, molecules such as reactive oxygen and nitrogen species, lysozyme,
complement, immunoglobulins A and G, fibronectins, lactoferrin, defensins and pulmonary
surfactant (LeVine and Whitsett, 2001; Crouch, 1999).
1.6 - SURFACTANT AND THE COLLECTIN MOLECULES
Pulmonary surfactant is a complex mixture of lipids and proteins (85 - 90% lipids,
approximately 10% proteins and 2% carbohydrates) which are important for normal
respiratory function (Rooney et aI., 1994). It plays a distinct role in the regulation of alveolar
macrophage function and inflammation and contributes to the innate immune defence of the
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lung. Pulmonary surfactant is involved in the stabilization of alveolar walls in order to prevent
the collapse of the alveoli during exhalation (van Golde et aI., 1988). In order to maintain
surfactant homeostasis, surfactant needs to be continually degraded. Alveolar macrophages
have been shown to actively degrade surfactant thus playing an important role in its turnover
and clearance (Wright and Youmans, 1995; Grabner and Meerbach, 1991). The proteins
present in pulmonary surfactant are designated surfactant proteins (SP) -A, -B, -C and -D. The
major surfactant proteins A and -0 are hydrophilic whereas SP-B and -C are hydrophobic.
Their classification is based on the fact that they are found in lavage fluid, are synthesized by
alveolar type II cells and are present in large amounts specifically in the lung (Figure 1.4).
Clara cells, which are non-ciliated cells that are found in the epithelium of the respiratory and
terminal bronchioles, synthesize all the surfactant proteins except SP-c.
SP-B and -C confer surface-tension lowering properties and are important for the adsorption
and spreading of surfactant (Whitsett and Weaver, 2002).
SP-A and 0 belong to the group of mammalian lectins designated collectins, and are an
important part of the innate immune response to infectious agents. Other members of this
family include; MBL (Turner, 1996) which activates the serum complement system, and at
least two bovine serum lectins, conglutinin, bovine serum lectin 43 (CL-43) and a colleetin
discovered in liver cells, colleetin - liver 1 (CL-I) (Holmskov et aI., 1995; Ohtani et aI.,
1999).
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Air spaOQ
FIGURE 1.4: Schematic of pulmonary surfactant in an alveolus of the lung. Surfactant
constituents are synthesized by type II pneumocytes. The surfactant components are then
packaged into the concentric bilayers of lamellar bodies. After secretion, the bilayers unravel
and adsorb to the air/water interface (see inset). During exhalation, the decreasing alveolar
surface area compresses the interfacial film. Points of controversy simplified by this diagram
include the following: at least part of the interfacial film consists of a multilayer (Schurch et
al., 1995), the lateral extent of which is uncertain; although continuous (Bastacky et al.,
1995), the aqueous layer may at some points be too thin to be considered liquid (Dorrington
and Young, 2001); and although strong physiological evidence either for or against such a
process is lacking, respreading of collapsed material excluded from the interface by over
compression could contribute during re-expansion to the maintenance of a functional film
(Notter et al., 1980). Taken from Piknova et. al. (2002).
The overall structure of collectins is highly conserved between species. They have common
characteristics, being a short amino terminal, disulphide cross linking region and a triple
helical collagen-like domain connected to a calcium dependent carbohydrate recognition
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domain (CRD) by a short, trimeric coiled-coil linking domain or "neck" region (Hoppe et al.,
1994; Lu, 1997). The word colleetin is composed of "coll" for the collagen-like domain and
"lectin" for the lectin-like CRD. The amino terminal domain is held together as a trimer by
interchain covalent interactions that are important in the formation of higher order oligomers.
The collagen-like sequence forms the collagen-like triple helix (20 - 46nm long). The neck
region bridges the collagen-like arm and the globular CRD. This CRD forms the carboxy-
terminal domain of the collectins. The binding affinity of monomeric lectin domains for
carbohydrates is very low (Weis and Drickamer, 1996), but once they have associated into
their trimeric forms their binding affinity is significantly increased.
SP-A and MBL share a common "bouquet" arrangement made up of octadecamers consisting
of six trimeric subunits each composed of 26-35 kDa monomers (Figure 1.5). SP-D is
expressed as dodecamers consisting of four homotrimeric subunits composed of 43kDa
monomers (Crouch et al., 1994b) (Figure 1.6). SP-D and conglutinin have characteristic
"cruciform" structures. The collagen-like region of SP-D is highly conserved and lacks
interruptions of the Gly-X-Y repeats (where X and Y represent different amino acids) unlike
SP-A and MBL, which have a break in the collagen-like region causing the bouquet-like
formation.
C-terminal
globular head
region containing
the carbohydrate
recognition
Trimeric
helical
alpha
coiled-
coil neck region
Triple helical
collagen-like region
Cysteine containing N-
terminal cross-linking
domain
FIGURE 1.5: Schematic representation of the structure of Surfactant Protein A. SP-A has a
bouquet-like structure like that of MBL.
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FIGURE 1.6: Schematic representation of the dodecameric form of Surfactant Protein D.
1.6.1 - Chromosomal location of SP-A, -D and MBL
MBL, SP-A and SP-D are found in close proximity on the long arm of chromosome 10
(Figure 1.7). The SP-A locus has been placed at 10q21 - 24 and the MBL locus at 1Oq11.2 -
q21 (Bruns et al., 1987; Kolbie et al., 1993; Fisher et al., 1987; Sastry et al., 1989). SP-A is
composed of the product of two very similar, but non-identical genes SP-Al (White et al.,
1985) and SP-A2 (Katyal et al., 1992) each being approximately 5kb in length. These genes
are found in opposite transcriptional orientation with a pseudogene situated in between the
two (Korfhagen et al., 1991; Floros and Hoover, 1998; Hoover and Floros, 1998; Bruns et al.,
1987). The pseudogene is nonfunctional and contains sequences highly homologous to exons
encoding the a-helical neck region and the CRD ofSP-A (Korfhagen et al., 1991). SP-D has
been placed at 10q22.2 - 23.1 (Crouch et al., 1993b). A single gene encodes the human SP-D
protein with a transcribed region spanning more than 11kb (Crouch et al., 1993b).
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FIGURE 1.7: The organisation of the human SP-A and SP-D loci determined by radiation
hybrid mapping (Hoover and Floros, 1998; Floros and Hoover, 1998). The arrows denote the
transcriptional orientation of SP-Al, -A2 and the SP-A pseudogene. C denotes the
centromeric end and T the telomeric end of chromosome 10.
1.7 - PULMONARY SURFACTANT PROTEIN A
SP-A exists as a single copy gene in mice (Korfhagen et aI., 1992), rabbits (Boggaram et aI.,
1988; Chen et aI., 1992) and rats (Fisher et aI., 1988) however humans possess two copies of
this gene, SP-Al and SP-A2. The genes have a high degree of structural homology (>95%).
They are 94% identical at the nucleotide level and 96% identical at the amino acid level. The
most significant difference between the SP-Al and -A2 transcripts is the presence of an extra
cysteine residue in the SP-Al gene at position 85, between the interruption of the collagen-
like region and the alpha helical neck region (Voss et aI., 1991). SP-Al and -A2 are in
opposite transcriptional oritentation with SP-A2 being closer to SP-Do The SP-Al and -A2
genes consist of 4 coding exons (Figures 1.8a and b). Both SP-A gene products are required
to form a functional and stable mature SP-A protein. Each functional SP-A gene is extremely
complicated. This complexity includes the numerous untranslated exons at the 5' end that
generate several alternately spliced transcripts, allelic variability which is based on
polymorphisms in the coding regions as well as sequence variability in the 3' untranslated
region (UTR) (Figure 1.9).
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SP-Al Gene
II III IV V
FIGURE: 1.8a The SP-Al gene showing exons I-V. Exon I is the first untranslated exon,
exon II encodes a portion of the untranslated region, the signal peptide, the N-terminus and
the first part of the collagen-like region. Exon III encodes the remainder of the collagen-like
region, exon IV encodes the alpha helical neck region and exon Vencodes the carbohydrate
recognition domain and the 3' untranslated region.
SP-A2 Gene
II III IV V VI
FIGURE: 1.8b The SP-A2 gene showing exons I - VI. Exon I is the first untranslated exon.
Exon II is unique to SP-A2 encoding an additional 5' untranslated sequence that is 30bp in
length and is absent from SP-Al. Exon III encodes a portion of the untranslated region, the
signal peptide, the N-terminus and the first part of the collagen-like region. Exon IV encodes
the remainder of the collagen-like region, exon Vencodes the alpha helical neck region and
exon VI encodes the carbohydrate recognition domain and the 3' untranslated region.
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FIGURE 1.9: 5' splice variants for the SP-Al and -A2 genes. There are numerous 5'
untranslated exons (A, BIB', CIC' and DID') in both SP-Al and SP-A2. These exons splice in
configurations specific for SP-Al (AD' - major transcrpit, ACD' and AB'D' - minor
transcripts) and for SP-A2 (ABD and ABD' - major transcripts). The arrows in exon A
represent different transcription start sites (Karinch et al., 1997). The blue box represents the
first coding exon 1 of both SP-A genes, with TGA denoting the translation start site.
The most common splice variant for SP-Al is AD' which is found at a frequency of
approximately 0.8 (Karinch and Floros, 1995). The most common splice variant for SP-A2 is
the ABD and ABD' transcripts. These transcripts are seen at different frequencies among
humans depending on the SP-A2 genotype of the individual (Karinch et al., 1997; Karinch
and Floros, 1995).
Five alleles have been characterised for SP-Al and six for SP-A2 based on differences within
the coding regions of these genes (Table 1.2). The most common SP-Al allele is 6A2 and the
most common SP-A2 allele is 1A° (Floros et al., 1996). One SP-A genotype in particular
(6A26A21Ao1Ao) has been shown to be associated with a low to moderate level of SP-A
mRNA (Karinch et al., 1997).
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TABLE 1.2: Alleles identified for SP-A 1 and -A2. Adapted from Floros and Hoover (1998).
The positions of the relative amino acids are: 9, 19,50,66,73,81,85,91,219 and 223 for
both SP-Al and -A2. The amino acids that distinguish SP-Al form SP-A2 are in bold.
Gene Allele Amino Acid Differences
The collagen-like region of the SP-A protein, encoded by exons II and III of SP-Al and III
and IV of SP-A2, is similar to collagen and contains 23 Gly-X-Y (where X and Y represent
different amino acids, usually proline in the X position and hydroxyproline in the Y position)
repeats with a break between the 13th and 14th repeat. The carboxy terminal region of the
protein encodes the CRD and is characteristic of other C-type lectins. This region is capable
of binding maltose (Drickamer et al., 1986; Haagsman et al., 1987). The collagen-like
domains consisting of three SP-A monomers (two SP-A 1 polypeptides and one SP-A2
polypeptide) form a triple helix with a bend where the Gly-X-Y repeats are interrupted
(Figure 1.10) (Hoover and Floros, 1998). Six of these triple helices oligomerise to form the
characteristic 'bundle of tulips' formation (King et aI., 1989) (Voss et aI., 1988). The
predominant molecular form of SP-A is a hexamer of trimers, however, smaller oligomeric
forms have been observed (Hickling et aI., 1998) as well as multi-molecular complexes
(Hattori et al., 1996a; Hattori et al., 1996b).
SP-Al 6A NALMDICPRQ
6A2 NVVMDICPRQ
6A3 NVLMDICPRQ
6A4 NVLMDICPWQ
6A5 NALMDICPWQ
SP-A2 lA TAVTNVRPRQ
lAo NAVTNVRARQ
lAl TAVTNVRARK
IA2 TAVTNVRARQ
IA3 NAVTNVRARK
IA4 TAVTNVRARK
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FIGURE 1.10: Structural model of the SP-A protein, showing the SP-A trimer (left) and the
mature octadecameric protein (right). Taken from Khubchandani and Snyder (2001).
1.8-- PULMONARY SURFACTANT PROTEIN D
The SP-D gene is made up of 8 exons (the first being untranslated) and spans more than l1kb.
The first translated exon (exon 1) encodes the signal peptide, the amino terminal domain, and
the first seven Gly-X- Y repeats of the collagen-like region. The remainder of the collagen-like
region is encoded by exons 2-5. The alpha helical coiled-coil neck region is encoded on exon
6 and the entire lectin domain is encoded by exon 7 (Figure 1.11).
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FIGURE: 1.11 Diagrammatic representation of the SP-D gene. 1-7 represents the seven exons
encoding the gene. These include the exon encoding the signal peptide, amino terminus and a
hydrophilic amino terminal collagen-like sequence (1); the remainder of the collagen-like
domain (2-5); a C-type lectin carbohydrate-binding domain (7); and a linking peptide (the
neck region) (6) between the collagen-like domain and the carbohydrate-binding domain. The
5'UTR is interrupted by at least one intron (Crouch et al., 1993b).
The amino terminal region is essential for the overall assembly of SP-D. It contains two
conserved cysteine (Cys) residues (Cys 15 and Cys 20), which are important in the formation
of interchain disulphide bonds that stabilize the dodecameric structure of SP-D (Crouch et al.,
1994b). It has been shown that if these two cysteine residues are substituted with serine,
trimeric SP-D is still secreted, but dodecameric forms of SP-D are not assembled thus
demonstrating the importance of the two cysteine residues (Brown-Augsburger et al., 1996).
Trimeric SP-D molecules are less effective at agglutinating microorganisms as has been
shown by Eda et al. (1997) who investigated the binding and agglutinating ability of truncated
SP-D molecules. They observed that these truncated molecules were not able to agglutinate
influenza A virus as efficiently as native, dodecameric SP-D molecules (Eda et al., 1997). It
stands to reason that if a polymorphism disrupts either of these cysteine residues a mature,
dodecameric protein may not be secreted, alternately an increased number of trimeric
molecules may be secreted leading to an individual who is more susceptible to infection as
SP-D is unable to efficiently agglutinate the pathogens. Zhang et al. (2001) generated
transgenic mice that expressed 'mutant' SP-D, which had cysteine 15 and 20 substituted with
serine in these positions (Zhang et al., 2001). They showed that an increased expression of
these mutant SP-D molecules decreased the amount of the normal disulphide cross-linked SP-
D molecules and lead to the accumulation of foamy macrophages and emphysema in the mice
without altering the alveolar phospholipid concentration.
The long collagen-like domain accounts for the pronounced linear characteristic of this
molecule. The collagen-like domain of SP-D determines the maximum spatial separation of
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the trimeric CRDs and it is possible that it has an impact on the correct molecular assembly
and secretion of the protein. Ogasawara et al. (1995) demonstrated that if the entire collagen-
like region of rat SP-D was deleted SP-D trimers were secreted instead of dodecamers
(Ogasawara and Voelker, 1995). There is an asparagine (asn) -linked oligosaccharide at asn70
in the collagen-like domain. Asn-linked sugars present in the collagen helix have been
implicated in maintaining the conformation of the triple helical domains during the assembly
of Type IV collagen tetramers (Langeveld et al., 1991). It has also been proposed that these
asn-linked sugars are important in intracellular targeting and secretion of SP-A (Alcorn et al.,
1992; O'Reilly et al., 1988).
The CRD is involved in pathogen binding by binding to carbohydratyes on the surface of
bacteria (Sastry and Ezekowitz, 1993; Botas et al., 1998). A trimeric cluster of CRDs is
required for high-affinity binding to carbohydrates present on pathogens and it has been
reported that monomeric CRDs have an approximately 10-fold lower binding affinity for
multivalent ligands than trimeric CRDs (Hakansson et al., 1999). The neck domain is
important for correct assembly and trimerisation of the CRDs, and interactions in the C-
terminal region of the neck stabilise the CRD trimer (Hakansson et al., 1999) (Hoppe et al.,
1994). The neck region appears to be highly conserved as no polymorphisms have been
reported in this region.
Each member of the colleetin family has a different degree of higher order oligomerisation
(Lawson and Reid, 2000). A monomeric SP-D molecule is 43kDa in the reduced state. Each
molecule is made up of three trimeric subunits that associate by their amino termini forming
docecameric structures (~520kDa). The majority of SP-D is purified in the dodecameric form,
but the proportions of various oligomers may vary between species. This can be seen in
alveolar proteinosis patients where the majority of SP-D molecules are of higher order
oligomerisation containing up to or more than 32 trimeric subunits (Crouch et al., 1993a).
Hartshorn et al. (1998) were able to show that the degree of multimerisation of SP-D was a
critical determinant of both aggregating activity and potency in enhancing bacterial uptake,
and Zhang et al. (2001) demonstrated that the activity of SP-D in vivo is dependent on the
oligomeric structure of the SP-D molecule. SP-D is able to bind to and agglutinate a wide
variety of microorganisms and it is thought that the agglutination activity is dependent on the
oligomerisation and the ability of SP-D to bridge large distances between organisms (Eda et
29
Stellenbosch University http://scholar.sun.ac.za
al., 1997). SP-D and conglutinin have a characteristic "cruciform" structure. It has been
shown that SP-D dodecamers are able to form highly ordered stellate multimers sometimes
referred to as astral bodies (Figure 1.12) (Crouch et al., 1994a; Crouch et al., 1994b). The
final multivalent molecules have diameters of 25 to 100nm and this probably allows for
efficient cross-linking or agglutination of bound pathogens, which is a characteristic of
collectins.
a) b) c)
FIGURE 1.12: Transmission electron micrographs of SP-D showing differing degrees of
oligomerisation. a) SP-D dodecamer, b) intermediary molecule, c) astral body (Crouch et al.,
1994a; Crouch et al., 1994b).
SP-D is expressed primarily in the respiratory epithelium, specifically by alveolar type II cells
and Clara cells (Korfhagen et al., 1998; Crouch, 1998; Voorhout et al., 1992). Expression of
SP-D has also been detected in the gastrointestinal tract, genitourinary tract, the skin and soft
tissue as well as in organs such as the heart, brain, testis, pancreas (endocrine) and the
placenta (Leth-Larsen et al., 2004; Murray et al., 2002; Bourbon and Chailley-Heu, 2001). A
SP-D like gene has been identified in rodents, birds as well as amphibians (Lawson et al.,
1999), however as yet there has not been a related gene identified in fish.
1.9- SP-A AND -D KNOCKOUT STUDIES
Transgenic mice studies (SP-A and -D knockouts) have been conducted using SP-A and -D.
These studies have provided some information about the function of these colleetin molecules
in agglutination, phagocytosis and killing of numerous microorganisms. LeVine et al. (2000)
showed that SP-D deficient (SP-D-1-) mice, infected intratracheally with group B
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streptococcus (GBS), were able to kill the bacteria as efficiently as the wild-type mice and the
number of bacteria associated with macrophages was lower than observed in the wild-type
mice. In contrast to this SP-A deficient (SP-A-1-) mice infected with the same microorganism
did not kill the bacterium as efficiently as the wild type or SP-D-1- mice, however the number
of bacteria associated with macrophages was also decreased in the SP-kl- mice compared to
wild type. In the presence of SP-D there was increased association of GBS with alveolar
macrophages but phagocytosis was not altered. The same group also infected SP-kl- and D-1-
mice with Haemophilus injluenzae and observed a similar situation in that these mice were
able to kill this bacterium as efficiently as the wild-type. Also the number of bacteria
associated with and internalised by alveolar macrophages was significantly less in SP-A-1- and
D-1- mice compared to the wild-type mice. This suggests that there is a defect in opsonisation
and/or phagocytosis. In both cases SP-A-1- and D-1- mice showed increased inflammation and
inflammatory cell recruitment into the lung after infection. LeVine et al. (2000) showed that
SP-D-1- mice were susceptible to respiratory syncytial viral pneumonia. The uptake of viral
particles by alveolar macrophages and the clearance of the virus from the lung were deficient
in SP-D-1- mice. These results suggest that the colleetin molecules play distinct roles in the
innate immune response to different microorganisms. Studies of this nature have not yet been
conducted in connection with M tuberculosis but would be useful in elucidating the function
of SP-D in the progression ofTB.
1.10- SP-A AND DINBRONCHO ALVEOLAR LAVAGE FLUID AND SERUM
Alterations of the levels of pulmonary surfactant may contribute to the pathogenesis of
numerous lung diseases including, respiratory distress syndrome (RDS), acute respiratory
distress syndrome (ARDS), interstitial lung diseases, lung cancer and perhaps TB.
The abundant expression of SP-A and -D in the lung makes these collectins possible markers
for lung diseases. The use of enzyme-linked immunosorbent assays (ELISA) for these
collectins has enabled the determination of the absolute amount of proteins in bronco alveolar
lavage fluid (BALF) (Kuroki et al., 1985; Inoue et al., 1994), and although lung surfactant has
previously been believed to exist solely in the lung, both SP-A and -D have been detected in
serum (Nagae et al., 1997; Greene et al., 1999). Since the detection of surfactant proteins in
serum, it was speculated that this could be a useful and non-invasive diagnostic tool for
specific lung diseases.
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1.11- INTERACTIONS OF SP-A AND -D AND MICROORGANISMS
The collectins are able to recognise and bind a wide variety of bacteria, fungi and viruses.
Table 1.3 summarises some microbial targets of SP-A and SP-Do
There are numerous overlaps between microbes recognised by both SP-A and -D. However,
the overlaps of the individual collectins are only partial and the actual interaction between the
specific colleetin molecule and a microorganism, and outcome, can vary greatly (Figure
1.13). For example it has been shown that SP-A and -0 are able to bind M tuberculosis,
however, SP-A enhances the adherence to macrophages and phagocytosis of M tuberculosis
whereas SP-D binding to M tuberculosis decreases the adherence of bacteria to human
macrophages (Gaynor et al., 1995; Ferguson et al., 1999).
SP-D elicits different responses to various microorganisms. It is able to cause agglutination,
allowing more efficient removal of pathogens from the lung (Lawson and Reid, 2000). SP-D
is able to act as an opsonin although this does not always promote phagocytosis. For example,
SP-D is able to enhance the binding of Pneumocystis carinii to alveolar macrophages but this
does not result in phagocytosis (O'Riordan et al., 1995). Surfactant proteins act as chemotactic
agents by recruiting or curtailing phagocytic cells at the sites of inflammation and immune
reaction. SP-D acts as a potent chemoattractant for phagocytes, neutrophils and monocytes
(Madan et al., 1997; Crouch et al., 1995; Cai et al., 1999). The mechanism and receptors
behind this process are not fully characterised, but a central feature of chemotaxis is actin
breakdown and repolymerisation (Tino and Wright, 1999).
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TABLE 1.3: Microbial Targets ofSP-A and SP-Do
Collecitn Microorganism
Reference
SP-A Escherichia coli J5 (Pikaar et al., 1995)
Group A Streptococcus (Tino and Wright, 1996)
Group B Streptococcus (LeVine et al., 1997; LeVine et al., 1999b)
Haempohilus influenza type a
(McNeely and Coonrod, 1994; Tino and
Wright, 1996)
Herpes simplex (van Iwaarden et al., 1991)
Mycoplasma pulmonis (Hickman-Davis et al., 1998)
SP-D
Certain strains of Escherichia
(Hartshorn et al., 1998)
coli
Salmonella minnesota (Lim et al., 1994)
Candida albicans (van Rozendaal et al., 2000)
SP-A and D Staphylococcus aureus (Hartshorn et al., 1998; Geertsma et al., 1994)
Streptococcus pneumoniae
(Hartshorn et aI., 1998; McNeely and
Coonrod, 1993; Jounblat et al., 2004)
Klebsiella pneumoniae (Kabha et al., 1997)
Pseudomonas aeruginosa (LeVine et al., 1998)
Mycobacterium tuberculosis (Gaynor et al., 1995; Ferguson et al., 1999)
Influenza A
(Hartshorn et al., 1997; Hartshorn et al., 1994;
Malhotra et al., 1994)
Respiratory syncytial virus (LeVine et al., 1999a; Hickling et al., 1999)
Aspergillus fumigatus (Madan et al., 1997)
Pneumocystis carinii
(Phelps and Rose, 1991; O'Riordan et aI.,
1995)
Cryptococcus neoformans (Schelenz et al., 1995)
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FIGURE 1.13: A schematic diagram of how the pulmonary collectins, SP-A and -D influence
host defence against invading pathogens. They regulate inflammation and oxidant production.
Taken from McCormack and Whitsett (2002). In some cases phagocytosis of microorganisms
is increased however in the case of M tuberculosis SP-D serves to decrease the uptake of this
bacterium into the alveolar macrophage.
SP-D is able to mediate changes in the architecture of alveolar macrophages, unlike C1q and
MBL (Tino and Wright, 1999). The surfactant collectins have been shown to enhance
phagocytosis in some cases. SP-D is able to bind and enhance macrophage phagocytosis of
mucoid and non-mucoid srains of Pseudomonas aeruginosa but it is unable to aggregate
either strain, which suggests that SP-D enhances phagocytosis through receptor mediated
opsonisation and killing (Restrepo et al., 1999). The mucoid strains of Pseudomonas
aeruginosa are important in the pathogenesis of chronic lung disease associated with cystic
fibrosis and this could be related to the decreased levels of both SP-A and D that have been
reported in lung lavages of at least some patients with cystic fibrosis (Postle et al., 1999).
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1.12 - SP-A AND -D AND Mycobacterium tuberculosis
The initial immunologic response to M tuberculosis in the lung is important, as entry of this
inhaled pathogen into the alveolar macrophage is the defining event in disease pathogenesis
(Ferguson et aI., 1999). The clearance of pathogenic organisms from the lung is dependent on
a rapid and directed response that includes migration of macrophages to the site of infection,
extension of filipodia and pseudopodia to capture and surround the particles, followed by
retraction of the plasma membrane to internalize the bacteria (Warheit and Hartsky, 1993). It
is important that an immune cell is able to control its cytoskeletal redistribution in an effective
manner. In this respect Tino and Wright (1999) were able to demonstrate that the collectins
SP-A and -D, induced a directional actin-based response in alveolar macrophages but not in
peripheral blood monocytes. It is hypothesized that these effects are mediated by a receptor(s)
that is expressed on alveolar macrophages only. This result contrasts with those that were
found for the other members of the colleetin family, Clq and MBL, which induced a non-
directional actin response in alveolar macrophages. These results show that the pulmonary
collectins have specific effects on alveolar macrophages, which are the primary immune cells
present in the lungs. SP-D is able to bind directly to alveolar macrophages (Miyamura et aI.,
1994; Voorhout et al., 1992) and a putative receptor, glycoprotein-340 (gp-340), has been
identified on alveolar macrophages. Gp-340 appears to playa role in the internalization of sp-
D by macrophages (Holmskov et al., 1997).
M tuberculosis is likely to come into contact with surfactant when inhaled into the alveolus
and it is proposed that the interaction between M tuberculosis and surfactant components
alters the ultimate fate of the bacterium (Ferguson et aI., 1999). Ferguson et al. (1999)
investigated the binding of SP-D to M tuberculosis and the effect of this binding on the
adherence of M tuberculosis to human macrophages. They demonstrated that specific binding
of SP-D to M tuberculosis is saturable, calcium dependent and carbohydrate inhibitable. On
incubation with SP-D, the virulent Erdman strain of M tuberculosis agglutinated but there
was minimal binding to the avirulent strain of M smegmatis. SP-D was found to bind
predominantly to the LAM of M tuberculosis Erdman, but was unable to bind to the
AralAM of M smegmatis. Itwas observed that SP-D was able to agglutinate M tuberculosis,
but the adherence of the bacteria to human macrophages was decreased. In contrast, Gaynor
et. al. (1995) found that SP-A acts to enhance M tuberculosis adherence to macrophages as
well as phagocytosis of the bacteria. Within this context, mechanisms that enhance entry of
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M tuberculosis into the alveolar macrophage (its natural host cell) may be detrimental to the
host, whereas mechanisms that reduce the entry of M tuberculosis may be protective.
Sumiya et al. (1991) showed that children carrying MBL mutations were more susceptible to
recurrent infections, which supports the concept that collectins are part of the innate immune
response against microbial pathogens. In support of this Matsushita et al. (1995), found that
polymorphisms in the nucleotide sequences of the collagen domain of the MBL gene altered
oligomerisation and were associated with defects in host defence function. It is therefore
thought that increased levels of variant SP-D that are unable to form higher orders of
multimerisation, might influence the function of SP-Do This, in tum, could contribute to the
pathogenesis of various lung diseases including TB (Zhang et al., 2001).
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CHAPTER2
STUDY OVERVIEW
Every now and again take a good look at something not made with hands - a mountain, a star,
the turn of a stream. There will come to you wisdom and patience and solace and, above all,
the assurance that you are not alone in the world.
Sidney Lovett
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2.1. OVERVIEW
Surfactant protein (SP) -A and -D play major roles in the first line defence, or innate immune
response to a number of pathogens, including M tuberculosis. It is therefore important to
investigate these proteins in order to determine and understand their role in the innate immune
response to infection with M tuberculosis.
A single nucleotide polymorphism (SNP) (SP-DIl) within the amino terminal region of the SP-D
gene was found to be associated with susceptibility to tuberculosis (TB) in a Mexican population
(Floros et al., 2000) as well as in the South African Coloured population in the Western Cape (T.
Lundwall-Roos, unpublished data). The amino terminal region is important in the trimerisation of
SP-D monomers into trimers and subsequently into dodecameric structures. These dodecameric
structures are the minimal structural requirement for efficient bacterial agglutination. Because of
the location of the SNP we hypothesized that this amino acid substitution (threonine/methionine)
could disrupt the usual formation of the SP-D molecule resulting in an increase in the number of
monomeric and trimeric SP-D molecules being formed leading to decreased bacterial
agglutination and therefore increased uptake of the bacilli into their preferred environment of the
alveolar macrophage.
SP-A also plays an important role in the innate immune response to microorganisms including M
tuberculosis. Polymorphisms within the SP-A gene have been investigated in population based
case-control association studies in order to determine whether the polymorphisms influence an
individual's susceptibility to TB or not. Recently a number of polymorphisms were identified
within the collagen-like region of the SP-A gene in an Indian population (Madan et al., 2002).
Floros et al. (2000) have also studied polymorphisms in the SP-A genes and have reported
significant associations with susceptibility to TB. We determined which polymorphisms were
found in a local population and performed population based case-control association studies to
ascertain their possible effect on susceptibility to TB.
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HYPOTHESIS
Polymorphisms in SP-A and -D, which affect the level or function of these molecules, are likely
to affect, directly or indirectly, the ability of the individual to control an infection with M
tuberculosis.
2.2. AIMS
1. Perform a TDT analysis using South African Coloured families from the same community
as the cases and controls used in the study that showed an association between SP-DIl
and susceptibility to TB.
2. Sequence the proximal promoter, amino terminal and neck regions of the SP-D gene to
screen for novel polymorphisms in our population.
3. Determine if SP-DIl has an impact on the overall structure of the SP-D protein by
partially purifying SP-D from serum using a Superose 6 HR 10/30 affinity column and
detecting the presence ofSP-D in the fractions collected using an ELISA assay.
4. Investigate the relationship between the SP-DIl genotype and concentration of SP-D in
serum of patients and controls using an ELISA assay.
5. Purify SP-D from broncho alveolar lavage fluid of individuals with a known SP-DIl
genotype and use this purified SP-D to determine whether SP-D produced by different
genotypes impacts on the ability of the protein to bind to different mycobacterial strains
and whether the genotype has an effect on the ability of the protein to agglutinate different
mycobacterial strains.
6. Sequence approximately 500bp of the collagen-like region of the SP-Al and -A2 genes to
determine whether SNPs identified by Madan et. al. (2002) are present in our population.
7. Determine whether there are any novel polymorphisms within the collagen - like region
ofSP-Al or -A2 genes in our population.
8. From the sequence data determine which SNPs are polymorphic in our population and use
the selected SNPs to genotype TB patients and controls to be used in a case-control
association study.
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CHAPTER3
MATERIALS AND METHODS
Vision is the art of seeing things invisible to others.
Jonathon Swift
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A) MATERIALS
1. Buffers and Solutions
• 5x Tris-Borate-EDT A buffer (TBE)
54g Tris-HeL
27.5g Boric acid
20ml 0.5M EDT A (pH8.0)
Make up to IL with distilled water
• Ix TBE
200ml of 5x TBE made up to IL with distilled water
• TE buffer
I.2Ig Tris-Hel
0.372g EDTA
Add approximately 800ml distilled water and mix. Once dissolved adjust the pH to 8.0
with concentrated Hel and make up to a final volume of IOOOml.
Autoclave
• Ethidium Bromide stock solution
Ethidium bromide was dissolved in TE buffer to a final concentration of IOmg/ml
• 0.5MEDTA
93.06g EDTA.2H20
Approximately lag NaOH pellets
Add 400ml distilled water, adjust the pH to 8.0 using the NaOH pellets.
Make up to 500ml
Autoclave and store at room temperature
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• Organe G Gel loading dye
0.1% Orange G
20% Ficoll
10mM EOTA pH 7
Filter through a 0.22)..1.mfilter
• 4 x SOS Loading Buffer
60mM Tris-HCl
800mM Urea
30ml 10% SOS stock
12% Glycerol
O.lg Bromophenol blue
O.Olg OTT added to 250)..1.1of this 4 x loading buffer
• 5x SOS Electrophoresis Buffer
94g Glycine
15.1g Tris-HCl
50mlIO% SOS
Make up to 1L with distilled water
Store at 4°C. Warm to room temperature if precipitate forms. Dilute to a lx working solution.
• Ix Western Blot Transfer Buffer
3.03g Tris-HCl
14.4g Glycine
200ml Methanol
Make up to IL with distilled water
The pH should be between 8.1 and 8.4, if it is <8.0 re-make the buffer.
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• Maltose-Agarose Column Wash Buffer
20mM Tris-HCl, pH 7.4
10mM CaCh
0.02% Sodium Azide
1M NaCI
Store at 4°C
• Maltose-Agarose Column Equilibration Buffer
20mM Tris-HCl, pH 7.4
10mM CaCb
0.02% Sodium Azide
Store at 4°C
• SP-D Column Elution Buffer
20mM Tris-HCl, pH 7.4
100mMMnCb
Store at 4°C
• Sodium Carbonate Coating Buffer
15mMNa2C03
35mMNaHC03
pH 9.6
• Coomassie Brilliant Blue R250 Stain
0.5g Brilliant Blue R250
90ml methanol
90ml distilled water
20ml CH3COOH
• Protein gel destain
200ml CH3COOH
600ml methanol
1.2L distilled water
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• 40mM Sodium Thiosulphate
496.37mg dissolved in 50ml distilled water
• Superose 6 Wash Buffer
20mM Tris-HCl, pH 7.4
0.5M EDT A, pH 8.3
5MNaCI
1ml 25% Tween 20
Filter with a 0.2).!m filter and degas
• Dialysis Buffer
3.45g Na2HP04
24gNaCI
0.6g KCI
0.6g KH2P04
30ml 0.5M EDT A
Make up to 3L with distilled water
• Superose 6 Equilibration and Running Buffer
See dialysis buffer
• Acrylamide/bis-Acrylamide 40% stock solution mixture (19: 1 Ratio)
63ml of distilled water is added to the powdered mixture provided (Sigma, Catalogue
number A-2917) and dissolved.
Filter and store between 2°C and 8°C.
• Middlebrook 7H9 broth
4.7g Middlebrook 7H9 broth
0.5g Tween 80 per litre
Make up to 900ml with distilled water
Autoclave
Once autoclaved ADC supplement (Merck, Darmstadt, Germany) is added to make up to 1
litre
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• Carbo I-Fuchsin Stain
lag Basic fuchsin (pararosaniline chloride)
50g Phenol
IOuml Absolute ethanol
Make up to 1 litre with distilled water.
• 5% Acid-Alcohol
5ml HCI
95ml 95% ethanol
• Methylene Blue
0.3% Methylene Blue in distilled water
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2. Gels for electrophoresis
• 6% SOS Polyacrylamide gel
2ml Acrylamide/bis-Acrylamide (19: 1)
5.3ml distilled water
2.5ml I.5M Tris-HeI pH 8.8
100fll 10% APS
8fll TEMEO
100fll 10% SOS
• 8% SOS Polyacrylamide gel
2.7ml Acrylamide/bis-Acrylamide (19:1)
4.6ml distilled water
2.5ml I.5M Tris-HeI pH 8.8
100fll APS
6fll TEMEO
IOOfll 10% SOS
• 3.75% Stacking Gel
625fll Acrylamide/bis-Acrylamide (19: 1)
3.7ml distilled water
625fll 1M Tris-HCl pH 6.8
50fll 10% APS
4fll TEMEO
50fll 10% SOS
• 10% non-denaturing polyacrylamide gel
3ml 40% Acrylamide/bis-Acrylamide (19: 1)
2.4m15x TBE
120fll APS
I2fll TEMEO
6.5ml distilled water
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• Agarose Gels
1% w/v to 2% w/v were made up with Ix TBE electrophoresis buffer
3. Oligonucleotide Primers
All primers (Tables 3.1 and 3.2) used in this study were synthesised in the Synthetic DNA
Laboratory at the University of Cape Town, South Africa using a Beckman Oligo IOOOM
DNA Synthesizer.
TABLE 3.1: Primers used for SP-A 1 and -A2 sequencing and genotyping reactions.
Primer Name Orientation Seguence 5' ~ 3' r,COC)* Location
SP-Al Gene
SP-AIFF Sense ACT CCA TGA CTG ACC ACC TT 60 Intron A
Specific SP-AIRR Antisense ATG TCG AAG GCC AAG GCT AA 60 Intron EPrimers
SP-Al nested SP-AIFnest Sense GAT GGG CTC ACG GCC ATC CC 68 Intron A
primers for
seguencina:; SP-A IRnest Antisense GAA AA GAGA CAT GGA TGT 70 Intron BGTA GGA T
SP-Al Gene SP-A2FF Sense ATC ACT GAC TGT GAG AGG GT 60 Intron I
specific
primers SP-A2RR Antisense TCC ATC TCA TGC CAA AGG CC 62 Exon 6
SP-Al nested SP-A2Fn Sense CCT TTT CAG GAG GCC CAT CT 62 Intron 3
primers for
seguencina:; SP-A2Rn Antisense ACC TGC AGG GTT TGT CTG A 58 Intron 4
Genotl:ping SP-A2alleleC Sense GGA CTT CAG TCT GCA GCGC 62 Intron 3cissac 1382
SP-A2alleleG Sense GGA CTT CAG TCT GCA GCGG 62 Intron 31382
SP-A2Rn Antisense ACC TGC AGG GTT TGT eTG A 58 Intron 4
SP-A2F Sense TeC AGG eTG TGG GCC CTA T 62 Intron 1
Genotl:pina:; SP-A2alleleC Antisense TGG AGG GCC TCT CTC GCC 74 Exon 4Gl64ge 1649 GGG
SP-A2alleleG Antisense TGG AGG GCC TCT eTC GCC 74 Exon 41649 GGC
SP-A2Fn Sense CCT TTT CAG GAG GCC CAT CT 62 Intron 3
SP-A2R Antisense CGC ATT CAC CCT TCA GAe TGC 66 Intron 4
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Genoll::l!inl:; SP-A2alleleA Antisense TGC CCA TGT TIC CAC TGT CC 62 Intron 4
SP-A21691 1691
SP-A2alleleG
Antisense TGC CCA TGT TIC CAC TGT CT 60 Intron 4
1691
SP-A2Fn Sense CCT TTT CAG GAG GCC CAT CT 62 Intron 3
SP-A2R Antisense CGC ATI CAC CCT TCA GAC TGC 66 Intron 4
TABLE 3.2: Primers used for SP-D sequencing and genotyping reactions.
Primer Name Orientation Seguence (5' ~ 3') r,(OC)* Locationin Gene
Seguencinl:; SP-DFN-term Sense TTG GAT TCC TGC TGC TCT AG 60 Intron I
SP-D N-
terminal
Region SP-DRN-term Antisense TGG TGG AGC AGT GTG GAA CT 62 Intron 2
Seguencinl:; SP-DneckF Sense CTG TGT CAG TAG ATG TGG GCT 64 Intron 6
SP-D neck
Rel:;ion SP-DneckR Antisense AGA CCC AGG GCA GCT CTG CCT 70 Intron 7
Seguencinl:; SP-DproF Sense CTG GGC AGT GCT GGT GAG AC 66 Promoter
SP-D
I!romoter
Rel:;ion SP-DproR Antisense CCC ATG CCT CCT AGA CCA GA 64 Intron I
Genotïl!inl:; SP-D2F Sense CTG GAA GCA GAA ATG AAG AC 58 Exon I
SP-DH
SNP SP-D2R Antisense ACC AGG GTG CAA GCA CTG CG 66 Exon 1
*Theoretical Tm= 4 (G + C) + 2 (A + T)
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B) METHODS
1. Patients and Controls
This study was conducted in the Western Cape Province of South Africa where the incidence
ofTB is greater than 500 per 100 000 population per year (Department of National Health and
Population Development).
Two classes of TB patients were used for this study: active and previous TB patients. All
active TB patients had clinical as well as microbiological evidence of TB. The group of
previous TB patients had received anti-TB therapy in the past, but at the time of sampling
there were no clinical symptoms of TB. The control group consisted of apparently healthy
people with no history of TB, living in the same high incidence community. Some of the
controls were Mantoux skin tested but this was not done routinely. It is assumed that, because
of the high incidence of TB in the community, the majority of the controls would have been
exposed to TB. All cases and controls used in the various studies were 15 years old or older.
The TB patients and controls were from the same community and from the same ethnic group,
known in the Western Cape as Coloured. Ethical approval was obtained for these studies from
the Stellenbosch University Institutional Review Board.
2. Genomic DNA Isolation
Genomic DNA was isolated using the Nucleon BACC3 Kit for blood and cell cultures
(Amersham Biosciences, Buckinghamshire, UK) according to manufacturer's instructions.
The isolated DNA was reconstituted with TE buffer and stored at -80°C until required. The
purified samples were diluted to a final concentration of 100ng/f..d with autoclaved distilled
water and used as templates in PCR.
3. Control for Contamination
Throughout the project care was taken (especially when performing the nested PCR reactions
required for the SP-A 1 and -A2 sequencing and genotyping) to control for contamination
during PCR amplification by including water blanks in every batch of samples that was
amplified. In addition to this precaution the DNA and PCR mixture was made up and
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aliquotted in a designated DNA laboratory in which there were no amplicons. The PCR
amplicons were opened for electrophoresis in an amplicon specific laboratory, so that no
amplicons would come into contact with the DNA samples used in PCR reactions.
4. Genotyping the SP-DU SNP
DNA was extracted from approximately 7ml of blood using the Nucleon BACC3 DNA
extraction kit (Amersham Biosciences, Buckinghamshire, UK) according to manufacturer's
instructions and genotyped as follows.
4.1. peR Amplification
PCR reactions and oligonucleotide primers used were according to DiAngelo et al. (l999)
(DiAngelo et aI., 1999). PCR reactions were carried out in a total volume of 50~1, containing
100ng of genomic DNA, 5~1 enzyme buffer (lOx) provided by manufacturer, 4~1 dNTPs
(1.25mM stock) (Bioline, New Jersey, USA), 1.5~1 of both forward and reverse primers
(l O~M stock), 2~1 MgCh (25mM stock) and 1U HotStarTaq DNA Polymerase (Qiagen). An
Eppendorf Mastercycler Gradient PCR Machine (Eppendorf, Hamburg, Germany) was used
and a touchdown PCR program was employed in order to increase the specificity of the
reaction. Amplification was started by activating the HotStarTaq DNA Polymerase (Qiagen)
at 95°C for 15 minutes, thereafter amplification was performed for 5 cycles of 95°C for 30
seconds, 62°C for 45 seconds and noc for 30 seconds, decreasing the melting temperature by
1°C every cycle until the optimum melting temperature (57°C) was reached. After 5 cycles
the reaction was carried out for a further 35 cycles of 95°C for 30 seconds, 57°C for 30
seconds and noc for 30 seconds. After the last cycle the samples were incubated at noc for
5 minutes.
4.2. Polyacrylamide Gel Electrophoresis and Genotyping
The PCR amplified products (59bp) were subjected to restriction endonuclease digestion
using Fspl (New England Biolabs, Beverly, MA, USA). The digestions were carried out in a
total volume of 5~1, containing 2~1 of PCR amplified product, 0.5~1 enzyme buffer (lOx)
provided by manufacturer, and 1U Fspl enzyme. The samples were digested at 37°C
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overnight and electrophoretically fractionated in 10% non-denaturing Polyacrylamide (PA)
gels at 120 volts for approximately 1 hour in Ix TBE buffer, and silver stained. The expected
restriction products were 40bp, 19bp and 59bp.
4.3. Silver Staining
Silver staining was carried out according to Bassam et al. (1991). Briefly, the PA gel was
placed in 7.5% CH3COOH for 10 minutes at 37°C in order to fix the DNA in the gel. The gel
was then rinsed in distilled water three times for two minutes. Thereafter the gel was stained
with 0.1% AgN03 containing 7511137% formaldehyde for 10 minutes at 37°C. The gel was
then rinsed briefly with distilled water, (approximately 10 seconds) and then developed with
an ice cold solution of 3% Na2C03 containing 7511137% formaldehyde and 1011140mM
sodium thiosulfate at room temperature. Once the bands had developed sufficiently the
Na2C03 was poured off and cold 7.5% CH3COOH was poured onto the gel in order to stop
the reaction. The gels were sealed in plastic sleeves to serve as a permanent record. The
CH3COOH solution, AgN03 and water were all heated to 37°C at the start of electrophoresis.
5. Sequencing the Amino Terminal, Neck and Promoter Regions of the SP-D Gene
In order to determine whether there were novel polymorphisms present in our population,
portions of the amino terminal, neck and promoter regions were sequenced. These regions of
the SP-D gene were amplified, purified and sequenced in the following manner. PCR
reactions were carried out in a total volume of 25111,containing 2.5111of enzyme buffer (lOx)
(supplied with Taq Polymerase), 2111of dinucleotide triphosphates (dNTPs) (2.5mM stock)
(Bioline, New Jersey, USA) and I.5U of the specified Taq Polymerase. PCR profiles for the
individual reactions are shown in Table 3.3. For sequencing the amino terminal and neck
regions, Prom ega Taq (Promega, Madison, WI) was used and for the promoter region,
Supertherm Gold DNA Polymerase (Southern Cross Biotechnology) was used. An Eppendorf
Thermal Cycler Gradient (Eppendorf, Hamburg, Germany) PCR machine was used. The
concentration of each primer was always 0.3IlM, and the product sizes were 490bp (amino
terminal region), 351 bp (neck region) and 590bp (promoter region).
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TABLE 3.3: PCR profiles for sequencing portions of the SP-D gene.
Primer Set MgCh To (0C) Time TM(0C) Time TE (0C)
Time Cycles
(mM) (sec) (sec) (sec)
SP-DFN-
term 2 94 30 61 30 72 45 30SP-DRN-
term
SP-DneckF
SP-DneckR 3 94 30 66.5 30 72 60
35
SP-DproF
SP-DproR 1.5 94 30 62 45 72 30
25
(To - denaturation temperature; TM- melting temperature; TE - extension temperature)
An initial denaturation step of 95°C for 5 minutes was used for the amino terminal and neck
region PCRs but for the promoter region an initial denaturation of 95°C for 10 minutes was
needed, and in each case there was a final extension time of 7 minutes at 72°C. These
products were purified using the Wizard SV Gel and PCR Clean-up System (Promega,
Madison, WI) according to the manufacturers' instructions.
5.1. Sequencing of the peR Products
Sequencing was performed using an ABI Prism 3100 Avant Genetic Analyzer (Applied
Biosystems, Foster City, CA, USA) in the Department of Medical Biochemistry at the
University of Stellenbosch. The sequence data was analysed using the Basic Local Alignment
Search Tool (BLAST) software which is found on the National Centre for Biotechnology
Information (NCBI) website (www.ncbi.nlm.nih.gov).
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6. Partial Purification of SP-D from serum
6.1. Sample Collection
Blood samples were obtained from healthy adult volunteers in the Department of Medical
Biochemistry, University of Stellenbosch. Approximately 20ml of blood was collected, 10mi
was collected in a VACUT AINER® tube with EDTA (BO Vacutainer Systems, Plymouth,
UK) and two 5ml VACUTAINER® tubes without EDTA of blood were collected in which
the blood was allowed to clot at room temperature. As much serum as possible was removed
from the clotted blood and centrifuged at 14 OOOrpm in an Eppendorf Centrifuge 5417C
(Eppendorf, Hamburg, Germany). After centrifugation the serum was transferred to clean
tubes and stored at -80DC until required. The EDTA blood samples were allowed to stand so
that the plasma could separate. Two ml of plasma was removed, and centrifuged at 14 OOOrpm
in an Eppendorf Centrifuge 5417C (Eppendorf, Hamburg, Germany) in order to pellet any red
blood cells still present. The centrifuged plasma was transferred to a clean tube and frozen at
-80DC until required. The blood remaining in the EDT A tube was transferred to a 50ml
Sterilin Centrifuge tube (Bibby Sterilin Ltd, Staffs, UK) and stored at -20DC until the DNA
was extracted using the Nucleon BACC3 DNA extraction kit (Amersham Biosciences,
Buckinghamshire, UK) according to manufacturer's instructions. The DNA was used to
genotype the individuals with respect to SP-Dil (Method described in section 4). The serum
was partially purified by affinity column chromatography during a visit to the MRC
Immunochemistry Unit, Department of Biochemistry, University of Oxford in Professor Ken
Reid's lab under the supervision of Mr. Paul Townsend.
6.2. Purification of SP-D using Affinity column Chromatography
Serum samples were dialysed in phosphate buffered saline (PBS), 5mM EDT A overnight at
4DC. The column used to purify the SP-D was a Superose 6 HR 10/30 column and a guard
column was also used which was Iml Superdex 200 HP resin. The serum was filtered through
a 0.22)-lm syringe filter before placing on the column. The column was equilibrated with 1.5
column volumes of Superose 6 equilibration buffer that had been filtered and degassed. In
order to clean the loading loop 2.5ml of 20% ethanol was injected and thereafter 2.5ml PBS,
5mM EDT A. Once the column had equilibrated the filtered serum was injected into the
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loading loop and onto the column. Approximately 70 fractions were collected (0,5ml volume)
into LP3 tubes. The fractions were stored at 4°C or at -20°C for long-term storage. These
fractions were used in the ELISA assay (Described in section 7 of this Chapter) to
investigate the molecular forms of SP-D present in the serum of individuals having the
different SP-D Il genotypes.
7. ELISA Assay
The ELISA assay was based on a sandwich method using two polyclonal antibodies. The
antibodies were rabbit anti-human SP-D IgG (primary (I") antibody) and biotinylated rabbit
anti-human SP-D IgG (secondary (2°) antibody). Both antibodies and recombinant SP-D
(rSP-D) were a donation from Professor Ken Reid of the University of Oxford. The microtitre
plates (Nunc Immuno plate, F96, Maxisorp) were coated with 100f.l1of 1° antibody (lug/ml
in sodium carbonate coating buffer) at 4°C overnight. After washing three times with 200f.l1of
PBS containing 0.05% Tween 20 (PBST), the wells were incubated with 150f.l1of 3% (w/v)
bovine serum albumin (BSA) in PBST at 37°C for two hours. Thereafter, the wells were
washed three times with PBST and 100f.l1 of sample was added to the wells including a
positive control consisting of 500ng of rSP-D and a blank consisting of 100f.l1 of 3%
BSAIPBST, and incubated overnight at 4°C. After washing three times with PBST, 100f.l1of
2° antibody (1 ug/rnl in 3% BSAIPBST) was added to each well and incubated for two hours
at 37°C. The plates were washed again three times and 100f.l1 of streptavidin peroxidase
conjugate diluted 1:10 000 with 3% BSAlPBST, was added to each well and incubated at
37°C for 30 minutes. After washing three times with PBST for the last time, 100f.l1 of
TMBlHydrogen peroxide (Bio-Rad Laboratories, Hercules, CA, USA) was added to each well
and left at room temperature for 15 minutes for the colour reaction to develop. The reaction
was terminated by adding 100f.l1of 0.5M sulphuric acid to each well and the absorbance was
measured at 450nm on a Benchmark Microplate Reader using Microplate Manager Software
both from Bio-Rad Laboratories, Hercules, CA, USA. The data was exported to Microsoft
Excel and analysed.
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8. Purification of SP-D from bronchoalveolar lavage fluid
8.1. Affinity Chromatography
The principle of affinity chromatography is based on separating proteins using a biospecific
method in which the particular biological property of the protein is exploited. In this case
maltose is a ligand for SP-Do Because lectin-receptor interactions are very specific and often
unique to the protein of interest, use of this method often yields highly purified proteins with
a minimal number of purification steps (Coligan et aI., 1996)
8.2. Lectin Affinity Chromatography
A protein is bound to an immobilised lectin through its sugar chain and the unbound proteins
are washed away. The protein of interest is then eluted with the correct buffer (Coligan et aI.,
1996).
8.3. Purification of SP-D
Patients who were undergoing bronchoscopy were asked to be part of this study for which
ethical approval was obtained and a patient information and consent form had to be completed
(Appendix 1 - 3). Native human SP-D was purified from bronchoalveolar lavage fluid
(BALF), from patients who had given consent to take part in the study, by modifications of
previously described methods (Jounblat et aI., 2004; Leth-Larsen et aI., 1999; Madan et aI.,
1997). The BALF was centrifuged at 2000 x g at 4°C for 10 minutes in an Eppendorf
Centrifuge 5810R (Eppendorf, Hamburg, Germany). The supernatant was transferred to a
clean tube and frozen at -20°C until required. Frozen BALF was thawed at 4°C and was made
10mM with respect to EDT A. The solution was recalcified by the addition of CaCh to a 5mM
excess of calcium over the amount of EDTA and the pH was adjusted to 7.4 with sodium
hydroxide. Maltose-agarose (Sigma, Missouri, USA) was packed into a column and washed
with the maltose-agarose wash solution. Thereafter the column was equilibrated with maltose-
agarose equilibration buffer. The recalcified BALF was applied to the maltose-agarose
column. Once the BALF had passed through the column it was washed as before and the SP-
D was eluted with SP-D elution buffer. The above purification was carried out at 4°C. The
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purified SP-O was judged to be the correct product by SOS-PAGE (Coomassie blue stained)
and Western Blotting (Method described in section 9 of this Chapter).
When the BALF was collected approximately 10 - 15ml of venous blood was collected from
the same individual in VACUT AINER® tubes containing EDT A (BO Vacutainer Systems,
Plymouth, UK) in order to extract DNA using the Nucleon BACC3 DNA extraction kit
(Amersham Biosciences, Buckinghamshire, UK) according to manufacturer's instructions.
The DNA was used to determine the SP-DIl genotype (Method described in section 4 of
this Chapter). The concentration of DNA was determined using the NanoOrop® NO-lOOO
Spectrophotometer and the NanoOrop v3.O.1 Software (Inqaba Biotechnology, Pretoria,
Gauteng, RSA).
9. Western Blotting
9.1. Sample Preparation
A 4x SOS loading buffer was used to denature the samples. 2.5f.l1 of the 4x SOS loading
buffer was added to IOf.l1of sample and was heated at 95°C for 5 minutes to denature the
protein before being loaded onto the gel.
9.2. Polyacrylamide Gel Electrophoresis and Western Transfer
A 6% SOS - PA gel was poured, overlayed with water-saturated butanol, and allowed to set
for an hour. Once the gel had set, the water-saturated butanol was poured off and the gel was
rinsed thoroughly with distilled water. The glass plates were blotted dry with blotting paper
and the 3.75% stacking gel was poured on top of the already set gel. The combs were inserted
and the gel allowed to set for an hour. The combs were removed, the denatured samples
loaded and the gel electrophoresed at 150 volts in SOS electrophoresis buffer for one hour. A
prestained protein ladder -IO-I60kOa (MBI Fermentas, Inqaba Biotectnology, Pretoria,
Gauteng, RSA) was used to judge when the gel had electrophoresed far enough. Once
electrophoresis was complete the gel was placed in western blot transfer buffer and allowed to
equilibrate. After 5 minutes in transfer buffer the gel dimensions were measured and two
pieces of Hybond™ Blotting Paper (Amersham Biosciences, Buckinghamshire, UK) were cut
to the correct size, and at the same time the membrane (Hybond™-P, Amersham Biosciences,
Buckinghamshire, UK) was also cut to the size of the gel. The membrane was placed into
54
Stellenbosch University http://scholar.sun.ac.za
100% Methanol for approximately 10 seconds until it changed colour (white to grey) and then
it was equilibrated in transfer buffer for 15 minutes. The blotting paper and the filter pads for
the Mini Trans-Blot® Cell (Bio-Rad Laboratories, Hercules, CA, USA) were also soaked in
the transfer buffer for 15 minutes. After equilibration had taken place the blotting apparatus
was assembled, the tank filled with western blot transfer buffer and transfer took place at 150
volts for one hour. When transfer was complete the membrane was placed in blocking buffer
(2% BSA/PBST) and left overnight at 4°C.
9.3. Protein Detection
The membrane was washed three times in PBST, the first and last wash for five minutes and
the second wash for 10 minutes at room temperature. The membrane was then incubated with
2° antibody (biotinylated rabbit anti-human SP-D IgG) diluted I:2000 with blocking solution
(2% BSAlPBST), for one hour at 37°C. After this was complete the membrane was washed as
before with PBST and incubated with Streptavidin peroxidase conjugate (Sigma, Missouri,
USA), diluted 1:10000 with blocking buffer (2% BSAIPBST), at 37°C for 30 minutes. The
membrane was then washed for the last time as previously with PBST. In the dark room the
western blotting ECL reagents (Amersham Biosciences, Buckinghamshire, UK) were mixed
together in the ratio I: I and the membrane was placed, protein side down, into the mix for a
few seconds and then placed, protein side up, into a light proof cassette (Hypercassette™,
Amersham Biosciences, Buckinghamshire, UK) lined with cling wrap. The cling wrap was
folded over the membrane and the film placed on top. The film was exposed for the desired
amount of time (lO seconds to 10 minutes) and then developed using the Hyperprocessor
(Amershem pharmacia biotechnology, Buckinghamshire, UK). The exposure was repeated
with greater or less time of exposure if necessary.
9.4. Staining with Coomassie Brilliant Blue R-250
Once western transfer had taken place the gel was placed in approximately 100ml Coomassie
Brilliant blue R-250 stain (See page 40) in order to check the efficiency of transfer. The
following morning the gel was destained in the Protein Gel Destain solution (See page 40) to
check that transfer was efficient. Coomassie Brilliant Blue R-250 binds non-specifically to
almost all proteins allowing detection of protein bands in PA gels. Proteins that have been
separated in PA gels are simultaneously fixed and stained in the Coomassie Brilliant Blue R-
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250 staining solution, turning the entire gel blue. Destaining eliminates the background colour
while the protein bands remain blue.
10. Ziehl-Neelsen (ZN) Staining for mycobacteria
The ZN stain was used In order to detect the presence of mycobacteria in a sample.
Approximately 50J.ll of ZN fixing solution (purchased from the NHLS, Greenpoint, Western
Cape, South Africa) was placed on a microscope slide (Labstar 1000 microscope slides, LASEC,
Cape Town, South Africa) and approximately 50J.ll of bacterial culture was mixed with this.
Thereafter the slide was placed on a 100°C heating block for two hours to dry and kill the
bacteria. Once the sample had dried the slide was flooded with carbol-fuchsin stain. The slide
was heated intermittently with a flame until steam came off the surface. It was important to
ensure that the stain did not boil or that the sample did not dry out. The stain was left on the slide
for 7 - 10 minutes. The slide was rinsed with tap water in order to remove most of the stain,
flooded with 5% acid-alcohol (see page 42) in order to remove the remaining carbol-fuchsin stain
(see page 42), and rinsed with tap water again. The sample was counter-stained with methylene-
blue (see page 42) and left for 5 minutes. The slide was rinsed again with tap water and blotted
dry. The sample was examined using an Olympus BX41 phase contrast microscope using the oil
immersion objective (lOOx magnification). Under the microscope the mycobacteria appeared as
red/pink stained rods (Figure 3.1).
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FIGURE3.1: ZN staining of mycobacteria, appearing as pink/red rods (40x magnification).
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11. Growth of mycobacteria
Three strains of mycobacteria were grown up in the Department of Medical Biochemistry,
University of Stellenbosch Medical School, Tygerberg, South Africa for use in the
agglutination assays. Culturing of mycobacteria was carried out in a P3 facility by Ms. Rabia
Johnson, Department of Medical Biochemistry, Stellenbosch Medical School, Tygerberg,
South Africa. H37Rv ATC 27294 was obtained from Ms. Amor Venter, Department of
Medical Biochemistry, University of Stellenbosch Medical School, Tygerberg, South Africa,
the Beijing/W-like R433, found in 72 clinics in the Boland/Overberg South Cape/Karoo
Region, was obtained from the National Health Laboratory Services (NHLS, Greenpoint,
Western Cape, South Africa) and Family 11 SAWC 1925 was obtained from Prof. Robin
Warren, Department of Medical Biochemistry, University of Stellenbosch Medical School,
Tygerberg, South Africa. The two clinical isolates (Beijing/W-Iike R433 and Family 11) were
cultured on Lowenstein-Jensen (LJ) slants. A scrape was taken from the LJ slants and placed
in 5ml of 7H9 broth containing ADC (Merck, Darmstadt, Germany) as a supplement. A 1:5
dilution was made of an H37Rv liquid culture in 7H9 broth containing ADC (Merck,
Darmstadt, Germany) as a supplement. These initial cultures were grown to an OD6oo of 0.8
(approximately two weeks). A ZN stain (see above) was performed on these initial cultures in
order to determine whether there was any contamination, and a drop of culture was placed on
a blood agar plate (obtained from the NHLS). The blood agar plates were checked after two
days for any growth. Growth on the blood agar plate at this stage indicated that the culture
was contaminated with a mycobacterium other than tuberculosis (MOTT) and the initial
culture was set up again. MOTTs are mycobacteria that can cause opportunistic infections and
do not belong to the M tuberculosis complex. MOTT bacteria include M avium complex, M
kansasii, M marinum, M scrofulaceum and M ulcerans. These bacteria are able to grow on
blood agar plates but this is usually seen only after two weeks incubation of the blood agar
plate.
Once the initial culture was judged to be pure a 10ml starter culture was set up by making a
1:10 dilution of the initial culture in 7H9 broth containing ADC (Merck, Darmstadt,
Germany) as a supplement. This starter culture was again allowed to grow to an OD6oo of 0.8.
Once this growth has been attained, a ZN stain was once again performed on the culture and a
blood agar plate was set up to determine whether or not the culture was contaminated.
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Once the cultures had been shown to be pure the agglutination assay (see below) was carried
out on the individual samples.
12. SP-D Agglutination Assay
The agglutination assay was carried out by modifications of previously described methods
(Jounblat et aI., 2004; Ferguson et aI., 1999). SP-D purified (method described in Section 9
of this Chapter) from BALF of individuals with a known SP-DIl genotype (CC, CT and IT)
was used to determine whether the different genotypes agglutinated mycobacterial species
more or less efficiently. Bacterial cultures were grown up according to Section 11 of this
Chapter.
Purified SP-D was added at a concentration of lOug/ml to a final volume of 50j.!1 of
mycobacterial culture and placed at room temperature for one hour to allow the SP-D to
agglutinate the bacteria. At the same time a control experiment was set up in which no SP-D
was added to the bacteria which was also allowed to stand at room temperature for an hour.
Once the SP-D had been allowed to agglutinate the bacteria a ZN stain (method described in
Section 10 of this Chapter) was used to assess the extent of agglutination.
13. Analysis of the Collagen-like Region of the SP-Al and -A2 genes
A nested PCR reaction was carried out for both SP-A I and -A2 in order to obtain smaller
fragments for sequencing, as the SP-A genes are more than 80% homologous making primer
design difficult. The first round of amplification amplified the entire SP-AI or -A2 genes and
the second round amplified smaller fragments (approximately 500bp) which were sent for
sequencing to determine whether the SNPs identified by Madan et al. (2002) or others were
found, and to detect any novel SNPs present in our population.
13.1. SP-Al and -A2 Gene Amplification
PCR reactions were carried out in a total volume of 25111containing lOOng genomic DNA,
2.51l1enzyme buffer (lOx) provided by the manufacturer, 2111dNTPs (2.5mM stock) (Bioline,
New Jersey, USA), 0.2j.!M of each primer and I.5U ExSel High Fidelity Taq DNA
polymerase (Southern Cross Biotechnology). The PCR profiles are shown in Table 3.4.
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TABLE 3.4: PCR conditions for amplification of the SP-A 1 and -A2 genes.
Primer MgCb
ToCC)
Time TM (0C) Time TECC)
Time Cycles
Set (mM) (sec) (sec) (sec)
SP-AIFF
SP- 2 94 60 60 60 72 180 35
AIRR
SP-A2FF
SP- 2 94 60 61 60 72 120 30
A2RR
(To - denaturation temperature; TM- melting temperature; TE - extension temperature)
A Gene Amp" 9700 PCR Machine (Applied Biosystems, Foster City, CA, USA) was used to
carry out the reactions, with an initial denaturing step of 95°C for 5 minutes and a final
extension at 72°C for 7 minutes. The products were purified using the Wizard SV Gel and
PCR Clean-up System (Promega, Madison, WI) according to the manufactufrer's instructions.
The expected size of the SP-A 1 gene product was 3124bp and the SP-A2 product 3150bp.
13.2. Nested peR Reactions
The whole gene products that were generated in the first round of amplification were diluted
1:50 with milliQ water and used as the templates for the nested reactions. Nested PCR
reactions were carried out in a total volume of 25Jll, containing 1Jll of the diluted purified
gene product, 2.5JlI of the enzyme buffer (lOx) provided by the manufacturer, 2Jll dNTPs
(2.5mM stock, Bioline, New Jersey, USA), O.3JlM of both the sense and antisense primers
and I.5U of Supertherm Gold Taq DNA Polymerase (Southern Cross Biotechnology). The
peR profiles are shown in Table 3.5.
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TABLE 3.5: PCR conditions for the nested reactions required for sequencing.
Primer Set MgCb To (0C) Time TM(0C) Time TE (0C) Time Cycles(mM) (sec) (sec) (sec)
SP-AIFn 1.5 94 30 70 45 n 30 30
SP-AIRn
SP-A2Fn 1.5 94 30 61 45 n 30 30SP-A2Rn
(To - denaturation temperature; TM- melting temperature; TE - extension temperature)
A Gene Amp" 9700 PCR Machine (Applied Biosystems, Foster City, CA, USA) was used to
carry out the reactions. An initial denaturation step was carried out at 95°C for 10 minutes and
a final extension of noc for 5 minutes. The PCR products were purified using the Wizard SV
Gel and PCR Clean-Up System (Promega, Madison, WI) according to the manufacturer's
instructions and sent for sequencing. The expected size of the SP-Al nested product was
530bp and the SP-A2 nested product 480bp.
13.3. Sequencing of the peR Products
The collagen-like regions of SP-A 1 and -A2 were sequenced using an ABI Prism 3100 Avant
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). The sequence data was
analysed using the Basic Local Alignment Search tool (BLAST) software which is found on
the National Centre for Biotechnology Information (NCB!) website (www.ncbi.nlm.nih.gov).
14. Amplification-Refractory Mutation System (ARMS)
In order to genotype the SNPs present in the SP-A genes an ARMS method was used
(Brightwell et aI., 2002; Newton et aI., 1989). This method is based on using sequence
specific PCR primers that will amplify only the target allele. An internal control primer is also
added to the reaction mixture that amplifies in every case in order to confirm that the PCR is
working. The allele specific primers were designed such that the last base at the 3' end was
complementary to the SNP and therefore would only amplify should the particular allele be
present in the sample. In order to make the allele specific primers more refractory to incorrect
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amplification an additional mutation of a single nucleotide was made three bases from the 3' end
of the primers. Therefore if there is no amplification of a specific allele band it can be concluded
that allele is not present provided that the internal control band has amplified. For each sample
two reaction tubes are set up with each tube containing a different allele specific primer. Figure
3.2 explains the ARMS method. This is a simple method for genotyping SNPs as it only requires
one round of amplification and electrophoresis in an agarose gel.
Genomic DNA
5' 3'
Allele Specific
Primers
Internal
Control
A
GInternal Control
Forward Primer
j PCR reaction andelectrophoresis
b)a) c)
Expected results observed after electrophoresis of samples. a) an AA homozygote, b) an AG heterozygote and c) a
GG homozygote.
FIGURE 3.2: Diagrammatic representation of the ARMS PCR and the products obtained in
genotyping reactions.
15. Genotyping SNPs in the SP-Al and -A2 genes
SNPs in the collagen-like regions of SP-A I and -A2 were genotyped using the ARMS method
described in section 12. The PCR profiles for genotyping are shown in Table 3.6. PCR reactions
were carried out in a total volume of 25~1 containing 2.5~1 of enzyme buffer (lOx) provided by
the manufacturer, 2~1 of dNTPs (2.5mM stock) (Bioline, New Jersey, USA) and 1.5U of
Supertherm Gold Taq Polymerase (Southern Cross Biotechnology). The concentration of primers
used in each individual genotyping reaction is shown in Table 3.7.
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TABLE 3.6: Primers and PCR conditions used to genotype SNPs in the SP-A 1 and -A2 genes.
Primer Set MgCh To Time TM Time TE
Time Cycles(mM) (0C) (sec) (0C) (sec) (0C) (sec)
SP-A 1alleleC
1193
SP-A 1aile leG 2 94 30 67 45 72 45 301193
SP-AIFn
SP-AIRn
SP-A2alleleC
1382
SP-A2alleleG 1.5 94 45 61.5 45 72 45 30
1382
SP-A2Rn
SP-A2F
SP-A2alleleC
1649
SP-A2alleleG 1.5 94 30 61 45 72 30 301649
SP-A2Fn
SP-A2R
SP-A2alleleA
1691
SP-A2alleleG 1.5 94 30 61 45 72 45 301691
SP-A2Fn
SP-A2R
(To - denaturation temperature; TM- melting temperature; TE - extension temperature)
In each reaction an intital denaturation step of 95°C for 10 minutes was carried out and a final
extension at 72°C for 7 minutes. An Eppendorf MastereyeIer Gradient Machine (Eppendorf,
Hamburg, Germany) was used to amplify the SP-A2 SNPs and a Gene Amp" 9700 PCR
Machine (Applied Biosystems, Foster City, CA, USA) was used for the SP-Al SNP.
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TABLE3.7: Concentration of primers used in the SP-A genotyping reactions.
Allele Forward/ Internal Control
Allele Internal Control
SNP Specific Reverse Primer Specific ProductPrimer Primer Product
SP-Al
1.4f.1M 0.6f.1M
0.04j.lM 347bp 530bpCII93G (SP-AIRn) (SP-AIFn)
SP-A2
1.2j.lM
0.6j.lM 0.04j.lM 404bp 1249bpC1382G (SP-A2Rn) (SP-A2F)
SP-A2
0.8f.1M
0.8j.lM O.4j.lM
383bp 716bpGl649C (SP-A2Fn) (SP-A2R)
SP-A2
0.8j.lM
0.6j.lM 0.08j.lM
432bp 716bpGI69IA (SP-A2Fn) (SP-A2R)
16. Examining the efficiency of amplification
In order to determine the efficiency of amplification as well as to genotype the SP-Al and -
A2 SNPs, the PCR products were electrophoresed in the appropriate percentage TBE agarose
gel containing 0.5j.lg/ml ethidium bromide (Table 3.8). The products were visualised under
ultra violet (UV) light using the Kodak Digital Science Electrophoresis Documentation and
Analysis System 120.
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TABLE 3.8: Percentage agarose gels used in for different PCR products for this work.
PCR Product Percentage Agarose
SP-D Amino Terminal Region 2%
SP-D Neck Region 2%
SP-D Promoter Region 2%
SP-D 11 PCR Product 2%
SP-Al Gene 1%
SP-A2 Gene 1%
SP-A 1 Nested Products 1.5%
SP-A2 Nested Products 1.5%
SP-Al 1193 CIG 1.5%
SP-A2 1382 CIG 1.5%
SP-A2 1649 CIG 1.5%
SP-A2 1691 AlG 1.5%
17. Statistical Analysis
17.1. Hardy-Weinberg Equilibrium
The Hardy-Weinberg Equilibrium (HWE) relates allele frequencies to the genotype
frequencies in a randomly mating population. The law is an application of the following
binomial equation: I= p2+ 2pq + p2, where pand q are the proportions of alleles pand q. The
proportions of the homozygotes pp and qq, and the heterozygotes, pq are represented by p2, q2
and 2pq respectively (Crow, 2001; Mange and Mange, 1990).
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This equation (1 = p2+ 2pq + p2) is used to calculate the expected genotype frequencies from
the known allele frequencies. Therefore, to calculate the expected number of pp genotypes,
the equation p2 x n, would be used, where p refers to the allele frequency of allele p, and n is
the total number of samples in that population (i.e. the control population or the TB
population). Similarly, to calculate the expected number of heterozygotes, the equation 2pq x
n would be used, where p is the allele frequency of the p allele and q the allele frequency of
the q allele. The equation to calculate the expected number of qq homozygotes would
therefore be q2 x n. Once the expected values have been calculated the X2 is calculated by
using the equation X2= 2:(observed number - expected numberjvexpected number. This value
(X2) must be less than 3.84 for the population not to be significantly out of HWE. The sample
sizes for the genotyping of the SP-A SNPs were chosen in order to provide 95% confidence
and 80% power to detect an allele resulting in an odds ratio of 1.7 or higher.
17.2. Association of Genotype with Cases or Controls
2 x 3 contingency tables were drawn up to determine whether there was a significant
difference in the distribution of genotypes between cases and controls, and 2 x 2 contingency
tables were drawn up to determine if there was a significant difference in the distribution of
alleles between cases and controls and a X2test was performed. Epi-Info 2000 version 1.1 was
used to calculate these values for the SP-Al and -A2 genotyping. The X2 statistic was
accepted as showing a significant difference in genotype or allele distribution when the
probability (p) of chance variation was <0.05. As mentioned in the Introduction (Section
1.3.2a) there are numerous tests to correct for multiple testing. In this study the stringent
Bonferroni test was used to correct p-values obtained for SP-A SNPs. In this test the p-value
of each SNP is multiplied by the number of SNPs that have been studied in that gene.
17.3. Association ofSP-D serum levels and TB
GraphPad Prism 4.01 was used to determine whether there was a significant association
between the levels of SP-D present in serum and the disease status of individuals or their SP-
DIl genotype.
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In order to compare data from two independent groups such as the serum SP-D concentration
and the SP-DIl genotype there is a non-parametric alternative to the t test, known as the
Mann-Whitney test (Altman, 1991).
When there are three or more independent groups of observations it is better to use a test that
enables one to examine all the data sets at one time. This method is known as a one-way
analysis of variance (ANOVA) (Altman, 1991). The Kruskall-Wallis test is a non-parametric
one-way ANOV A and was used to calculate whether there were significant differences
between the SP-D present in the serum from individuals with different disease states, as this
involves more than two groups of data.
17.4. Haplotyping
Haplotypes were constructed using the SP-A2 SNP genotype data with PHASE version 2.1
(Stephens et aI., 2001). PHASE uses a Bayesian statistical method to reconstruct haplotypes
from population genotype data. The software is able to construct haplotypes from SNP,
microsatellite or other multi-allelic loci data in any combination. The programme is also able
to deal with missing data and will construct the most likely haplotype using the allele
frequency observed in the population. The PHASE programme was obtained from the Internet
at the following address http://www.stat.washington.edu/stephens/software.html.
17.5. Linkage Disequilibrium Analysis
Linkage disequilibrium (LD) analysis was performed using LDMAX within the Graphical
Overview of Linkage Disequilibrium (GOLD) software package (Abecasis and Cookson,
2000). This package is available on the Internet at http://www.well.ox.ac.uklasthma/GOLD.
This programme provides a graphical summary of LD, and allows for the use of case-control
as well as family data. A disequilibrium coefficient (D'), p-value and the X2 statistic are
calculated. All cases and controls that were genotyped with respect to the three
polymorphisms in the SP-A2 gene were used in the analysis.
Various statistical measures can be used to summarize LD between two markers (Hedrick,
1987; Devlin and Risch, 1995), but only two are widely used: D' and ~. Both these statistics
are based on the basic pairwise-disequilibrium coefficient, D, being the difference between
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the probability of observing two marker alleles on the same haplotype and observing them
independently in the population. 0' is favoured in medical genetics and has the scale 0 to 1. A
value of 0 implies independence and a value of 1 means that all copies of the rare allele occur
exclusively with one of the two possible alleles at the other marker i.e. total LD. Estimates of
0' are heavily influenced by the sample size. r2 (also denoted as ~2) is in some ways·
complementary to 0', and is thought of as the measure of choice for quantifying and
comparing LO in the context of mapping (Weiss and Clark, 2002; Frisse et aI., 2001). This
measure is the correlation of alleles at the two sites. If r2 equals 1 this is an indication that the
markers have not been separated by recombination and have the same allele frequency.
LOMAX gives a p-value when a LD analysis is performed. The p-value depends strongly on
the sample size and cannot be used to compare LO between studies with different sample
sizes. A statistically significant result can be obtained even when there are low levels if LO if
the sample size is sufficiently large (Ardlie et aI., 2002).
In this study the 0' statistic was used as an indication of whether there was LO between
markers or not. 0' values that were >0.5 were considered to indicate positive LO between
SNPs.
17.6. Analysis of Family Data and the TDT test
The TOT was conducted in order to control for any possible population stratification or other
environmental factors that may have affected the population based case-control association
study that was performed previously. Spielman et al. (1993) introduced this test and it tests
for linkage where an association already exists. It tests for the unequal transmission of alleles
from heterozygous parents to affected offspring and does not produce a spurious association
due to population stratification (Ewens and Spielman, 1995). The program TRANSMIT 2.5.2
(Clayton, 1999) was used in this study and it compares the observed and expected rates of
transmission of marker alleles from parents to offspring. This programme is available at
www.hgmp.mrc.ac.uk.
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CHAPTER4
TRANSMISSION DISEQUILIBRIUM TEST
Obstacles are those frightful things you see when you take your eyes off your goal.
Henry Ford
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1. INTRODUCTION
Previously a single nucleotide polymorphism (SNP) within the amino terminal region of the sp-
D gene (at amino acid residue 11) was found, in a case-control association study, to be associated
with susceptibility to TB in a South African Coloured population (p = 0.008, T. Lundwall-Roos,
unpublished data). This SNP resulted in an amino acid transition from a threonine (C allele) to a
methionine (T allele), and in our population we found that the T allele was associated with
susceptibility to TB. Population based case-control association studies can produce false positive
results due to population stratification and environmental factors. Spielman et al. (1993) devised
a family-based statistical test for linkage called the transmission disequilibrium test (TDT) that
focuses on linkage between a specific marker and disease allele (Spielman et aI., 1993; Spielman
and Ewens, 1996). Originally the TDT was intended to test for linkage with a marker located near
a candidate gene, in cases where disease association had already been detected between the
specific marker and the disease status, however, if there is no prior evidence of association the
TDT test is still a valid test for linkage. The TDT therefore measures linkage in the presence of
association (Spielman et aI., 1993; Spielman and Ewens, 1998). The test uses parental data, not
unrelated controls, and therefore eliminates population stratification as an explanation for
association (Ewens and Spielman, 1995). Families used in a TDT study can be simplex families
(affected child and two parents) or multiplex families (having two parents and multiple affected
children). The affected status of the parents does not influence the TDT analysis. There are few
limitations to this test as there are many extensions to the test allowing for the evaluation of
multiple alleles and multiple linked loci. The TRANSMIT programme version 2.5
(www.hgmp.mrc.ac.uk) was used in this analysis and is able to analyse incomplete families i.e.
missing parental information can be assessed (Clayton, 1999).
In this study 135 families from the Ravensmead and Uitsig areas of Cape Town, Western Cape,
South Africa were used. The families used in this analysis were both simplex and multiplex
families; however in some families, genotype data was only available from one parent. In these
cases unaffected siblings of the affected child were genotyped in order for the programme to
estimate a parental genotype, for the missing parent(s).
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2. RESULTS
Family members were genotyped with respect to the SP-DIl SNP as described in Chapter 3,
section 4. The TRANSMIT programme was used to determine whether a particular allele was
preferentially transmitted to affected children. Table 4.1 shows the results obtained for four
different scenarios. Two analyses were conducted in each case: the first using the robust
estimator which includes all families, and the second using only one 'affected sibling randomly
selected by TRANSMIT.
In the first analysis all families were used, i.e. families having both parents, families with only
one parent as well as related families. Related families usually consisted of the affected child, or
a sibling, who had subsequently become a parent of another affected child. In other cases,
members of different families were half-sibs of each other. No association was found with the
SP-DIl T allele and TB susceptibility using either the robust estimator or when there was only
one affected sibling per family selected. In the second scenario, related families were excluded
and again there was no association found between a specific allele and TB susceptibility. In the
third and fourth scenarios we wished to determine whether the results varied between families
having both parents available and families with only one parent available. In both scenarios
related families were excluded. When families having two parents were analysed and only one
affected sibling was used there was a borderline significant excess in transmission of the T allele
to affected individuals (p = 0.047). In the fourth scenario families that had only one parent were
analysed and related families were again excluded as mentioned above. The results show that
there were fewer T alleles transmitted to affected siblings (p = 0.033 using the robust estimator).
When the analysis was repeated using only one affected sibling there were again fewer
transmissions of the T allele to affected siblings than expected (p-value = 0.038). This contradicts
the results in the third scenario and could be an indication the there is not sufficient statistical
power to detect the expected association.
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TABLE 4.1: TDT association of SP-DIl with TB.
Affected
sibs used Allele Observed Ex(!ected Chi sguare (!-value
n
1. All Families
All siblings 214 C 180 171 2.00 0.157
T 248 257
One per family 135 C 111 110 0.02 0.890
T 159 159
2. Related families excluded*
All siblings 172 C 147 139 1.56 0.212
T 197 205
One per family 114 C 93 92 0.08 0.777
T 135 136
3. Families having two (!arents, related families excluded*
All siblings 82 C 64 65 0.05 0.828
T 100 99
One per family 60 C 40 48 3.95 0.047
T 80 73
4. Families having only one (!arent, related families excluded*
All siblings 102 C 99 90 4.57 0.033
T 105 114
One per family 60 C 60 53 4.31 0.038
T 60 67
* In certain families, a member was related to a member of another family, either as a half
sibling, or where a sibling was a parent in another family. These families were designated related
families.
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3. DISCUSSION
The results of this study show that in the first two scenarios neither the C nor T allele was
observed at a level that was significantly different to what was expected, implying that SP-D may
not be associated with susceptibility to TB in the South African Coloured population. The fact
that a non-significant result was obtained does not necessarily mean that the result of the case-
control association study was due to population stratification as a TDT test does not have the
same statistical power as a case-control association study (Morton and Collins, 1998). In scenario
three the T allele appeared to be preferentially transmitted to affected siblings supporting the
case-control association study in which the T allele was found associated with susceptibility to
TB. The association in the TDT was found only in families with two parents and related families
excluded (scenario three in Table 4.1). This result contrasts with that of scenario four in which
there were fewer T alleles transmitted to affected siblings than expected. Out of the four
scenarios the analysis that one would expect to give the most accurate result would be that of
scenario three where related families are excluded, and families having two parents available for
genotyping are used, i.e. TRANSMIT is not relied upon to estimate the genotype of the missing
parent. This is the TDT sample that also produces a result which agreed with the previous case-
control association test, when one child per family was chosen randomly by the TRANSMIT
programme.
The different result obtained in scenario four in Table 4.1 could indicate that the study did not
have the power to detect the association previously observed in the case-control association
study, and possibly if a larger number of families were investigated the association would be
detected. It would be advisable to repeat the case-control association study using a new sample
set to determine whether the first association detected was due to chance or was a real
association. However it is always possible that the case-control association study was a false
positive result and there is no association between the T allele and disease.
In a case-control association study in a Mexican population, Floros et. al. (2000) found that the C
allele was associated with TB, but only when the active TB cases (n = 107) were compared with
skin-test positive controls (n = 71). When the same cases were compared with general controls
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i.e. a group of healthy individuals whose skin-test status was unknown (n = 101), no association
was detected (Floros et al., 2000). Due to the numbers involved, the above association studies
had less power than ours.
All the above confounding results indicate that SP-D is likely to be involved in susceptibility to
TB, but the dissection of the actual polymorphism involved is complex, and may be different in
populations with different histories.
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CHAPTER5
SEQUENCING OF THEAMINO TERMINAL, NECK AND
PROXIMAL PROMOTER REGIONS OF THE SP-D GENE
Not everything that can be counted counts, and not everything that counts can be counted.
Albert Einstein
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1. INTRODUCTION
A single nucleotide polymorphism (SNP) within the amino terminal region of SP-D involving a
threonine ---+ methionine amino acid change has been associated with susceptibility to TB as well
as with susceptibility to respiratory syncitial virus (RSV) (Floros et aI., 2000; Lahti et aI., 2002).
This polymorphism was also associated with TB in the South African Coloured population of the
Western Cape (T. Lundwall-Roos, unpublished data). However, the allele over represented in the
TB population was methionine in the Western Cape, but threonine in the Mexican population
(Floros et aI., 2000). It is possible for associations to differ between populations, with different
genetic history. It may also be that this polymorphism is in linkage disequilibrium (LD) with the
causative polymorphism.
Nine SNPs in total have been reported in the SP-D gene, including the SNP at amino acid 11.
There are two other reported SNPs in the amino terminal region of the SP-D gene, located at
amino acid positions 25 and 26, neither involving an amino acid change. Two SNPs are located
in the collagen-like region, one at amino acid residue 160 in exon 4 involving an alanine ---+
threonine amino acid change, and one in exon 2, which does not involve an amino acid change.
The SNP at amino acid residue 160 in exon 4 was studied by Floros et al. (2000) as well as by
our group and was not associated with susceptibility to TB in either population (Floros et aI.,
2000). There are four other SNPs present in the carbohydrate recognition domain (CRD). Lahti et
al. (2002) identified a SNP at amino acid position 270 involving a serine ---+ threonine amino acid
change, but this was not associated with susceptibility to RSV (Lahti et aI., 2002). This SNP has
not been investigated in a study involving pulmonary TB. No SNPs have been reported in the
neck region or the promoter of SP-D and since only three SNPs have been identified in the amino
terminal region, which is important in the overall assembly of the SP-D molecule, we
investigated whether there were any novel SNPs within these regions of the gene.
The regions of SP-D that were selected were amplified using standard PCR, purified and
sequenced (Chapter 3, section 5). The sequence data obtained was analysed using BLAST on
the NCB! website (www.ncbi.nlm.nih.gov) in order to determine whether there were any novel
polymorphisms within our population.
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2. RESULTS
2.1. Sequencing of the Amino Terminal Region
The whole of the first translated exon (exon 1) that encodes the amino terminal region of the SP-
D gene was sequenced. Samples from a total of 26 individuals were sequenced (13 TB patients
and 13 controls) and no novel polymorphisms were identified in our population. In the SNP
database on the NCB I web site three SNPs have been reported; one being the SNP at amino acid
position 11 (SP-DIl) which has been previously investigated and found to be associated with TB
in our population. There are two other SNPs described at amino acid positions 25 and 26. Neither
involves an amino acid change and were not detected in our population.
2.2. Sequencing of the Neck Region
The entire neck region (exon 7) of the SP-D gene (351 bp) was sequenced. A total of23 samples
(10 TB patients and 13 controls) were sequenced and revealed no novel polymorphisms. It
appears that this region is highly conserved, as there are no SNPs reported in the SNP database.
The neck region of SP-D is vital in the trimerisation of the CRD, and a polymorphism in this
region could cause inefficient or lack of trimerisation of SP-D monomers into trimers and
subsequently dodecamers.
2.3. Sequencing of the Proximal Promoter Region
A 42Ibp fragment located upstream of the first untranslated exon, the untranslated exon (39bp)
and the first 130bp of intron 1 were sequenced in a total of 12 samples (6 TB patients and 6
controls) in order to detect any novel polymorphisms. This fragment included the AP-I site,
TATA Box and E Box motifs, as well as 2 glucocorticoid response element (GRE ~) sites and 4
CCAAT/enhancer-binding protein (CIEBP) binding elements (Brown-Augsburger et al., 1996;
He et al., 2000; He and Crouch, 2002). A reported SNP present in the first intron was not
polymorphic in our population. From the sequences obtained no novel polymorphisms were
identified.
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3. DISCUSSION
In this investigation the amino terminal, neck and proximal promoter regions of SP-D were
sequenced to identify novel polymorphisms within our population. It was decided to perform
direct sequencing in order to discover the actual polymorphism in the first pass screening. These
regions all play important roles in the molecular assembly and function of the SP-D molecule.
The amino terminal region was investigated due to its importance in the overall assembly of SP-
D (See Chapter 1, section 1.8) and because Floros et. al. (2000) as well as our group (T
Lundwall-Roos, unpublished data) found a SNP within this region to be associated with
susceptibility to TB. However on further investigation we were unable to identify any new
polymorphisms. Similarly, no novel polymorphisms were found in the neck region.
In the present study only the proximal promoter region that included the first untranslated exon
was investigated. No polymorphisms within the promoter region have been reported in the
literature and we were not able to identify any in this investigation. A large portion of the
promoter was not sequenced and it is not known whether there are enhancer elements further
upstream that could have an effect on the transcription of SP-Do Promoter polymorphisms have
been associated with numerous diseases and have also been linked to phenotypes. Yamada et al.
(2001) investigated a SNP in the promoter region of interleukin 3 (IL- 3) and showed a significant
association (p = 0.002) with susceptibility to rheumatoid arthritis (RA) (Yamada et al., 2001).
Heesen et al. (2003) investigated two polymorphisms within the tumor necrosis factor alpha
(TNF-a) promoter region to determine whether they were in LD and if either had an influence on
the TNF-a response. This group demonstrated that the two polymorphisms were in LD and that
heterozygosity for both was associated with an increased TNF-a response (Heesen et al., 2003).
These and other results (Minagawa et al., 2002; Nakayama et al., 2000) show that promoter
polymorphisms do play important roles in diseases however not all promoter polymorphisms
influence disease outcomes or associations (Spurdle et al., 2000; Khoo et al., 2004). For these
reasons it is important to study the promoter in more depth to gain further insights into the
regulation of SP-D secretion.
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One of the reasons for no polymorphisms being detected is probably the small sample size used
in this study. Only 26 (13 TB patients and 13 controls) and 23 (10 TB patients and 13 controls)
individuals were screened for the amino terminal and neck regions respectively, and we would
therefore expect only alleles with a frequency of at least 7% to be detected. Similarly in the case
of the proximal promoter region (6 TB patients and 6 controls) only alleles having a frequency of
at least 16% would be detected. Therefore this was not a conclusive study and there is a
possibility that a rare allele within the TB cases may not have been detected.
Neither the collagen-like region nor the CRD were sequenced. A polymorphism in the collagen-
like region of the SP-D gene could disrupt the Gly-X- Y repeat of this region leading to an
interruption of the cruciform structure of SP-Do It is possible that if the collagen-like region is
influenced by an amino acid changing polymorphism it could lead to incorrect assembly of the
protein and even interfere with SP-D secretion thereby possibly altering the host defence
properties. The CRD needs to be investigated further because of its role in pathogen binding. A
polymorphism within this region that disrupts the binding sites of the pathogens could result in an
individual with heightened susceptibility to disease.
The intronic regions were not investigated. Polymorphisms in the intronic regions of genes could
alter splice sites as well as protein translation and therefore these regions should not be
overlooked.
Once polymorphisms have been identified and associated with a certain disease it is important to
investigate the SNP further in order to determine whether it has an impact on the overall structure
and function of the protein such as with the SP-DIl polymorphism that has been associated with
TB in two populations and associated with susceptibility to RSV (Floros et al., 2000; Lahti et al.,
2002) (T. Lundwall-Roos, unpublished data). It is not known whether this SNP has an influence
on the overall structure of the SP-D molecule and should be investigated further.
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CHAPTER6
THE IMPACT OF SP-D It o» THE OVERALL STRUCTURE
AND SERUM LEVELS OF SP-D
Science is organized knowledge. Wisdom is organized life.
Immanuel Kant (1724 - 1804)
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1. INTRODUCTION
The impact of polymorphisms on the overall structure of proteins is important to confirm
especially when the polymorphism has been associated with disease susceptibility. The sp-
D11 polymorphism discussed in Chapters 4 and 5 may affect the overall structure of the Sl'-
D molecule because of its position within the amino terminal region of the gene. There is no
report in the literature linking a polymorphism in the SP-D gene to SP-D structure or protein
concentration. In this investigation we tried to determine whether SP-DIl had an impact on
the overall structure of the SP-D molecule and whether it affected serum levels ofSP-D.
2. RESULTS
2.1. Impact of SP-DH on the structure of SP-D
A sandwich ELISA was used to detect differences in the molecular forms of SP-D within the
different genotypic categories of the polymorphism at SP-DIl (See Chapter 3 section 7).
Serum was purified through the Superose 6 HR 10/30 column and the fractions were used to
detect the presence of SP-D (See Chapter 3 section 6.2). Figures 6.1 - 6.3 show the results
for the three genotypic groups. Each line on the graphs represents a different individual. The
results show that there are a number of different molecular forms of SP-D present in the
serum of all individuals. It was expected that the SP-D astral bodies would be eluted first,
approximately within the first 10 fractions, thereafter the dodecamers would follow up to
approximately fraction 20. Up to about fraction 30 one would expect the trimeric SP-D to be
eluted and then the monomeric SP-Do However, no clear consistency could be seen between
the column profiles of serum from individuals with the same genotype.
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FIGURE 6.1: Profiles of individuals having a CC genotype (n = 5).
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FIGURE 6.2: Profiles of individuals having a CT genotype (n = 7).
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Comparison of profiles for TT genotypes
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FIGURE 6.3: Profiles of individuals having a TT genotype (n = 7).
2.2. Measurement of SP-D in serum
The concentration of SP-D in serum was measured using the same sandwich ELISA as above
(See Chapter 3 section 7). SP-D concentration was measured in active TB patients,
confirmed previous TB patients i.e. patients who had recovered from TB and were healthy at
the time of sampling, and controls. A total of 115 active TB patients, 32 confirmed previous
TB patients and 164 control individuals were analysed (Figure 6.4). The results showed that
the level of SP-D in the active TB group was significantly higher when compared to either the
controls or the previous TB group (p < 0.0001, Mann-Whitney Test). There was no statistical
difference between the control group and the previous TB group (p = 0.216, Mann-Whitney
Test).
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FIGURE 6.4: SP-D concentration (ng/ml) in the different disease states. Active TB Cases;
Previous TB Cases and Controls. N is the total number of individuals in each diagnosis
category.
These groups were further subdivided according to SP-DIl genotype (Figure 6.5). The
results showed that within the active TB group, individuals with a TT genotype had
significantly higher SP-D serum levels than those with a CC genotype (CC vs TT; p < 0.0001,
Mann- Whitney Test), while individuals with a CT genotype had intermediate levels. There
are no significant differences within the previous TB or control groups with respect to
genotype.
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FIGURE 6.5: SP-D concentration (ng/ml) in the different diagnosis groups according to SP-
DIl genotype. Concentration (ng/ml) is on the Y axis with Diagnosis on the X axis.
Diagnosis 1 - Active TB Cases; Diagnosis 2 - Previous TB Cases and Diagnosis 6 -
Controls. N is the number of individuals in each genotypic category.
3. DISCUSSION
The results obtained give no indication whether individuals having a TT genotype produce
altered molecular forms of SP-Do We hypothesised that since the SNP is located near two
highly conserved cysteine residues that are important in the trimerisation of monomeric SP-D,
it may interfere with correct assembly of the trimeric and hence the dodecameric structures of
SP-Do The threonine ~ methionine amino acid change is also a significant one in that
threonine is a hydrophilic amino acid and methionine is hydrophobic and the amino terminal
region of SP-D is predominantly hydrophilic which may also influence the overall assembly
of SP-Do However, serum is a notoriously complex material and it is possible that the column
could not efficiently separate the different forms of SP-D and therefore the technology is not
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sensitive enough to detect the different forms of SP-D, an alternate method should be
investigated in the future.
Levels of SP-D have been measured in broncho alveolar lavage fluid (BALF) and serum of
patients with a variety of pulmonary diseases, including TB. SP-D was found to be decreased
in the BALF of patients with idiopathic pulmonary fibrosis (IPF) and interstitial pneumonia
with collagen vascular disease (IPCD) compared to controls, however the serum
concentration of SP-D was found to be significantly increased in pulmonary alveolar
proteinosis (PAP) patients compared to controls (Nagae et aI., 1997; Honda et aI., 1995;
Kuroki et aI., 1998). Greene et al. (1999) have suggested that a major epithelial injury is
required in patients with respiratory distress syndrome (RDS) before the SP-A and D
concentrations increase significantly in serum (Greene et aI., 1999). These results seem to
indicate that serum SP-D concentration increase is due to spillover of the protein into the
circulation because of the destruction of the barrier between the alveolar epithelium and
endothelium. Thus when this barrier is destroyed surfactant proteins that are produced by
alveolar type II cells may leak into the bloodstream and appear at elevated concentrations in
the serum of patients with severe lung damage (Honda et aI., 1995; Kuroki et aI., 1998).
Kondo et al. (1998) investigated levels of serum SP-D in patients with TB (Kondo et aI.,
1998). They found that SP-D levels in patients with active pulmonary TB (smear and/or
culture positive) were significantly higher than in the healthy controls (p<0.05) and levels of
SP-D were significantly higher in patients with cavity formation than in those without
(p<0.05). There was a significant positive correlation between the serum SP-D level and the
number of tubercle bacilli in the sputum (r = 0.416, P = 0.0017) as well as with the C-reactive
protein (CRP) (a measure of the acute phase response) level (r = 0.383, P = 0.003). They
concluded that the level of SP-D in serum might be a useful indicator of the disease activity in
pulmonary TB. In our study we confirmed these results by also showing that the levels of SP-
D in active TB patients were significantly higher (p < 0.0001) than controls.
The acute phase response (APR) is a manifestation of the innate immune response. It is an
early set of inflammatory reactions, which are induced by infection or tissue injury, and
pattern recognition molecules initiate these responses. The APR results in fever, leukocytosis,
changes in vascular permeability, increases in metabolic responses and enhances non-specific
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host defenses (Suffredini et aI., 1999; Baumann and Gauldie, 1994). Acute phase protein
concentrations increase rapidly after infection and their production is primarily controlled by
IL-6 and IL-l type cytokines and provide enhanced protection against pathogens and are able
to modify inflammatory responses by effecting trafficking and mediator release. The
concentrations of these acute phase proteins return to normal once the infection has been
contained. MBL, a pattern recognition molecule, is involved in modulating the hepatic APR
and by binding to microbial cell wall saccharides it activates complement, promotes
phagocytosis and modulates CD-14 induced cytokine production. Conglutinin is also
recognised as an acute phase protein and has been implicated in various aspects of the
systemic response to microbial challenge. In the same way the surfactant proteins are pattern
recognition molecules and may be involved in a pulmonary APR as the levels of SP-D are
significantly elevated in individuals with active disease and inflammation, yet the levels
return approximately to those of the controls once the individuals have been cured.
CRP is an indicator of the APR. It was the first acute phase protein described and is an
extremely sensitive systemic marker of inflammation and tissue damage (Pepys and Baltz,
1983). Healthy adults have a median CRP concentration of O.8mg/l (Shine et aI., 1981), but
following an acute phase stimulus values of CRP can increase to more than 500mgll. The
CRP status for the individuals investigated in this study was not always known and if they
were known exact concentrations of CRP were not measured and only a yes/no status was
recorded. It would be worthwhile to investigate as Kondo et al. (1998) did whether there is a
positive correlation between the serum SP-D level and CRP level (Kondo et aI., 1998).
Furthermore it would be interesting to determine the extent of lung damage and cavity
formation present in individuals with active TB. Since it is thought that surfactant proteins
leak into the blood stream due to tissue damage it is possible that individuals with a greater
extent of lung damage have a higher concentration of SP-D in their serum. It may be possible
to correlate the extent of lung damage with the SP-Dll genotype, which may provide an
explanation as to why higher levels of SP-D are observed in patients with a TT genotype and
to a lesser extent those with a CT genotype. Patients with active TB and a TT genotype may
in fact be more susceptible to lung damage or experience a more severe infection and
inflammation leading to severe lung damage and therefore more surfactant proteins are able to
leak into the blood circulation.
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When we further subdivided the groups of patients and controls according to the SP-DIl
genotype we were able to show that the individuals with active TB and a TT genotype had
significantly higher serum SP-D levels than the CC genotypes in the same diagnosis category.
Individuals with a CT genotype demonstrated intermediate SP-D serum levels. This seems to
imply that it is the T allele that plays the most important role in determining the levels of SP-
D in the active TB group. It is possible that the T allele prevents formation of higher order
protein structures; the smaller SP-D structures may more effectively leak out into the serum
when APR sets in. Interestingly, the levels of SP-D seen in the previous TB group and the
controls are for the most part the same, with no significant difference between the two groups.
In a case-control association study we found that the T allele was associated with
susceptibility to TB (T. Lundwall-Roos, unpublished data) and it appears that it is this allele
that accounts for the higher levels of SP-D observed in the active TB group.
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CHAPTER 7
PURIFICATION OF SP-D FROM BRONCHO ALVEOLAR
LAVAGE FLUID
Having once decided to achieve a certain task, achieve it at all costs of tedium and distaste.
The gain in self-confidence of having accomplished a tiresome labour is immense.
Arnold Bennett
Stellenbosch University http://scholar.sun.ac.za
1. INTRODUCTION
The main function of SP-D is thought to be the agglutination of microorganisms, but the
degree of specificity or sensitivity involved with different bacterial strains or different SP-D
structures is unclear. Jounblat et al. (2004) investigated the binding and agglutination of
Streptococcus pneumoniae (S pneumoniae) by SP-D that had been isolated and purified from
broncho alveolar lavage fluid (BALF) (Jounblat et al., 2004). In these experiments different
serotypes were incubated with full length SP-D and it was found that SP-D aggregated some
serotypes more efficiently than others. Furthermore this group went on to incubate strains of
S pneumoniae which had different capsule types but in some cases had the same serotypes.
They found that SP-D induced the aggregation of several but not all of the strains and that the
extent of aggregation differed. It was observed that pneumococcal strains having the same
serotype showed differences in the amount of aggregation (Jounblat et al., 2004).
The lipopolysaccharides of mycobacteria lipoarabinomannan (LAM) and lipomannan (LM)
are important in host-pathogen interactions, with LAM being considered a mycobacterial
virulence factor. LAMs are thought to playa major role in immunopathogenesis of TB. They
regulate cytokine secretion (Sibley et al., 1988; Barnes et al., 1992; Roach et al., 1993; Zhang
et al., 1995; Gilleron et al., 1997; Yoshida and Koide, 1997; Nigou et al., 1997; Riedel and
Kaufmann, 1997), block the transcriptional activation of interferon gamma (IFN-y) (Riedel
and Kaufmann, 1997) and neutralise potentially cytotoxic oxygen free radicals (Chan et al.,
1991). LAMs are envelope molecules which are unique lipoglycans of the Mycobacterium
genus and are considered major mycobacterial antigens (Chatterjee and Khoo, 1998). LAM is
heavily expressed on the surface of M tuberculosis resembling a bacterial capsule (Hunter
and Brennan, 1990).
The LAM present on the cell wall of the virulent Erdman strain is heavily mannosylated
(manlAM) which is common amongst other pathogenic strains such as Mycobacterium
leprae and the vaccine strain Mycobacterium bovis BCG. Compared to this the attenuated
strain H37Ra has arabinofuranosyl-terminated LAM (aralAM) which does not have the
mannose caps. It has been shown that these different LAM molecules affect the immune
response differently. Moreno et al. (1989) showed that LAM is capable of inducing tumor
necrosis factor alpha (TNF-a) production and secretion from macrophages (Moreno et al.,
1989). TNF-a is rapidly induced in macrophages after exposure to M tuberculosis and
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Kindler et al. (1989) showed that the localised production of TNF-a at the sites of Mbovis
BCG infection was necessary for granuloma formation and subsequent bacterial containment
and clearance (Kindler et al., 1989). AralAM from the attenuated strain H37Ra was able to
dramatically increase the induction of TNF-a when compared to the manlAM from the
virulent Erdman strain. NF-KB is a critical component in regulating many genes central to
immune function including TNF-a. Brown et al. (1995) demonstrated that aralAM derived
from H37Ra is capable of rapid activation of NF-KB binding activity in bone marrow derived
macrophages and murine macrophage-like cell lines, whereas manlAM is less potent at
stimulating NF-KB (Brown and Taffet, 1995).
Another interesting comparison between aralAM and man LAM is that the binding of H37Ra
(posessing aralAM) to macrophages is mediated through complement receptors, but binding
of the virulent Erdman strain (posessing manlAM) to macrophages is mediated by both
complement receptors and mannose receptors. It has been speculated that the mode of uptake
by macrophages may affect the intracellular survival of the pathogen (Schlesinger, 1993) and
is therefore possible that different LAM structures may influence whether the bacteria grow
within the macrophage or are killed. Analysis has revealed that the virulent Erdman strain has
a significantly faster doubling time than H37Ra or Mbovis BCG (North and Izzo, 1993). This
suggests that the more mannosylated the LAM is the better the bacterium is able to evade the
host defence mechanisms and persist in the macrophage.
SP-D binds to the terminal mannosyl units of M tuberculosis LAM due to the fact that SP-D
is able to bind to mannose. Ferguson et al. (1999) investigated the binding of SP-D to the
avirulent Mycobacterium smegmatis (M smegmatis) and to the virulent Erdman strain of M
tuberculosis (Ferguson et al., 1999). This group found that SP-D binds minimally to the
avirulent M smegmatis. M smegmatis has aralAM which lacks the mannose capping as is
found in the avirulent H37Ra strain. AralAM is approximately 10% capped with inositol
phosphate (Khoo et al., 1995). This is believed to be another reason why M tuberculosis
LAM stimulates much less TNF-a production by macrophages than aralAM (Chatterjee et
al., 1992), and it is the mannose cap that mediates binding of LAM to the mannose receptor
(Schlesinger et al., 1994). It is possible that other carbohydrates present on the surface of M
tuberculosis may also participate in the binding of SP-Do Free, complex carbohydrates such as
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mannan, arabinomannan and glucan have been described on the surface of M tuberculosis
(Ortalo-Magne et al., 1995).
The marked differences between SP-D binding to pathogenic and non-pathogenic
mycobacteria may indicate that the host immune system has developed a mechanism to
distinguish virulent bacteria possessing unique carbohydrates on their surfaces, or conversely
pathogenic bacteria evade the immune function of SP-Do Until the exact function of SP-D is
known this will remain unclear.
To investigate this further, three strains of M tuberculosis were studied; the laboratory strain
H37Rv and two clinical isolates. The first isolate belonged to the Beijing/W-like family and
the second was a Family Il isolate. These two strains of M tuberculosis are highly prevalent
within the Western Cape communities of South Africa (Victor et aI., 2004; Streicher et aI.,
2004).
Our hypothesis therefore was that SP-D purified from individuals with different SP-DIl
genotypes shows variant forms that results in differential agglutination of mycobacterial
strains. In addition, a given SP-D form binds to a greater or lesser extent to different strains of
mycobacteria.
2. RESULTS
2.1. SP-DH Genotyping
Ethical approval was obtained in order to collect BALF samples from consenting volunteers
(Appendix 1 to 3). A total of nine BALF and blood samples were received. DNA was
extracted and genotyped for SP-DIl (See Chapter 3, section 4 for detailed methods). At least
one representative of each SP-DIl genotype (CC, CT, TT) was obtained (Figure 7.1).
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2 3 MM
FIGURE7.1: Restriction digestion products of SP-DIL M corresponds to the lObp standard
ladder (Promega, Madison, WI, USA) that was used to confirm that the correct restriction
products were obtained. ~ indicates IOObpand ~ indicates 50bp band. Lanes I - 3 contain
DNA from: 1 - TT homozygote (40bp), 2 - CT heterozygote (59bp, 40bp), 3 - CC
homozygote (59bp).
2.2. Purification of SP-D from BALF
Out of the nine samples received SP-D was successfully purified from four BALF samples
using a maltose-agarose affinity column (See Chapter 3, section 9 for detailed methods) and
used in the agglutination assays. Of these four samples there were two samples that had a CT
genotype, one sample with a CC genotype and one sample with a TT genotype. Western
blotting was used to confirm that the eluted protein from the affinity column was SP-D
(Figure 7.2) (See Chapter 3, section 8 for detailed methods).
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60kDa
50kDa
40kDa
25kDa
FIGURE 7.2: Autoradiograph of a BALF sample purified by affinity chromatography and
detected in a western blot to determine whether the protein purified was SP-D and of the
correct size. Lane A and B: Fractions collected by affinity chromatography containing
purified SP-Do A PageRuler™ Protein Ladder 200 - 10kDa (MBI Fermentas, Inqaba
Biotechnology, Pretoria, Gauteng, RSA), used to determine whether the purified SP-D was of
the correct size (approximately 43kDa). The protein ladder was graphically manipulated in
order make the bands more visible.
2.3. Agglutination Assay
The agglutination assay was carried out by modifications of the methods described by
Ferguson et al. (1999) and Jounblat et al. (2004) (Ferguson et al., 1999; Jounblat et al., 2004)
(See Chapter 3, section 12 for detailed methods). Three mycobacterial strains were studied;
H37Rv ATC 27294, Beijing/W-like R433 found in 72 clinics in the Boland/Overberg South
Cape/Karoo Region and an isolate from Family 11 SAWC 1925. The number of clumps was
counted in at least 20 fields of view using an Olympus BX41 phase contrast microscope. The
average area covered by a clump was estimated by estimating the average diameter of each
clump by visual observation. GraphPad Prism version 4.01 was used for statistical analysis.
Mycobacteria were identified as red/pink rods after Ziehl- Neelsen staining.
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In the analysis of the median number of clumps in H37Rv control (n = 20 fields of view
(FOV), median number of clumps = 4) versus after the addition of SP-DIl of a specific
genotype (Figure 7.3), there appears to be a significant difference between the groups (p <
0.0001, Kruskal-Wallis Test). Fewer clumps were observed in the CC genotype group (n = 18
FOV, median number of clumps = 1) compared to the control as well as in the CT (n = 40
FOV from two samples, median number of clumps = 3) and TT (n = 19 FOV, median number
of clumps = 2) groups. These preliminary results suggest that there is a difference in the sizes
of clumps between the different groups (p = 0.0073, Kruskal-Wallis Test). Median size of all
clumps was 0.49ll-lm2 (Figure 7.4). It does not appear that fewer clumps are observed in the
CC group because they represent larger clumps. The median size of clumps is in fact larger in
the TT and CT genotype groups and the median number is higher. Figures 7.5 to 7.9 show
examples of the clumping observed in the individual samples analysed.
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FIGURE 7.3. Number of clumps per field observed in H37Rv that was incubated with lOug/rnl
of SP-D from individuals with SP-DIl genotypes CC, CT or TT or without SP-D (control).
The horizontal bar indicates the median number of clumps within each category.
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Area of clumps inH37Rv
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FIGURE 7.4. Area of clumps (urrr') observed in H37Rv that was incubated with l Oug/ml of sp-
D with SP-DIl genotypes CC, CT or TT or without (control). The horizontal bar indicates the
median area of clumps in each category.
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FIGURE 7.5: H37Rv control i.e. no SP-D or any other agglutinating agent was added (lOOOx,
oil immersion).
FIGURE 7.6: H37Rv sample 1 agglutinated with SP-DIl CT genotype (lOOOx, oil immersion).
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FIGURE 7.7: H37Rv sample 2 agglutinated with SP-DIl CT genotype (lOOOx,oil
immersion).
FIGURE 7.8: H37Rv agglutinated with SP-DIl CC genotype (lOOOx,oil immersion).
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20lJm
FIGURE 7.9: H37Rv agglutinated with SP-DIl TT genotype (lOOOx,oil immersion).
2.3.2. BeijinglW -like strain
Control Beijing/W-like bacilli appeared dispersed with little clumping evident (Figure 7.10),
however this did not appear to change once SP-D was added to the bacteria (Figures 7.11 -
7.14). In the SP-D treated samples there were a few larger clumps observed compared to the
control sample however these clumps were very widely dispersed and one could not conclude
that the SP-D treated samples agglutinated the Beijing/W-like strain more efficiently than
when SP-D was not added. Overall there was little evidence of clumping in any of the
samples.
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FIGURE 7.10: Beijing/W-like control i.e. no SP-D or any other agglutinating agent was added
(1000x, oil immersion) .
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FIGURE 7.11: Beijing/W-like sample I agglutinated with SP-DIl CT genotype (1000x, oil
immersion).
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FIGURE 7.12: Beijing/W-like sample 2 agglutinated with SP-DIl CT genotype (lOOOx, oil
immersion).
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FIGURE 7.13: Beijing/W-like agglutinated with SP-DIl CC genotype (lOOOx,oil immersion).
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FIGURE 7.14: Beijing/W-like agglutinated with SP-DIl TT genotype (lOOOx,oil immersion).
2.3.3. Family 11
The slide showing agglutination of the second CT and TT samples was accidentally destroyed
before it could be read. More clumps were observed in the control group (n = 20 FOV,
median number = 2) compared to either of the experimental groups, CC and CT (n = 20,
median number of clumps = 1 and n = 20 FOV, median number of clumps = 1 respectively)
(p = 0.0064, Kruskal-Wallis Test) (Figure 7.15). This appears to coincide with the fact that
the median size of the clumps in the CC (n = 20 FOV, median size of clumps = 1.96Jlm2) and
CT (n = 20 FOV, median size of clumps = 1.96Jlm2) groups were larger than those observed
in the control group (n = 20 FOV, median size of clumps = 0.177Jlm2) (Figure 7.16) (p
<0.0001, Kruskal-Wallis Test). Figures 7.17 to 7.19 show the extent of clumping observed in
the individual experiments.
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FIGURE 7.15 Number of clumps observed in Family 11 that was incubated with lOug/ml of
SP-D with SP-DIl genotypes CC and CT or without (control). The horizontal bar indicates
the median number of clumps in each category.
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Area of clumps in Family 11
FIGURE 7.16 Area of clumps (urrr') observed in Family 11 that was incubated with l Oug/rnl
ofSP-D with SP-DIl genotypes CC and CT or without (control). The horizontal bar indicates
the median area of clumps in each category.
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FIGURE 7.17: Family 11 control i.e. no SP-D or any other agglutinating agent was added
(1000x, oil immersion).
o
FIGURE 7.18: Family 11 agglutinated with SP-DIl CT genotype (lOOOx,oil immersion).
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FIGURE 7.19: Family 11 agglutinated with SP-DIl CC genotype (1000x, oil immersion).
3. DISCUSSION
Only four different BAL samples were used in this study comprising at least one sample from
each SP-DIl genotype. The preliminary data from this pilot study suggests that SP-D
agglutinates mycobacteria differently depending on the strain investigated. The small sample
size precludes any definitive conclusions, but the following agglutination characteristics were
observed. In general, the Beijing/W-like SAWC1925 strain did not agglutinate notably, while
the Family 11 strain from the 72 clinics (Boland/Overberg South CapelKaroo Region) treated
with SP-D of SP-DIl genotypes CC or CT formed about half the number of clumps seen with
the untreated control, but these clumps covered an area about five times larger. No difference
was seen between SP-DIl genotypes CC and CT as regards agglutination. Similarly, the
laboratory strain H37Rv ATC 27294 formed fewer clumps in SP-DIl treated samples than in
controls, and these clumps were slightly larger in the CT and TT groups than in the control
and CC groups. The CC group produced fewer clumps per field than the CT and TT groups,
which in turn produced fewer than the untreated control group. The significance of the
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agglutination of mycobacteria to their future uptake and survival is not yet clear, but it is
interesting to note that both the Family Il strain from the 72 clinics (Boland/Overberg South
CapelKaroo Region) and the H37Rv ATC 27294 were agglutinated into fewer, but larger
clumps by SP-Do This pattern was also evident in the area covered by agglutinated
mycobacteria, Table 7.1, where, with the exception of the SP-DIl CC with H37Rv, the area of
agglutinated mycobacteria was larger with SP-D than in the untreated control mycobacteria.
TABLE 7.1: Total area (urn'') covered by agglutinated mycobacteria.
SP-DIl CC very low 114.49 14.25
Beijing/W-like R433 FIl SAWC 1925
Control very low 19.88 39.87
SP-DIl CT very low 117.61 64.24
SP-DIl TT very low no result 50.46
Differential patterns of agglutination by SP-D purified from individuals with different SP-
D Il genotypes will require larger numbers to confirm and expand the results. Preliminary
results indicate that CC individuals may produce smaller and fewer clumps than CT and TT
individuals. The reason for the lack of agglutination by any SP-D of the Beij ing/W -likeR443
strain is not known.
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CHAPTER8
POLYMORPHISMS WITHIN THE COLLAGEN-LIKE REGION
OF THE SP-Al AND SP-A2 GENES
The only man who never makes mistakes is the man who never does anything.
Theodore Roosevelt (26th President of The United States)
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1. INTRODUCTION
Polymorphisms within the SP-A genes have been investigated in numerous populations in
order to determine whether any allelic variants are associated with respiratory diseases such as
TB or not. Given that SP-A is important in the lung it is a good candidate gene for
investigating susceptibility to a variety of respiratory pathogens such as acute respiratory
distress syndrome (AROS), respiratory distress syndrome (ROS) and TB. Several
polymorphic sites have been identified within the SP-A 1 and -A2 genes. Certain SNPs within
the SP-A genes have been associated with diseases including ROS and chronic obstructive
pulmonary disease (COPD) and TB (Kala et al., 1998; Ramet et al., 2000; Guo et al., 2000;
Floros et aI., 2000). More recently Madan et al. (2002) reported novel polymorphisms within
the collagen-like region of SP-Al and -A2 and association with TB in an Indian population
(Madan et aI., 2002). This group also investigated some previously reported SNPs. Significant
associations were found with one SNP in intron B of SP-A 1 and with three SNPs in SP-A2,
one in intron 3 and two in exon 4, one of which involved an amino acid change. However,
this was a very small study and confirmation is required.
The collagen-like region of SP-A has been shown to be involved in receptor binding on
macrophages, surfactant regulation and secretion and lipid uptake by type II cells
(McCormack et aI., 1999). Due to the importance of the collagen-like region and the
associations found by Madan et al. (2002), we investigated these polymorphisms in a South
African population in order to determine firstly whether they were present in our population
and secondly whether any of them are associated with susceptibility to or protection against
TB. We also wished to determine whether there were any novel polymorphisms in our
population.
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2. RESULTS
2.1. SP-Al and -A2 Whole Gene Product Amplification.
The entire coding sequence of the SP-Al and -A2 genes were amplified (See Chapter 3,
section 13.1) and the products electrophoresed in a 1% agarose gel to validate the product
(Figure 8.1). These products were then purified and a nested PCR reaction was performed to
obtain smaller fragments.
4000bp __ ".
3000bp -----+
FIGURE 8.1: 1% agarose gel showing SP-Al and -A2 whole gene products generated in the
intial PCR amplification. Lane 1: lkb DNA Ladder (Promega, Madison, WI), Lane A: SP-Al
whole gene product (3l24bp), Lane B: SP-A2 whole gene product (3150bp).
2.2 SP-Al and -A2 Nested PCR Reactions
The whole gene products that were generated in the first round of amplification were diluted
1:50 with distilled water and used as the templates for a second round of amplification (See
Chapter 3, section 13.2). The products obtained were electrophoresed in a 1.5% agarose gel
in order to determine whether the correct products were amplified (Figure 8.2). These
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products were judged to be correct and were purified and sent for sequencing. Table 8.1
shows a summary of the SNPs that were investigated for this work.
100bp
SP-Al nested
products (530bp)
1000bp -- ....
500bp SP-A2 nested
products (480bp)
FIGURE 8.2: 1.5% agarose gel showing the SP-Al and -A2 PCR products obtained in the
nested PCR reactions. Lane 1: 100bp DNA Ladder (Promega, Madison, WI), Lanes A and B:
SP-Al nested products from two individuals, Lanes C and D: Nested SP-A2 products of two
different individuals.
TABLE 8.1: Summary of the SP-Al and -A2 SNPs investigated.
Gene Location Nucleotides Amino Acids
Position Change Position Change
SP-Al
Exon2 1162 CIT 39 His-His
Exon2 1193 CIG 50 Leu-Val
Intron B 1416 CIT - -
SP-A2
Intron 3 1382 CIG - -
Intron 3 1492 TIC - -
Exon4 1649 GIC 91 Ala-Pro
Exon4 1660 AlG 94 Arg-Arg
Intron 4 1691 GIA - -
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2.3 SP-Al Sequencing
A total of 16 samples (7 TB cases and 9 controls) were sequenced to determine whether the
three SNPs investigated by Madan et al. (2002) were present in our population and if so at
what frequencies. Table 8.2 shows the allele frequencies, in our South African population, of
the SP-AI SNPs reported by Madan et al. (2002). Of the three SNPs present, CI416T was not
polymorphic in our population. Madan et al. (2002) found this polymorphism to be
significantly associated with TB (p=0.0024) (Madan et aI., 2002). The other two
polymorphisms (C 1162T and C 1193G) were not found to be significantly associated with TB
in the Indian population. After sequencing CI193G was chosen for further investigation as it
appeared a more worthy candidate for further investigation.
TABLE8.2: Polymorphisms reported by Madan et al. (2002) in the collagen-like region ofSP-
A I and their allele frequencies in a South African population.
Pol_ymornhism Allele Frequencies (%}
Tuberculosis (n=7) Controls (n=9)
C1162T
C 93 83
T 7 17
C1193G
C 57 83
T 43 17
Cl416T
C 100 100
T 0 0
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2.3.1 Genotyping SP-Al C1193G
A total of 311 TB patients and 328 controls were genotyped with respect to this intronic SNP
using an Amplification-Refractory Mutation System (ARMS) technique explained in
Chapter 3 section 14 and 15. After amplification the PCR products were electrophoresed in
a 1.5% agarose gel in order to genotype the individuals. Figure 8.3 shows an example of an
agarose gel and an example of each genotype expected. Although the nested reactions
produced reasonably pure products (Figure 8.2), some non-specific priming occurred
resulting in non-specific bands, which did not affect accurate genotyping. At least 20 samples
of various genotype were validated by sequencing. Genotype and allele frequencies for this
SNP are shown in Table 8.3a and b. Statistical analysis showed that this SNP is not
significantly associated with TB susceptibility in our population and that the control groups
were in Hardy-Weinberg equilibrium .
.1
1000bp
500bp ~ 530bp Internal Control
+'-----Non-specific Band
~347bp Allele Specific
100bp --+
FIGURE 8.3: A 1.5% agarose gel of SP-Al CI193G genotype patterns obtained using an
ARMS PCR (See Chapter 3, section 12). Lane 1: IOObp DNA Ladder (Promega, Madison,
WI), Lane A: CC homozygote, Lane B: CG heterozygote and Lane C: GG homozygote.
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TABLE 8.3: The distribution of Cl193G genotypes (a) and alleles (b) in the TB and control
populations in this study
(a)
Genotype Observed Numbers Chi Square p-value
TB Patients
(%)
Controls (%)
CC 173 (56) 193 (59)
1.25 0.535
CG 120 (39) 113 (34)
GG 18 (6) 22 (7)
Total 311 328
(b)
Chi OR*
Allele TB Patients Controls p-value
Square (95% Cl)
Number Frequency Number Frequency
0.95
C 466 0.75 499 0.76 0.23 0.634
(O.73<OR<1.24)
G 156 0.25 157 0.24
*OR = Odds Ratio Cl = Confidence Interval
2.4 SP-Al Sequencing
A total of23 samples (lO TB cases and 13 controls) were sequenced to determine whether the
four SNPs investigated by Madan et al. (2002) were present in our population. Of the four
SNPs, AI660G was not polymorphic in our population. Madan et al. (2002) reported this
polymorphism to be significantly associated with TB in their population (Madan et al., 2002).
Of the other three SNPs, the ones that appeared most promising in our population were
C 1382G and G 1649C (Table 8.4). Madan et al. (2002) reported that both of these SNPs were
associated with TB in the Indian population (p-values = 0.0054 and 0.0096 respectively),
however re-analysis of the reported data by our group using Epi-Info version 1.1, shows that
neither C1382G (n=16) nor G1649C (n=16) were associated with susceptibility to TB (p =
0.60 and 0.32 respectively) (Madan et al., 2002). Cl492T was not associated with
susceptibility to TB in the Indian population and was therefore excluded from this study.
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TABLE8.4: Polymorphisms reported by Madan et al. (2002) in the collagen region of SP-A2
and their allele frequencies in a South African population.
Polymor(!hism Allele Freguencies {%}
Tuberculosis (n= lal Controls (n=13)
C1382G
C 90 10
G 10 35
C1492T
C 35 55
T 65 45
G1649C
C 20 32
G 80 68
A1660G
A 100 100
G 0 0
Sequence analysis revealed a novel polymorphism at nucleotide position 1691 in the SP-A2
collagen-like region. This SNP is previously unreported and is present in intron 4. Figure 8.4
shows the sequencing results allowing the identification of this polymorphism.
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BC AG G T!;]G G C A CA GGT~GCACA G G TBG G CA
(\
FIGURE 8.4: Chromatograms of a portion of the collagen-like region of SP-A2 and the SNP
identified at nucleotide position 1691. A is a heterozygote AG and Band C show
homozygotes A and G respectively.
2.4.1 Genotyping SP-A2 C1382G
A total of 321 TB patients and 327 controls were genotyped using an ARMS technique with
respect to this intronic SNP (See Chapter 3, section 15). Figure 8.5 shows an example of the
agarose gel used to genotype samples and the expected genotypes. Genotype and allele
frequencies for this SNP are shown in Table 8.5a and b. Statistical analysis showed that this
SNP is not significantly associated with TB susceptibility in our population. It was also
determined that the control group was in Hardy-Weinberg equilibrium.
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1500bp ----+
IOOObp ----+..
FIGURE 8.5: A 1.5% agarose gel of SP-A2 CI382G genotype patterns using an ARMS PCR
(See Chapter 3, section 12). Lane 1: IOObpDNA Ladder (Promega, Madison, WI), Lane A:
CC homozygote, Lane B: CG heterozygote and Lane C: GG homozygote.
TABLE 8.5: The distribution of CI382G genotypes (a) and alleles (b) in the TB and control
populations in this study
(a)
Genotype Observed Numbers Chi Square p-value
TB Patients (%) Controls (%)
CC 179 (56) 193 (59)
CG 123 (38) 112 (34) 1.21 0.547
GG 19 (6) 22 (7)
Total 321 327
(b)
Chi OR* p-
Allele TB Patients Controls
Square (95% Cl) value
Number Frequency Number Frequency
0.94
C 481 0.75 498 0.76 0.26 0.608
(O.72<OR<1.22)
G 161 0.25 156 0.24
*OR = Odds Ratio Cl = Confidence Interval
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2.4.2 Genotyping SP-A2 G1649C
A total of 358 TB patients and 399 controls were genotyped with respect to this exonic SNP
using an ARMS method (See Chapter 3, section 15 for a detailed method). Genotype and
allele frequencies for this SNP are shown in Table 8.6a and b. Figure 8.6 shows the agarose
gel that was used to genotypes the individuals for this SNP and examples of the genotypes
expected.
500bp
Non-specific band
Internal control
(716bp)
Allele specific
Band (383bp)
FIGURE 8.6: A 1.5% agarose gel of SP-A2 G1649C genotype patterns using an ARMS PCR
(See Chapter 3, section 12). Lane 1: 100bp DNA Ladder (Promega, Madison, WI), Lane A:
CC homozygote, Lane B: CG heterozygote and Lane C: GG homozygote.
100bp
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TABLE 8.6: The distribution of G 1649C genotypes (a) and alleles (b) in the TB and control
populations in this study
(a)
Genotype Observed Numbers Chi Square p-value
TB Patients
(%)
Controls (%)
0.014
CC 74 (21) 98 (25)
8.49 (Uncorrected)
CG 146 (41) 187(47)
0.042
GG 138 (39) 114(29)
(Corrected)
Total 358 399
(b)
Chi OR*
Allele TB Patients Controls p-value
Square (95% Cl)
Number Frequency Number Frequency
0.0067
C 294 0.41 383 0.48 0.75
7.34 (Uncorrected)
(0.61 <OR <0.93)
0.0201
G 422 0.59 415 0.52 (Corrected)
*OR = Odds Ratio Cl = Confidence Interval
Statistical analysis showed that this SNP is significantly associated with susceptibility to TB
in our population and that the control group was in Hardy-Weinberg equilibrium. There is a
higher frequency of the GG genotype in the TB group when compared to controls. In this
analysis corrections were made for multiple testing. The stringent Bonferroni method (See
Chapter 3, section 17.2) was used to correct and after correction this polymorphism is still
associated with susceptibility to TB.
2.4.3 Genotyping SP-Al G1691A
A total of 303 TB patients and 300 controls were genotyped with respect to this intronic SNP
using an ARMS technique (See Chapter 3, section 15 for a detailed method). Figure 8.7
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shows an example of an agarose gel that was electrophoresed in order to genotype the
individuals as well as an example of the genotypes expected. Genotype and allele frequencies
for this SNP are shown in Table 8.7a and b. Statistical analysis showed that this SNP is not
significantly associated with TB susceptibility in our population and that the control group
was in Hardy-Weinberg equilibrium.
1000bp •
•...-- Internal Control
(716bp)
.. Allele Specific
(432bp)
500bp ---+.
FIGURE 8.7: A 1.5% agarose gel of SP-A2 G1691A genotype patterns obtained using an
ARMS PCR (See Chapter 3, section 12). Lane 1: 100bp DNA Ladder (Promega, Madison,
WI), Lane A: AA homozygote, Lane B: AG heterozygote and Lane C: GG homozygote.
TABLE 8.7: The distribution of G1691A genotypes (a) and alleles (b) in the TB and control
populations in this study
(a)
Genotype Observed Numbers Chi Square p-value
TB Patients
(%)
Controls (%)
AA 52 (17) 48 (16)
0.33 0.85
AG 158 (52) 154(51)
GG 93 (31) 98 (33)
Total 303 300
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(b)
Chi OR* p-
Allele TB Patients Controls
Square (95% Cl) value
Number Frequency Number Frequency
1.07
A 262 0.43 250 0.42 0.3 0.582
(O.84<OR<1.35)
G 344 0.57 350 0.58
*OR = Odds Ratio
2.5 Haplotyping
Cl = Confidence Interval
Haplotypes using the genotypes of the three SP-A2 SNPs (C1382G, A1649C, A1691G) were
constructed using PHASE version 2.1 (Stephens et aI., 200 I).(Chapter 3, section 17.4)
Haplotype frequencies are shown in Table 8.8. Eight possible haplotypes were identified
from the genotype data.
TABLE8.8: Haplotype frequencies within the population that was studied in this investigation.
Haplotype Sample Frequency StandardDeviation
CCA 0.11 0.008
CCG 0.17 0.008
CGA 0.15 0.014
CGG 0.33 0.016
GCA 0.08 0.010
GCG 0.04 0.007
GGA 0.09 0.009
GGG 0.04 0.010
The PHASE program is able to determine whether there is a difference between the
distribution of haplotypes amongst cases compared to controls. Table 8.9 shows the
distribution of the haplotypes constructed using this program and their frequencies in the TB
and control groups.
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The frequencies that are reported are estimates of the sample haplotype frequencies but can
also be used as estimates of the population haplotypes frequencies. The results show that the
GGG and GCG haplotypes are the least frequent in this population with the CGG haplotype
being the most prevalent, having a frequency of 0.33. When the data was analysed to assess
whether there was a tendency for one haplotype to be found more frequently in the cases
compared to controls a p-value of 0.23 was obtained indicating that there was no significant
association with a particular haplotype and the cases or controls.
TABLE8.9: Haplotype frequencies in the case and control groups.
Control Standard Case StandardHal!lotvl!e Hal!lotvl!e Hal!lotvl!eDeviation DeviationFrequencies Frequencies
CCA 0.11 0.010 0.11 0.008
CCG 0.19 0.010 0.16 0.008
CGA 0.14 0.008 0.15 0.009
CGG 0.32 0.010 0.34 0.009
GCA 0.09 0.008 0.08 0.008
GCG 0.04 0.006 0.03 0.006
GGA 0.07 0.008 0.10 0.009
GGG 0.04 0.006 0.03 0.007
2.6 Linkage Disequilibrium (LD)
LO analysis for the SP-A2 data was performed using the LOMAX programme within the
Graphical Overview of Linkage Disequilibrium (GOLD) software package (See Chapter 3,
section 17.5) (Abecasis and Cookson, 2000). This package provides the disequilibrium
coefficient (D') values, X2 statistics and p-values for all possible combinations of SP-A2
C1382G, G1649C and G1691A. The results obtained indicate that SP-A2 C1382G and
G1691A are in LD with each other (0' = 0.597) (Table 8.10). Figures 8.8a, band c illustrate
the 0', p-values and X2 statistics obtained as GOLD graphical LD matrices respectively.
Figure 8.9 shows a summary of the LD results obtained in this analysis.
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TABLE 8.10: Analysis of LD between SP-A2 alleles using GOLD. All combinations were
significant and SP-A2 1382 and SP-A2 1691 are in complete LD.
SNP 1 SNP2 N LDx2 ~-value D'
SP-A2 SP-A2
614 9.76 0.00178 0.202
C1382G G1649C
SP-A2 SP-A2
574 97.55 0.00000 0.597
C1382G G1691A
SP-A2 SP-A2
586 5.9 0.01517 0.l05
G164C9 G1691A
G1691A
0.60
Gl649C
0.11
C1382G
40bp 200 bp
C1382G G1691A
Gl649C
FIGURE 8.8a: A graphical illustration of the D' values observed between SP-A2 C1382G,
G1649C and G1691A.
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FIGURE 8.8b: A graphical illustration of the p-values obtained.
G1691A
G1691A
G1649C
C1382G
G1649C
C1382G
0.00
0.02
40 bp 200bp
C1382G G1691A
G1649C
5.90
97.55
40 bp 200bp
C1382G G1691A
G1649C
FIGURE 8.8c: A graphical representation of the X~values obtained.
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D' = 0.597
P = 0.0000
III V VIIV
FIGURE 8.9: Summary of LD found between the polymorphisms studied within the SP-A2
gene. The LD was obtained using LDMAX, within the GOLD Software package (Abecasis
and Cookson, 2000). The diagram only shows Exons III to VI of the SP-A2 gene (not drawn
to scale).
3. DISCUSSION
3.1 Association Analysis
Case-control analysis revealed that there was no statistical difference between cases and
controls with respect to the SP-Al Cl193G, SP-A2 C1382G and SP-A2 G169lA SNPs,
however a statistically significant association was found between the GG genotype and G
allele of SP-A2 G l649C and susceptibility to TB.
SP-Al Cl193G was not associated with TB in our population (p = 0.535, genotypic analysis,
p = 0.634, allelic analysis), these results were supported by Madan et al (2002) who also did
not find a significant association with the SNP and susceptibility to TB in the Indian
population (Madan et al., 2002). This SNP was however reported to be associated with
susceptibility to TB in a Mexican population (Floros et al., 2000). This association was found
when the TB cases (n = 107) were compared to a group of skin-test positive controls (n = 71)
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(p = 0.095) as well as when the TB cases were compared to a group of general controls (n =
101) (p = 0.05) (Floras et al., 2000). These association studies conducted by Floras et. al.
(2000) had less power than our study.
SP-A2 G 1649C was found to be associated with susceptibility to TB in our population
(corrected p = 0.0201). Floros et al. (2000) investigated the SP-A2 G 1649C SNP and found
no association with this SNP and susceptibility to TB (TB cases = 107, skin-test positive
controls = 71 and general controls = 101) (Floros et al., 2000). Madan et al. (2002) also
investigated this SNP in an Indian population and reported a significant association with
susceptibility to TB (Madan et aI., 2002), however re-analysis of the reported results by our
group using Epi-Info version 1.1 indicated that this SNP is not associated with susceptibility
to TB in the Indian population studies. SP-A2 G 1649C results in an amino acid change from
proline to alanine at amino acid residue 91, and could have an impact on the overall assembly
of the SP-A molecule itself. Proline is an important component on the repetitive Gly-X-Pro
subunit in the collagen-like region of SP-A and is known to provide stability to triple helical
collagenous structures (Improta et aI., 2001). At this stage however it is not know what effect
this amino acid change would have on the protein. Karinch et al. (1997) showed that the
levels of mRNA varied amongst the different SP-A alleles within the 5' splice regions and
that the ratio of the SP-Al and -A2 transcripts also varied suggesting that the protein level
may be genetically determined (Karinch et aI., 1997). One SP-A genotype in particular
(6A26A21Ao1Ao) has been shown to be associated with a low to moderate level of SP-A
mRNA (Karinch et aI., 1997) (See Chapter 1 section 1.7 for an explanation ofSP-A alleles).
These results suggest that either one or both of the alleles are low producers.
In this investigation we were able to identify a novel polymorphism (SP-A2 G1691A) within
the collagen-like region of the SP-A2 gene. This polymorphism was not associated with
susceptibility to TB (p = 0.85).
3.2. Haplotype Analysis
Eight haplotypes were identified using the PHASE 2.1 program of Stephens et al. (2001),
however no particular haplotype segregated with either the cases or controls (p = 0.23)
(Stephens et aI., 2001).
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3.3. LD Analysis
LD analysis shows that SP-A2 C1382G and SP-A2 G1691A are in LD with each other (D' =
0.597). Significant p-values were obtained for the LD analysis and therefore we are confident
that the LD values that are reported are accurate.
3.4. General Discussion
The critical determinant of whether M tuberculosis is able to survive within the macrophages
is dependent on the organism's abitlity to evade the bactericidal mechanisms of the host.
Rodent macrophages are able to kill ingested mycobacteria through the induction of inducible
nitric oxide synthase (iNOS) and subsequent production of nitric oxide (Nathan 1995 p876).
iNOS deficient mice are unable to produce nitric oxide and mycobacteria are able to grow
well within the macrophages of these mice (Macmicking et al., 1997). Le Vine et al. (2000)
investigated SP-A deficient mice (SP-k'-) as well as wild type mice that were infected with
Group B streptococcus (GBS) (LeVine et aI., 2000). They observed that the killing of GBS
was decreased in SP-k'- mice and that deficiency in SP-A was also associated with increased
inflammation and inflammatory cell recruitment in the lung after infection. This group
observed that macrophages isolated from SP-k'- mice generated significantly less superoxide
and hydrogen peroxide compared with wild type alveolar macrophages.
ELISA assays have been developed in order to detect the amount of SP-A present in broncho
alveolar lavage fluid (BALF) as well as in serum of patients with respiratory diseases (Kuroki
et aI., 1985). The levels of SP-A have been found to be increased more than 10fold in the
BALF of patients with pulmonary alveolar proteinosis (PAP) (Honda et aI., 1993), however in
patients with idiopathic pulmonary fibrosis (IPF), interstitial pneumonia with collagen
vascular disease (IPCD) and acute respiratory distress syndrome (ARDS) levels of SP-A were
significantly decreased (McCormack et aI., 1991; McCormack et aI., 1995; Gregory et aI.,
1991). The SP-A concentration has also been investigated in serum of individuals with a
variety of pulmonary diseases. It was demonstrated that serum SP-A levels were significantly
increased in patients with PAP and IPF (Kuroki et aI., 1993; Honda et aI., 1995; Takahashi et
aI., 1995; Kuroki et aI., 1998). The SP-A levels in patients with pneumoconiosis, TB,
bacterial pneumonia and chronic pulmonary emphysema increase moderately but the levels
are not significantly increased compared to controls.
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During intitial infection with M tuberculosis the bacilli reach to distal airways and are
phagocytosed by alveolar macrophages. Gaynor et al. (1995) demonstrated that SP-A
enhanced the uptake of M tuberculosis into human macrophages and suggested that SP-A
upregulates the activity of the macrophage mannose receptor (MR) (Gaynor et aI., 1995).
Alveolar macrophages express particularly high levels of functional MR and Beharka et al.
(2002) were able to show that SP-A does in fact up-regulate the activity of the MR (Beharka
et aI., 2002) however SP-A does not alter the expression of the complement receptor (CR).
Mutant SP-A molecules that lack the collagen-like region are only expressed as trimers and
hexamers, and mutants lacking both the amino terminal and collagen-like regions only form
trimers (McCormack, 1998). It has been shown that neither of these variants is able to
stimulate an optimal increase in MR expression (McCormack, 1998). This upregulation of the
MR by SP-A may provide a mechanism for enhanced phagocytosis of invading infectious
organisms, such as M tuberculosis whose uptake is enhanced by binding to SP-A. Figure
8.10 represents the possible scenarios regarding the interaction of SP-A, M tuberculosis and
the MR.
This however would only explain part of the whole mechanism as it has been shown that SP-
A enhances the uptake of bacillus Calmette-Guérin (BCG) by rat macrophages and human
macrophages through a specific SP-A receptor designated SPR21 0 (Weikert et aI., 1997). SP-
A is also able to interact with complement receptors on macrophages.
SP-A plays an important role in defence functions in the host and in response to a variety of
pathogens and it has been shown that SP-A enhances the uptake M tuberculosis into the
alveolar macrophage (Gaynor et aI., 1995). It appears that it would be detrimental to the host
to have a defence molecule that enhances uptake of M tuberculosis into its preferred
environment and that in the same way as MBL it would be advantageous to have a
polymorphism within the SP-A genes that leads to decreased secretion of SP-A. A decreased
serum concentration of SP-A may lead to protection against pulmonary TB, as was found
with an allelic variant in the MBL gene (Hoal-van Heiden et aI., 1999) possibly resulting in a
decreased uptake of M tuberculosis into the alveolar macrophage.
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Low Levels ofSP-A V&riantSP-A Molecules
~
Macrophage
~
Mycobacterium tuberculo~i~ Mycobacterium tuberculo~i~Mycobacterium tubercul o~i~
~ Mycobacterium tuberculo~i~ ~ Surfactant Protein A
• Complement Receptor
• Mannose Receptor
~ Mutant Surfactant Protein A
FIGURE 8.10: Possible scenarios regarding the interaction of SP-A, M tuberculosis and the
MR adapted from Soborg et al. (2003). In the first diagram, when SP-A binds to M
tuberculosis there is an upregualation of the MR on the surface of macrophages leading to
enhanced pahgocytosis of bacilli into the macrophage. The middle diagram shows a scenario
where should there be low levels of SP-A produced it is feasible to speculate that the low
levels of SP-A would not stimulate increased expression of the MR to such a great extent
resulting in a decreased phagocytosis of M tuberculosis into the alveolar macrophage. The
last diagram proposes that should a polymorphism cause a variant SP-A molecule to be
produced, such as trimeric or hexameric SP-A instead of the mature octodecameric structure,
it would not lead to suffucient upregulation of the MR and may contribute to a decrease in
phagocytosis of M tuberculosis, however lipoarabinomannan (LAM) expressed on
mycobacteria is also a ligand for both the MR and CR and therefore this may lead to direct
uptake and phagocytosis of M tuberculosis by the receptors on the surface of the
macrophage.
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CHAPTER9
CONCLUDING REMARKS
I have learned this at least by my experiment: that if one advances confidently in the direction
of his dreams, and endeavours to live the life which he has imagined, he will meet with a
success unexpected in common hours.
Henry David Thoreau
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There are three factors that need to be considered when investigating genetic susceptibility to
infectious diseases and these are firstly, the bacterium, secondly, environmental factors and
thirdly, host response linked to genetics. All play an equally important role in determining
whether one individual will be susceptible to infection but another individual may not be.
Once an association has been made between a polymorphism within a gene it is important to
carry this association further and determine whether this polymorphism alters the protein at a
functional level.
The colleetin molecules, Mannose Binding Lectin (MBL), Surfactant Protein A (SP-A) and
Surfactant Protein D (SP-D), have been shown to play important roles in the host response to
infection by a wide variety of microorganisms and most importantly in the context of this
work they are important in the host defence against M tuberculosis (Crouch, 1998; Hickling
et aI., 2004; McCormack and Whitsett, 2002; Gaynor et aI., 1995; Ferguson et aI., 1999). A
great deal of work has been conducted on MBL, which was described about 30 years ago
(Robinson et aI., 1975). Some 10 years later the protein, cDNA and genomic sequence for SP-
A was elucidated and it was shown that the molecule had colleetin properties (White et aI.,
1985; Floros et aI., 1986). SP-D is the most recently described of the three (Persson et aI.,
1988; Persson et al., 1989).
MBL has been shown to bind to M tuberculosis and acts as an opsonin, allowing the
activation of the classical complement pathway resulting in the phagocytosis of bacilli by
macrophages. This suggests that MBL may facilitate the entry of the pathogenic
microorganisms into their preferred host environment of the alveolar macrophage. SP-A acts
in a similar way to MBL in that it binds to M tuberculosis and leads to the enhanced uptake
of bacilli into the macrophage. Polymorphic variants within the MBL gene have been
associated with low levels of MBL (Hoal-van Heiden et aI., 1999) and a SP-A genotype has
been shown to be associated with a low to moderate level of SP-A mRNA (Karinch et aI.,
1997) leading one to speculate that low levels of either of these two proteins could be
advantageous to the host as both lead to decreased uptake of the bacilli into alveolar
macrophages.
SP-D does not function in the same way as MBL and SP-A. Upon binding M tuberculosis,
SP-D agglutinates the bacilli and reduces their uptake into the alveolar macrophage (Ferguson
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et aI., 1999). This would appear to be more advantageous as it would decrease the chance of
the bacilli reaching their preferred environment of the alveolar macrophage.
In this study the two surfactant proteins were investigated. Regions of the SP-O gene were
sequenced in order to determine whether there were any novel polymorph isms within our
population. We were not able to identify any new polymorphisms within the amino terminal,
neck or proximal promoter regions of the gene. Concentrations of SP-O were investigated
within control, previous TB and active TB groups and the concentration of SP-O was found to
be significantly higher in the active TB group compared to controls, leading to the hypothesis
that SP-O plays some role in a pulmonary acute phase response. Furthermore it was observed
that the higher levels of SP-O were associated with a particular sp-o genotype that has been
associated with susceptibility to TB as well as respiratory syncytial virus infection. These
results imply that this polymorphism plays a role in susceptibility to disease, however it is not
known whether this is the polymorphism that plays the main role in this observed
susceptibility and influences the serum levels of SP-O or if it is fact in linkage disequilibrium
(LO) with the causative polymorphism. The role of this polymorphism should be investigated
further and we would propose to do this by investigating the binding and agglutinating ability
of native sp-o purified from bronco alveolar lavage fluid (BALF) of individuals with the
different SP-O genotypes. These experiments would indicate whether SP-O produced by
individuals having the susceptibility genotype bind and agglutinates M tuberculosis less
efficiently than individuals having the other genotypes. A more sensitive technique seems to
be required should we wish to investigate whether this polymorphism has an impact on the
overall structure of the molecule.
A case control association study was carried out for polymorph isms within the collagen-like
region of SP-Al and -A2. We were able to demonstrate that there was a significant
association between a single nucleotide polymorphism (SNP) in exon 4 of the SP-A2 gene
with susceptibility to TB. Upon sequencing a portion of the collagen-like region of SP-A2 we
identified a novel SNP in intron 4 (SP-A2 GI691A), which was not found to be associated
with susceptibility to TB. LO analysis showed that there was LO between the novel SNP
identified (SP-A2 G1691A) and a SNP in intron 3 (SP-A2 C1382G). The impact of these
polymorphisms on the function of SP-A should be investigated further. It would be advisable
to conduct a family-based study such as the transmission disequilibrium test (TOT) using SP-
A2 G 1649C to determine whether this is indeed a true association. It would be interesting to
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determine whether the levels of SP-A are significantly increased in patients with active TB
compared to previous TB cases and controls as was seen with respect to the SP-D serum
concentrations (See Chapter 6). Furthermore the disease groups should be subdivided
according to the SNPs that were investigated in this study in order to determine whether any
particular genotype or haplotype in the case of SP-A2 contributes to an increase or decrease in
SP-A serum concentration. Levels of SP-A have been measured in serum using a sandwich
ELISA assay in numerous respiratory diseases such as PAP and IPF (Honda et aI., 1995;
Kuroki et al., 1993; Kuroki et aI., 1998). It would be interesting to genotype individuals
within this population according to the 5' splice polymorphisms that have been characterised,
to determine whether the distribution of alleles is similar to those found in other populations
and then to conduct LO analyses between these and the SNPs in the collagen-like region of
SP-A2.
Limitations of the study:
1. The collagen-like region and carbohydrate recognition domain of the SP-D gene were
not sequenced to determine whether there were any novel polymorphisms. Folding of
the collagen-like region is important in the trimeric association of subunits into triple
helices (King et aI., 1989) and is therefore important for the overall assembly of the
SP-D molecule. The carbohydrate recognition domain (CRD) binds pathogens thereby
playing an important role in the elimination of microorganisms.
2. More polymorphisms within the SP-D gene should be typed in order to construct
haplotypes and to determine whether the SP-DIl SNP is in linkage disequilibrium
with another polymorphism in the gene.
3. No family based study was conducted once significance was established with SP-A2
G1649C, therefore it is not possible to state with certainty whether this is purely a
chance association or whether there is population bias. A family-based study would be
able to ascertain whether this was a true association or not.
4. In order to improve the SNP typing a primer extension or SNaPshot method (Pati et
al., 2004; Quintans et al., 2004) using the AB! sequencer could be employed in the
future, as it is not subject to bias or human error when typing SNPs. The method
should improve genotyping and provide more consistent and reliable results.
TB is a complex disease with factors such as the environment and host genetic factors
impacting on the outcome of disease. It is unlikely that there is one major susceptibility locus,
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rather, there is probably a complicated interaction between many genetic factors including the
surfactant proteins and collect in molecules as a whole. Genotypic information should be used
in order to gain a better understanding of what impact these polymorph isms have on the
structure and function of the proteins in question.
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It may be that the gulfs will wash us down,
It may be we shall touch the Happy Isles, and though
We are not now that strength which in old days
Moved earth and heaven, that which we are, we are ...
Made weak by time andfate, but strong in will
To strive, to seek, to find, and not to yield.
Alfred, Lord Tennyson
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IMPACT OF THE MOLECULAR FORM OF SURFACTANT PROTEIN-D
PURIFIED FROM BRONCHO ALVEOLAR LAVAGE ON BINDING TO, AND
AGGLUTINATION OF, MYCOBACTERIA
Principal Investigators: Eileen Hoal, Gerhard Walzl
SU/MRC Centre for Molecular and Cellular Biology and Department of Medical
Biochemistry, Faculty of Health Sciences, Stellenbosch University.
Background
Tuberculosis (TB) is an infectious disease caused by the tubercule bacillus, Mycobacterium
tuberculosis (M tuberculosis). Worldwide, TB causes approximately 3 million deaths
annually, which is estimated to be the most deaths caused by a single infectious agent (Harth
and Horowitz, 1999). Furthermore, it is believed that one third of the human population is
latently infected with TB, of whom 10% are expected to develop the disease in their lifetime
(Pym and Cole, 1999). The World Health Organisation predicts that without changes in the
present TB control strategies, 200 million people living today will eventually develop the
disease (Grange and Zumla, 1999).
In developing countries, such as South Africa, TB is a major problem. It is known that
infection with M tuberculosis does not always lead to clinical disease and the question that
arises is: are some people more susceptible to the development of clinical disease than others?
Although socio-economic status is a major factor, there is evidence that the progression to
clinical TB, as well as susceptibility to TB, is affected by interactions between environmental
and genetic factors (Schluger and Rom, 1998; Fine, 1981). It is therefore important to
investigate the genetic aspect by either performing linkage analyses, requiring large families
or many families with affected sibling pairs (Blackwell et al., 1997; Bellamy et aI., 2000), or
association studies with candidate genes that are potentially involved in the host response to
M tuberculosis infection. Genes that have been shown to be associated with susceptibility to
TB include; HLA-DR2 (Singh et al., 1983), natural resistance associated macrophage protein
1 (NRAMP1) (Bellamy et al., 1998a), mannose binding lectin (MBL) (Hoal-van Helden et
al., 1999), vitamin D receptor (Bellamy et al., 1999) and surfactant protein A 1 and A2 (Floros
et al., 2000).
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Pulmonary Surfactant
Pulmonary surfactant is a complex mixture of lipids and proteins important for normal
respiratory function (Rooney et aI., 1994), playing a distinct role in the regulation of alveolar
macrophage function and inflammation and contributing to innate immune defence of the
lung. Its major role is to stabilise the alveolar walls and prevent collapse of the alveoli during
exhalation (van Golde et aI., 1988). It is composed of four proteins; SP-A, SP-B, SP-C and
SP-D whose classification as surfactant proteins is based on the fact that they are found in
lavage fluid, synthesised by alveolar type II cells, and are present in large amounts
specifically in the lung.
SP-A and SP-D belong to the group of mammalian lectins, designated collectins (Bezouska
et aI., 1991). Collectins are a group of multi me ric proteins organised into either 'bundles of
tulips' or 'X-like' structures. These molecules are assembled at their amino termini by
disulphide bonds; possess a collagen-like region and clusters of three lectin domains at the
end of the collagen-like triple helices (Lu, 1997). Other members of this family include MBL
(Turner, 1996), which activates the serum complement system, bovine serum conglutinin and
bovine serum lectin 43 (CL-43) (Holmskov et al., 1995).
Agglutination of microorganisms is thought to be an important part of innate immune
defence. Agglutinated bacteria may be cleared more readily from the respiratory tract by the
mucocillary system or may have altered interactions with host cells (pikaar et al., 1995; Kuan
et al., 1992). SP-A and SP-D are able to bind a wide variety of non-self structures ranging
from bacteria, viruses and fungi to allergens and environmental inorganic substrates (Lawson
and Reid, 2000). SP-D has been shown to be able to effect the aggregation of various
microorganisms and fungi, including certain strains of Escherichia coli, Streptococcus
pneumoniae, Staphylococcus aureus (Hartshorn et al., 1998), influenza virus (Hartshorn et
al., 1997; Hartshorn et al., 1994; Eda et al., 1997), Cryptococcus neoformans (Schelenz et al.,
1995),Aspergillus fumigatus (Mandan et al., 1997a) and Candida albicans (van Rozendaal et
al., 2000). These findings suggest that collectins recognise carbohydrate structures in the cell
wall of the initial infectious forms of fungi and bacteria (Schelenz et al., 1995).
By binding to microorganisms SP-D is able cause agglutination, allowing more efficient
removal of pathogens from the lung (Lawson and Reid, 2000). SP-D is able to act as an
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opsonin although this does not always promote phagocytosis. For example, SP-D is able to
enhance the binding of Pneumocystis carinii to alveolar macrophages but it does not promote
phagocytosis (O'Riordan et al., 1995). Surfactant proteins act as chemotactic agents by
recruiting or curtailing phagocytic cells at the sites of inflammation and immune reaction. SP-
D acts as a potent chemoattractant for phagocytes, neutrophils and monocytes (Madan et al.,
1997b; Crouch et al., 1995; Cai et al. 1999). The mechanism and receptors behind this
process are not fully characterized. The surfactant collectins have been shown to enhance
phagocytosis in some cases. SP-D is able to bind and enhance macrophage phagocytosis of
mucoid and non-mucoid strains of Pseudomonas aeruginosa but it is unable to aggregate
either strain, which suggests that SP-D enhances phagocytosis through receptor-mediated
opsonisation and killing (Restrepo et al., 1999). The mucoid strains of P. aeruginosa are
important in the pathogenesis of chronic lung disease associated with cystic fibrosis and this
could be related to the decreased levels of both SP-A and SP-D that have been reported in
lung lavages of at least some patients with cystic fibrosis (Postle et al., 1999).
Transgenic mice studies (SP-D knockouts) have been conducted using SP-Do These studies
have provided some information about the function of SP-D in agglutination, phagocytosis
and killing of numerous bacterial and fungal species. LeVine et aI., (2000a) showed that SP-
0-1- mice, infected intratracheally with group B streptococcus (GBS), were able to kill the
bacteria as efficiently as the wild-type mice and the number of bacteria associated with
macrophages was lower than observed in the wild-type mice. In the presence of SP-D there
was increased association of GBS with alveolar macrophages but phagocytosis was not
altered. The same group also infected SP-D-I- mice with Haemophilus injluenzae and
observed a similar situation in that these mice were able to kill this bacterium as efficiently as
the wild-type, that the number of bacteria associated with and internalised by alveolar
macrophages was significantly less in SP-D-I-mice compared to the wild-type mice. This
suggests that there is a defect in opsonization and/or phagocytosis. In both cases SP-D-I-mice
showed increased inflammation and inflammatory cell recruitment into the lung after
infection. Le Vine et al., (2000b) showed that SP-D-I- mice were susceptible to respiratory
syncytial viral pneumonia. The uptake of viral particles by alveolar macrophages and the
clearance of the virus from the lung were deficient in SP-D-I-mice. Studies of this nature
have not yet been conducted in connection with M tuberculosis but would be useful in
elucidating the function of SP-D in the progression ofTB.
Stellenbosch University http://scholar.sun.ac.za
Structure of SP-D
The surfactant genes: two SP-A genes, one SP-A pseudogene and the SP-D gene, are found
on chromosome l O (lOq22.2-q23.1) in close proximity to MBL (Crouch et al., 1993; Hoover
and Floros, 1998). These colleetin molecules are composed of four domains. Firstly, a short
amino terminal region containing two conserved cysteine residues (Cysl5 and Cys20), which
are important in the formation of interchain disulphide bonds that stabilise the dodecameric
structure of SP-D (Crouch et al., 1994a). The long collagen like domain accounts for the
pronounced linear characteristic of the molecules (Fig 1). There is a coiled-coil neck region
and a calcium dependent carbohydrate recognition domain (CRD) that is necessary for
carbohydrate binding (Sastry and Ezekowitz, 1993; Botas et al., 1998). Each member of the
colleetin family has a different degree of higher order oligomerisation. (Lawson and Reid,
2000). Hartshorn et al., (1998), were able to show that the degree of multimerisation of SP-D
was a critical determinant of both aggregating activity and potency in enhancing bacterial
uptake, and Zhang et al., (2001), demonstrated that the activity of SP-D in vivo is dependent
on the oligomeric structure of the SP-D molecule. Conglutinin and SP-D have a characteristic
cruciform structure that is assembled as tetramers of three identical polypeptides. It is thought
that the agglutination activity is dependent on the oligomerisation and their ability to bridge
•TrIm!Htc eRD
the large distances between organisms (Eda et al., 1997).
Figure 1: The alternative molecular forms of SP-Do Monomeric carbohydrate recognition
domains (CRDs), trimeric CRDs, a recombinant rat single arm mutant (RrSP-DserI5/20), the
natural dodecameric structure (RrSP-D) and an SP-D multimer or 'astral body'. Monomeric
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CRDs have a weak binding affinity to various ligands. Trimeric CRDs and single arm mutant
forms of SP-D cannot mediate effective agglutination of microorganisms, the minimal
structure required for this is the dodecameric form of SP-D (Crouch, 1998).
SP-D and Mycobacterium tuberculosis
The initial immunologic responses to M tuberculosis in the lung are important, as entry of
this inhaled pathogen into the alveolar macrophage is a defining event in disease pathogenesis
(Ferguson et al., 1999). M tuberculosis is likely to come into contact with surfactant when
inhaled into the alveolus and it is proposed that the interaction between M tuberculosis and
surfactant components alters the ultimate fate of the bacterium (Ferguson et al., 1999).
Ferguson et al., (1999), investigated the binding of SP-D to M tuberculosis and the effect of
this binding on the adherence of M tuberculosis to human macrophages, and demonstrated
that specific binding of SP-D to M tuberculosis is saturable, calcium dependent and
carbohydrate inhibitable. On incubation with SP-D, the virulent Erdman strain of M
tuberculosis agglutinated but there was minimal binding to the avirulent strain of
Mycobacterium smegmatis. SP-D was found to bind predominantly to the lipoarabinomannan
(LAM) of M tuberculosis Erdman, but was unable to bind to the AralAM of M smegmatis.
It was observed that SP-D was able to agglutinate M tuberculosis, however, SP-D was shown
to decrease the adherence of the bacteria to human macrophages. This result contrasts with the
findings regarding SP-A (Gaynor et al., 1995), which showed that SP-A acts to enhance M
tuberculosis adherence to macrophages as well as phagocytosis of the bacteria. Therefore,
mechanisms that enhance entry of M tuberculosis into the alveolar macrophage may be
detrimental to the host, whereas mechanisms that reduce the entry of M tuberculosis may be
protective. Recently Jounblat et aI., (2004) showed that SP-D was able to bind to and
agglutinate various strains of Streptococcus pneumoniae however; the extent of binding as
well as agglutination differed between strains. This led us to the hypothesis that SP-D binding
to and agglutination of M tuberculosis could differ among M tuberculosis strains.
Sumiya et al., (1991), showed that children carrying mutations in MBL were more susceptible
to recurrent infections, which supports the concept that collectins are part of the innate
immunity against microbial pathogens. In support of this, Matsushita (1995), found that
polymorphisms in the nucleotide sequences of the collagen domain of the MBL gene altered
oligomerisation and that it was associated with defects in host defence function. It is therefore
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thought that increased levels of mutant SP-D that are unable to form higher orders of
multimerisation, might influence the function of SP-D which, in tum, could contribute to the
pathogenesis of various lung diseases including TB (Zhang et al., 200 I). Kondo et al (1998)
found that patients with active pulmonary TB had approximately three-fold the concentration
of serum SP-D as healthy controls.
Previous work in this laboratory: We have shown in a case-control association study, (317
cases and 228 controls), that a polymorphism in the amino terminal region of SP-D was
significantly associated with susceptibility to tuberculosis (unpublished). From this we
hypothesized that this polymorphism could lead to a structural change in the molecule causing
decreased agglutination of and binding to M tuberculosis due to inefficient oligomerisation of
the SP-D molecule. Subsequently, serum samples were taken to the University of Oxford
(MRC Immunochemistry Unit of Prof Ken Reid) and purified by our student, T. Roos (Med.
Biochem) on a Superose 6 HR 10/30 column to partially purify SP-D from serum obtained
from healthy volunteers. The aims of the investigation were to identify, by ELISA, which
fractions, collected from the column, contained SP-D using purified rabbit antibodies to
recombinant SP-D, and to separate proteins in a SDS-PAGE gel under reducing conditions
and then Western blot to detect SP-Do The results thus far look promising.
We would like to further refine this study by using BAL fluid, from which we can directly
purify SP-D in the form required for bacterial agglutination as opposed to using a complex
mixture of proteins such as plasma.
Aim of the study and hypothesis
Hypothesis: SP-D purified from individuals with different SP-D genotypes shows variant
forms which result in differential agglutination of M tuberculosis. In addition, a given SP-D
form binds to a greater or lesser extent to different strains of M tuberculosis.
Aim: To test this hypothesis we propose to purify SP-D from the BAL of individuals of the
three possible genotypes and measure the binding to, and agglutination of, Mtuberculosis.
We will therefore take a small blood sample from volunteers to determine their genotypes.
These same volunteers will undergo BAL and from this BAL fluid we will purify SP-Do We
intend to recruit approximately 20 to 30 volunteers and are aiming to obtain at least 6
volunteers in each genotypic category (CC, CT, TT). This should allow us to detect whether
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there are measurable differences in the molecular form of SP-D, which impact on the binding
of SP-D to M tuberculosis strains and their ability to agglutinate M tuberculosis. From the
allelic frequency we estimate that this sample size will be sufficiently large to yield the
numbers required in the genotype categories. When 6 to 10 individuals in each category have
been identified and sufficient BAL fluid obtained, recruitment will be stopped.
Study design
Structure
This is a cross-sectional observational study.
Study population
Twenty to thirty, adult, non-smoking volunteers, aged 18-45 years and not taking any regular
medication will be recruited. Only patients scheduled for bronchoscopy where this is
indicated for diagnostic reasons (e.g. cancer, fibrosis) will be approached and asked to
participate in the study. Patients undergoing broncho alveolar lavage for any disease other
than infectious disease will also be recruited, and the lavage fluid not required for assessment
of the patient will be brought to the laboratory and used for this project. Other suitable
candidates will be patients with mass lesions of the lung requiring further investigation,
without collapse of any lobe in order to avoid BAL contamination with proteins resulting
from the infective process.
Exclusion criteria
Smoking, known asthma, current tuberculosis or other infectious disease, or other
current or previous serious lung, cardiac or other systemic disease will be exclusion
criteria.
Pre Study Procedures
Preparation of volunteers
After written informed consent has been obtained from the volunteer, eligible volunteers will
be allocated a study number in numerical ascending order. Volunteers will be briefed on the
necessary preparation for BAL and anaesthesia and given a date and time for the next visit.
Volunteers will be questioned to ensure that they remain fit for anaesthesia and continue to
fulfil the inclusion and exclusion criteria. An intravenous catheter will be inserted and
Stellenbosch University http://scholar.sun.ac.za
preserved with heparin. BAL will then be carried out, followed by blood sampling as
specified below.
BAL and Blood Sampling
The broncho alveolar lavage of the right middle lobe will be performed in the standard
manner using a fibre-optic flexible bronchoscope under mild sedation with intravenous
midazolam and fentanyl after premedication with intravenous atropine. This procedure will be
carried out in the endoscopy suite of Tygerberg Hospital by Prof Walzl or similarly qualified
persons delegated by him.
A venous blood sample of 10ml will be collected in a VACUT AINER® tube with EDT A.
Laboratory tests
DNA Isolation
The VACUT AINER® tube with EDT A will be stored at room temperature for less than 24
hrs until centrifugation. If DNA extraction is not performed that day, the white cell pellet will
be stored at -20° C until the time of DNA extraction, which will be within one week.
Genomic DNA will be isolated from the venous blood sample using the Nucleon BACC3 Kit
for blood and cell cultures (Amersham Biosciences) and stored at -80°C until required.
Purification of SP-D from BAL Fluid
This will be carried out according to Madan et al. (l997b) using affinity chromatography of
the BAL fluid on maltose agarose columns.
Binding and Agglutination Assays
These will be carried out according to the protocol of Scott Ferguson et al. (1999). Briefly a
bacterial ELISA assay will be used to determine the extent of SP-D binding to various
mycobacterial strains. Bacteria will be fixed into the wells of a microtiter plate and killed by
5mM nitrite at pH 4.5 or formaldehyde. In the case of M tuberculosis strains being
investigated; this step will be carried out in the P3 facility in the Dept. Medical Biochemistry.
After blocking, the wells will be incubated with recombinant or native SP-D at the
appropriate concentration, thereafter the wells will be incubated with biotinylated rabbit anti-
human SP-D IgG. After incubation substrate will be added and once the reaction is complete
the absorbance will be read using a microplate spectrophotometer, and the degree of binding
of SP-D to the bacteria determined.
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Similarly the agglutination assay will be carried out according to Scott Ferguson et al. (1999).
M tuberculosis will be incubated with an appropriate concentration of native human SP-Do
Thereafter aliquots will be dried on glass coverslips, fixed with formaldehyde, stained with a
fluorescent stain and viewed by fluorescence microscopy.
Personnel
Professor Walzl will make all clinical assessments and perform or supervise the taking of
blood samples and the broncho alveolar lavage. Laboratory tests (SP-D purification and DNA
extraction) will be performed by Dr Hoal's team in the Dept. Medical Biochemistry.
Data analysis
All data will be analysed using a software package (SPSS or Graphpad Prism). The degree of
agglutination effected by SP-D from individuals of different genotype will be compared. This
type of comparison has not been done before, and we therefore cannot predict the magnitude
of the differences that will be seen, if any. If the differences are modest, these sample
numbers will not provide sufficient power, but even a descriptive study will be novel. An
initial ANOV A test will be performed and any significant differences between the groups will
be further investigated by appropriate grouping into two categories, either T- or C-containing
genotypes, followed by at-test.
Ethical considerations
Approval is requested from the institutional ethical committee at Tygerberg Hospital. All
subjects will receive a detailed information leaflet regarding the study and all possible
dangers regarding blood sampling and bronchoscopy will be explained. Fibre-optic
bronchoscopy under mild sedation and employing local anaesthesia can be used with low risk
even in severely ill patients and should pose a very small risk for serious adverse events in
healthy young adults when performed by an experienced operator. Written consent will be
obtained. Subjects will be informed of their right to cease participation in the study at any
point in time and confidentiality will be maintained at all times.
Importance of the study
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This study will yield novel results. Some agglutination studies have been done, but the
functional comparison of SP-D from individuals of different genotype has not been
performed. Other workers in this field have suggested that the polymorphism resulting in the
different genotypes may affect the form and/or function of the molecule, and we have
preliminary results from column chromatography suggesting that this may be true. If this
study confirms our hypothesis, it will indicate the importance of the mode of entry of M
tuberculosis into the macrophage in subsequent disease development.
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APPENDIX2
STUDY INFORMATION SHEET FOR BAL VOLUNTEERS
(THIS INFORMATION SHEET WAS ALSO SUPPLIED IN AFRIKAANS)
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INFORMATION SHEET FOR VOLUNTEERS
Study: IMPACT OF THE MOLECULAR FORM OF SURFACTANT PROTEIN-D
PURIFIED FROM BRONCHO ALVEOLAR LAVAGE ON BINDING TO, AND
AGGLUTINATION OF, MYCOBACTERIA
Principal Investigators: Dr Eileen Haal, Prof Gerhard Walzl
SUIMRC Centre for Molecular and Cellular Biology and Department of Medical
Biochemistry, Faculty of Health Sciences, Stellenbosch University.
Background
Tuberculosis (TB) is a major health problem in the world and especially in the Western Cape. It is a
disease that can be cured with medication, but we need more scientific information on the nature of
the disease to be able to come up with better ways of diagnosis, prevention and treatment. We also
need more information on the manner in which healthy people fight off the disease. One of the ways
the body combats the TB bacterium is to use a protein in the lungs called Surfactant Protein-D to bind
to the bacteria and make it easier for the macrophages (one of the types of white cells in the blood) to
take them up and destroy them. We have been working on the gene that produces different types of
this protein and have found that people with a certain genotype may be more likely to get TB. We
would now like to investigate whether the different forms of the protein bind the bacteria more or less
efficiently, which may explain why some people seem to be more able to resist TB.
Design of Experiments
We aim to purify Surfactant protein-D from the lungs of people without TB. Thirty volunteers will be
recruited. In order to obtain samples of fluid from the lung we will use a process called bronchoscopy
and bronchoalveolar lavage. You have already been scheduled to undergo bronchosopy and/or
bronchoalveolar lavage, and we are therefore asking for only a small additional procedure i.e. the
bronchoalveolar lavage if you were not scheduled to undergo this. If you consent to take part in this
research project, you will be asked to undergo this process once only. A small blood sample will be
taken at the same time to extract DNA and type the genes influencing TB susceptibility, especially the
form of the surfactant protein-D gene.
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Procedures
Blood samples will be obtained from a vein in the arm using a sterile needle and syringe. The amount
of blood drawn will be 15ml (3 teaspoons) divided into two or three tubes. This is not an amount that
poses any dangers to a child or an adult. All blood samples will be labelled with numbers to ensure
that none of the researchers are able to recognise who the samples came from, to maintain
confidentiality. Only the Principal Investigators at Stellenbosch University and the nursing sister who
takes consent from you will have access to the information that links the blood samples to the nominal
data (names and addresses). Confidentiality will be protected by the Health Professional Council of
South Africa's guidelines.
The bronchoscopy and washing of one lung segment (lavage) will be performed by an experienced
physician. This is a straightforward and safe procedure and provides a simple means for sampling the
cells and fluid in the airways of the lungs. It involves the passage of a fine flexible tube through the
nose or mouth and into the lung. A volume of sterile solution is then instilled into a lobe of the lung,
followed by the sucking up of the accumulated contents. This procedure usually lasts about five
minutes. A mild sedative will be administered before this procedure to help make the test a more
comfortable experience.
Possible side-effects of these procedures
The only side-effects that you might experience are an irritating cough during the procedure,
occasional sore throat and mild fever afterwards. All these symptoms are short lived. In the 1970's a
study was reported that investigated the side effects of the procedure in patients, many of them
seriously ill and therefore more likely to develop problems. The number of patients that developed
mild symptoms were 3 in 10 000, a further 3 in 10 000 developed more serious side effects Iike
bleeding from the lung and there was a mortality of 1 in 10000. We would like to point out that these
were seriously ill patients who also had additional procedures like biopsies (the removal of small
pieces of lung tissue), which do not form part of this experiment. As you are not seriously ill, we do
not expect any serious problems. Because we administer a sedative, you will not be able to drive or
operate machinery for the rest of that day.
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Additional information
While the research project may not be directly beneficial to you, the results of the research
will help us to understand how the body protects itself against TB in the lungs and this
information may help us to develop a better treatment to prevent the development ofTB.
You are completely free to choose whether or not you decide to take part in this study. If you decide
to take part you may withdraw at any time without having to give a reason. Refusal to participate will
not involve any penalty or change in the standard of medical attention for you or your family in the
hospital or clinic. We will use the samples exclusively for research on TB and lung disease and will
not do other experiments with it. You will not receive any financial reward for participating in this
study. All personal information obtained from this study will be strictly confidential. The results of
the study will be published in medical journals, but without mentioning the name of any person on
whom blood was taken. Should you have any questions you are free to contact Prof Gerhard Walzl at
the Dept Medical Biochemistry Tel No. 938 9158 (office hours).
All proposals for research using human subjects are reviewed by an ethics committee before
they can proceed. This proposal was reviewed by the Stellenbosch University Ethics Committee
and will be in accordance with recognised standards of good clinical practice; in particular the
Declaration of Helsinki and the ICHlGCP guidelines.
We are covered by insurance against any expenses due to injury caused by participation in the
study.
If you experience any problems after the procedure, please contact Prof Gerhard Walzl at
Tygerberg Hospital Tel No0825923212 or the Department of Medical Biochemistry Tel No 938
9158 during office hours or the registrar on call at the Lung Unit at Tygerberg Hospital at
telephone no 938 4911 after hours.
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APPENDIX 3
PATIENT CONSENT FORM
(THIS INFORMATION WAS ALSO SUPPLIED IN AFRIKAANS)
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INFORMA TION AND INFORMED CONSENT DOCUMENT AND
INFORMATION AND INFORMED CONSENT DOCUMENT FOR DNA
ANALYSIS AND STORAGE
TITLE OF THE RESEARCH PROJECT: IMPACT OF THE MOLECULAR
FORM OF SURFACTANT PROTEIN-D PURIFIED FROM BRONCHO
ALVEOLAR LAVAGE ON BINDING TO, AND AGGLUTINATION OF,
MYCOBACTERIA
REFERENCE NUMBER:
PRINCIPAL INVESTIGATORS:
Walzl. .
Address:
Biochemistry .
Dr Eileen Hoal, Prof. Gerhard
Dept Medical
Faculty of Health
Sciences .
Stellenbosch
University .
DECLARATION BY OR ON BEHALF OF PATIENT/*PARTICIPANT:
I, THE UNDERSIGNED,
............................................................................. (name)
[ID No: ] the patient/*participant or* in my capacity as
................................................. of the patient/*participant [ID No:
........................ ] of .
........................................... (address).
A. HEREBY CONFIRM AS FOLLOWS:
1. I/*The patient/*participant was invited to participate in the
abovementioned research project which is being undertaken by the
Department of Medical Biochemistry, Faculty of Health Sciences,
Stellenbosch University.
2. The following aspects have been explained to me/*the
patient/* partici pant:
2.1 Aim: To investigate the binding of different forms of Surfactant
Protein- D (purified from human broncho alveolar lavage fluid) to
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mycobacteria. Additionally, this project aims to collect genetic
material (blood) to analyse for differences in the DNA
(polymorphisms) and to store excess material for future research.
2.2 Procedures: I will be requested to provide information about my
medical history. Blood (I5ml, about 3 teaspoonfuls) will be
collected from me. The investigators will perform broncho alveolar
lavage once.
2.3 Genetic considerations:
~ The blood or tissue may be used to create a cell line, which
can grow indefinitely and can be used to synthesize more of
my/*the participant's DNA at any time in the future;
~ The DNA may be stored for several years until the technology
for meaningful analysis becomes available;
~ The DNA will be maintained indefinitely, unless lI*the
participant request(s) to have it and/*or the stored clinical data
destroyed by contacting the investigator conducting the
present study, Dr Eileen Hoal at Tel No. 938 9412 or the
Chairperson of the Research Subcommittee ClEthics
Committee at Tel No 938 9207 if the former cannot be
located;
~ The analyses in the current study are specific to the
investigation or disease mentioned above and cannot
determine the entire genetic make-up of an individual;
~ Even under the best conditions, current technology of this type
is not perfect and could lead to unreliable results.
2.4 Risks: Possible side-effects I might experience from the broncho
alveolar lavage are an irritating cough during the procedure,
occasional sore throat and mild fever afterwards. In taking blood for
DNA, there are no more than minimal medical or psychological
risks associated with this study:
*Delete where not applicable
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~ I/*The participant may feel some pain associated with having
blood withdrawn from a vein and may experience discomfort,
bruising and/or slight bleeding at the site;
~ As some insurance companies may mistakenly assume that
my/*the participant's participation is an indication of a higher
risk of a genetic disease which could hurt my/*the
participant's access to health or other insurance, no
information about me/*the participant or my/*the participant's
family will be shared with such companies as this
investigation cannot be regarded as formal genetic testing for
the presence or absence of certain genes.
2.5 Benefits:
~ Although there may not be any direct benefits to me/*the
participant by participating at this stage, family members and
future generations may benefit if the researchers succeed in
scientifically delineating certain disorders further. Thereby
the rational approach to the clinical diagnosis and therapy of
its manifestations may be facilitated. The identification and
location of the genes involved in such disorders, could in the
end lead to the development of methods for prevention and to
forms of new treatment aimed at curing or alleviating these
conditions;
~ In the unlikely event that the research may lead to the
development of commercial applications, If*the participant or
my/*the participant's heirs will not receive any compensation,
but profits will be reinvested into supporting the cause of
further research which may bring benefits to my/*the
participant's family and to the community, such as health
screening, medical treatment, educational promotions, etc;
*Delete where not applicable
Stellenbosch University http://scholar.sun.ac.za
2.6 Confidentiality: My/*The participant's identity will be kept
confidential throughout. Information will not be associated with
my/*the participant's name. The research staffwill use only a coded
number, access will be limited to authorized scientists and any
scientific publications, lectures or reports resulting from the study
will not identify me/*the participant by name.
2.7 Access to findings: I understand that I may apply to the Principal
Investigators to share their findings with me.
2.8 Voluntary participation/refusal/discontinuation: I understand
that participation is voluntary and that the I may consequently refuse
to participate and that the I may discontinue participation at any time
and that such refusal or discontinuation would not prejudice my
future treatment at this institution and that the investigator may
withdraw me from the study should he/she feel that it would be in
my best interest.
2.9 Permission for further studies: Before my/*the participant's
material is used in further projects in the future, the written approval
of the Research Subcommittee C/Ethics Committee, Faculty of
Health Sciences, will be obtained.
3. The information above was explained to me/*the patient/*participant by
......................................................................... (name of
relevant person) in Afrikaans/*English/*Xhosa/*Other
........................................... and I am/*the participant/*patient is in
command of this language/*it was satisfactorily translated to
me/*him/*her by (name of translator).
I/*The participant/*patient was given the opportunity to ask questions and
all these questions were answered satisfactorily.
4. No pressure was exerted on me/*the patient/*participant to consent to
participation and l/*the participant/*patient understand(s) that I/*the
participant/*patient may withdraw at any stage without any penalization.
5. Participation in this study will not result in any additional costs to
myself/*the participant/*patient.
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B. HEREBY CONSENT VOLUNTARILY TO PARTICIPATE IN THE
ABOVEMENTIONED PROJECT/*THAT THE PATIENT/*POTENTIAL
PARTICIPANT MAY PARTICIPATE IN THE ABOVEMENTIONED
STUDY.
Signed/confirmed at (place)
on 20 (date)
Signature or right thumb print of
patient/*representative of the patient/*participant
Signature of witness
STATEMENT BY OR ON BEHALF OF INVESTIGATOR(S):
I, ,
declare that
• Iexplained the information given in this document to
........................................... (name of the patient/*participant) and/*or
his/*her representative (name of the
representative) ;
• he/*she was encouraged and given ample time to ask me any questions;
• this conversation was conducted in Afrikaans/*English/*Xhosa/*Other
.................. and no translator was used/*this conversation was translated into
.......................... (language) by (name).
Signed at (place)
on 20 (date)
Signature of investigator/*investigator 's representative
Signature of witness
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DECLARATION BY TRANSLATOR:
I, (name),
confirm that I
• translated the contents of this document from English into ..
(indicate the relevant language) to the patient/*the patient's
representative/*participant;
• explained the contents of this document to the patient/*participant/*patient's
representative;
• also translated the questions posed by ..
(name), as well as the answers given by the investigator/*the investigator's
representative; and
• conveyed a factually correct version of what was related to me.
Signed at (place) on .
20 ...... (date)
Signature of translator Signature of witness
IMPORTANT MESSAGE TO PATIENT/*REPRESENTATIVE OF
PATIENT/*P ARTICIP ANT:
Dear patient/*representative of the patient/*participant,
Thank you for your/*the patient's participation in this study. Should, at any time
during the study,
• an emergency arise as a result of the research, or
• you require any further information with regard to the study, kindly contact
Prof Gerhard Walzl at telephone number 9389158 (office hours) or the Lung
Unit at telephone number 9384911 (after hours).
19/02/02
bd/Guidelines
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